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Abstract 
Siglecs (Sialic Acid Immunoglobulin-like Lectins) are immune system protein 
receptors that play important roles in the down-regulation of cellular signals upon 
Sialic Acid ligand binding. At present, the human Siglec family is composed of 16 
members expressed by specific immune system cellular types. Due to their highly 
restrictive expression patterns and key regulatory function, Siglecs have been pointed 
out as interesting pharmaceutical targets to treat certain immune diseases where those 
specific cellular types are involved.  
This work is focused on Siglec8 which is expressed on the surface of mast cells and 
eosinophils and has demonstrated to induce their apoptosis upon ligand binding. This 
effect could be exploited to develop therapeutics that target and reduce the levels of 
eosinophils in the inflammatory diseases such as asthma where they are the main 
effectors. The aim of this thesis is to design some Siglec8-ligand mimetic small 
molecules, test their binding to the receptor and obtain affinity data about the 
interaction. 
We managed to express the Siglec8 Ig-like V-type carbohydrate binding domains in 
Escherichia coli, refold and purify them in solution and perform a biophysical 
characterization by means of different techniques such as Fluorescence, Absorbance, 
Mass Spectrometry (MS), Circular Dichroism (CD) and Single-Angle Neutron 
Scattering (SAXS). We also designed nine small Siglec8-ligand mimetic molecules 
and tested their binding to the receptor domains using the Octet technology and 
equilibrium dialysis-1 D H+ NMR measurements. We found the ligand Phospho-
Tyrosine to be our best Siglec8 binder and estimated a dissociation constant around 
100 μM for the interaction. Thus, the binding information obtained in this work could 
lead to the development of higher affinity and specific molecules that target Siglec8. 
This thesis also encompassed an industrial collaboration with the company Mologic 
Ltd where anti-Siglec8 antibodies where developed with chronic lung disease 
diagnostic purposes. 
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1. Introduction 
1.1 Importance of protein-glycoconjugate interactions in human health and 
disease. 
The term glycan is defined by IUPAC as "compound consisting of several 
monosaccharides linked glycosidically". In the human body, glycan biomolecules can 
be found associated with other glycans, proteins or lipids forming structures such as 
oligosaccharides, polysaccharides, glycoproteins, glycopeptides, glycolipids and 
proteoglycans (Marchetti, et al., 2016). Many of these structures participate in the 
molecular events that take place to support vital biological processes such as cell-cell 
interaction, signal transduction, inflammation, viral entry and host-bacterial 
recognition, which are relevant in disease and defence.  
Glycans achieve this through specific interaction with proteins such as lectins, 
antibodies or enzymes (Smith and Helenius, 2004). Lectins are carbohydrate-binding 
proteins highly specific for sugar moieties, which serve many different biological 
functions in animals. Viruses infect specific cell types by binding to receptors in cells’ 
surfaces, i.e. influenza virus displays in its surface the lectin hemagglutinin that 
recognizes sialic acid residues present on cell-surface glycoproteins, and this 
interaction leads to the virus internalization into the cell. Another example is the 
mannose-binding lectin (MBL), which recognizes carbohydrate patterns found in the 
surface of pathogenic microorganisms and initiates the activation of the immune 
response, leading to the production of specific anti-pathogen carbohydrate antibodies. 
Furthermore, in several inflammatory autoimmune diseases as systemic lupus 
erythematosus, effector T cell populations with altered glycosylation are highly 
upregulated leading to an excessive activation of other immune cellular effectors and 
response (van Kooyk and Rabinovich, 2008). Figure 1.1 displays the different kinds 
of physiological protein-glycan interactions that can occur in the body: cell-cell, cell-
virus, cell-antibody, cell-bacteria or cell-toxin.  
Chapter 1 – Introduction 
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Figure 1.1. Different protein-glycan interactions (cell-cell, cell-virus, cell-antibody, cell-bacteria, cell-toxin) 
which are relevant for the human immune system (van Kooyk and Rabinovich, 2008). 
 
Although in mammals there are only around ten monosaccharides which 
associate to build longer glycans, they can combine to form a huge variety of three-
dimensional structures, linking through different positions of the sugar units and 
forming branched structures that adopt a wide variety of spatial orientations. They also 
may undergo different modifications with non-carbohydrate substituents like sulphate, 
phosphate or acetyl groups (Nieto, et al., 2011). Figure 1.2 represents the different 
linking positions and some possible modifications for the sialic acid family, which 
includes 43 derivatives of the nine-carbon sugar neuraminic acid. Those glycans 
normally are found as components of oligosaccharide chains occupying terminal 
positions where they are very exposed and develop important functions. 
Chapter 1 – Introduction 
16 
 
 
Figure 1.2. Different linkages and modifications that the carbohydrate family of sialic acids can undergo. Red: 
sialic acids can link to other sugars in different positions. Blue: different substitutions that give place to different 
sialic acid molecules. Green: different modifications that sialic acids may undergo and affect their reactivity. 
This structural variability and complexity make glycans important carriers of 
biological information, which is transformed into biological activity when they 
interact in a very specific way with their protein receptor targets. An interesting 
example is the important biological effect of the human transmembrane lectin receptor 
expressed by endothelial cells DC-SIGNR on colon cancer illustrated in Figure 1.3 
(Na, et al., 2017). Patients with liver metastasis show higher levels of expression of 
DC-SIGNR compared with patients without metastasis. Both, in vitro and in vivo 
experiments suggest that the inhibition of DC-SIGNR activity or downstream 
regulated events could be a therapeutic intervention for liver metastasis formation. In 
liver metastasis formation, colon cancer cells detach from the primary sites, circulate 
in the surrounding tissues, and enter the blood vessels where they adhere to endothelial 
cells through the interaction between DC-SIGNR and DC-SIGNR glycan ligands 
expressed on their own surface. The interaction induces cellular expression changes 
leading to activation of biochemical pathways that make the cells able to extravasate, 
migrate and invade the liver, forming a metastatic tumour.  
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Figure 1.3. Representation of the biological effect of DC-SIGNR on colon cancer. Circulating colon cancer cells 
display DC-SIGNR ligands on their surface and interact with DC-SIGNR expressed by endothelial cells. The 
interaction triggers expression changes which enable the cancer cells to extravasate and adhere to other tissues 
inducing metastasis (Na, et al., 2017). 
Understanding the different aspects of carbohydrate-protein interactions, 
including the identification of ligand-receptor pairs, their three-dimensional structures, 
the dynamics and molecular basis of the interactions and the subsequent cellular 
signals, constitutes one of the main challenges of modern structural glycoscience. This 
is relevant for the discovery and development of new pharmaceuticals to treat those 
diseases in which glycan interactions are involved (Marchetti, et al., 2016).  
1.2 Structure and signalling of sialic acid-Siglec binding. 
Sialic acid-binding immunoglobulin-like lectins (Siglecs) participate in 
biologically critical protein-carbohydrate interactions. Siglecs are cell-surface 
transmembrane receptors that belong to the lectin family. They express in specific 
immune system cell types and participate in cell-cell communication and cellular 
signalling downregulation by interacting with their endogenous ligands, some sialic 
acids (Macauley, et al., 2014). 
Sialoadhesin (also known as Siglec1) was initially described as a macrophage 
adhesion receptor recognizing sialic acids, and later shown to be a member of the 
immunoglobulin (Ig) superfamily. CD22 (Siglec2) was initially characterized as a B 
cell inhibitory receptor of the Ig superfamily and afterwards it was discovered to bind 
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sialic acids. The structural homology of these proteins with CD33 (Siglec3) and the 
myelin-associated glycoprotein (Siglec4) led to the establishment of the Siglec family 
(Crocker, et al., 2007). To date, fourteen Siglecs have been identified in humans and 
nine in mice containing between 2 to 17 extracellular immunoglobulin domains 
(Macauley, et al., 2014). 
Figure 1.4 represents the general structure of Siglec membrane protein 
receptors (Macauley, et al., 2014). The extracellular region of all Siglecs include an 
amino-terminal V-set domain that contains the sialic acid-binding site and a variable 
number of Ig-like C2-type domains. The intracytoplasmic domains of most Siglecs are 
tyrosine-based motifs, but a few Siglecs such as Siglec14, Siglec15 and Siglec16 lack 
of them. Tyrosine-based inhibition motifs (ITIMs) are conserved sequences of amino 
acids found in the cytoplasmic tails of many receptors of the immune system. The 
characteristic sequence of amino acids for ITIM domains is S/I/V/LxYxxI/V/L. After 
receptor-ligand interaction, these motifs become phosphorylated by enzymes of the 
Src kinase family, allowing them to recruit other enzymes such as phosphotyrosine-
phosphatases or inositol-phosphatase which decrease the activation of molecules 
involved in cytoplasmic cell signalling. Table 1.1 summarizes the structure and 
disease relevance of each of the Siglec family members discovered until now 
(Macauley, et al., 2014). 
 
Figure 1.4. Schematic representation of the general structure of Siglec receptors. All Siglecs have an extracellular 
sialic acid-binding terminal Ig-like V-type domain, followed by a variable number of Ig-like C2-type domains and 
the transmembrane domain. Some Siglecs do not have any cytoplasmic domain and others have inhibition tyrosine 
based intra-cytoplasmic domains (ITIMs) (Macauley, et al., 2014). 
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Table 1.1. Summary of the Siglec family members discovered and some of their known features (Macauley, et al., 
2014). 
 
Human 
Siglec 
 
Expression 
 
N Ig 
domains 
 
 
Tyrosine 
motifs 
 
Disease 
Relevance 
 
1 
(Sialoadhesin 
or CD169) 
 
Macrophages and 
activated monocytes 
 
17 
 
None 
 
Autoimmunity and 
infections (HIV-1, 
GBS…) 
 
 
2 (CD22) 
 
B cells 
 
7 
 
ITIM, ITIM-
like and 
GRB2 
 
Lymphoma, leukaemia, 
SLE and rheumatoid 
arthritis 
 
 
3 (CD33) 
 
Myeloid progenitors, 
macrophages, monocytes, 
microglia and 
granulocytes 
 
 
 
2 
 
 
ITIM and 
ITIM-like 
 
 
Acute myeloid leukaemia 
and Alzheimer’s disease 
 
4 (MAG) 
 
 
Oligodendrocytes and 
Schwann cells 
 
5 
 
FYN kinase 
site 
 
Neurodegeneration 
 
5 
 
Neutrophils, monocytes 
and B cells 
 
 
4 
 
ITIM and 
ITIM-like 
 
 
GBS infection 
 
6 
 
Trophoblasts and B cells 
 
 
3 
 
ITIM and 
ITIM-like 
 
Pre-eclampsia 
 
7 
 
NK cells, monocytes and 
masts cells 
 
 
3 
 
ITIM and 
ITIM-like 
 
Cancer and C. jejuni 
infection 
 
8 
 
Eosinophils, mast cells 
and basophils 
 
 
3 
 
ITIM and 
ITIM-like 
 
Eosinophilia and asthma 
 
9 
 
Neutrophils, monocytes, 
DCs and NK cells 
 
 
3 
 
ITIM and 
ITIM-like 
 
Chronic Obstructive Lung 
Inflammation 
 
 
10 
 
B cells, monocytes and 
eosinophils 
 
5 
 
ITIM, ITIM-
like and 
GRB2 
 
 
Lymphoma, leukaemia, 
eosinophilia and allergy 
 
 
11 
 
Macrophages and 
microglia 
 
 
5 
 
ITIM and 
ITIM-like 
 
Neuroinflammation 
 
 
14 
 
Neutrophils and 
monocytes 
 
 
3 
 
None 
 
GBS infection and COPD 
 
 
15 
 
 
Osteoclasts, macrophages 
and DCs 
 
 
2 
 
 
None 
 
 
Osteopetrosis 
 
16 
 
 
Macrophages and 
microglia 
 
 
5 
 
None 
 
Unknown 
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The native ligands for Siglecs are sialic acids, sugars with a nine-carbon 
backbone which can undergo different chemical modifications and establish different 
linkages with other sugars, as represented in Figure 1.2, leading to more than 50 
naturally occurring structures (Macauley, et al., 2014). Most Siglecs are endocytic 
receptors that either constitutively cycle between the cell surface and intracellular 
endosomes or are induced to undergo endocytosis upon ligand binding when plasma 
membrane vesicles containing receptor with the bound ligand are internalised into the 
cell (both types of endocytosis are represented in Figure 1.5).  
 
Figure 1.5. A. Constitutive or continuous cycling of transmembrane receptors between the cell surface and vesicles. 
B. Endocytosis mediated by receptor-ligand binding. Cycling between the cell surface and vesicles is induced when 
the ligand binds to the receptor. 
Most Siglecs trigger the inhibition of cellular biochemical pathways upon 
ligand binding via their cytoplasmic immunoreceptor tyrosine-based inhibitory motifs 
(ITIMs). But there are also some Siglecs that activate cellular signals (such as 
Siglecs14, 15 and 16), as they associate with the immunoreceptor tyrosine-based 
activation motif (ITAM) adaptor DAP12 via a positively charged amino acid in their 
transmembrane region. Furthermore, some of those activating receptors as Siglec14 
and 16 possess extracellular regions identical to inhibitory Siglecs (Siglec5 and 11), 
indicating that they may have evolved as a defence mechanism against pathogens that 
take advantage of inhibitory pathways to infect cells (Cao, et al., 2008; Cao and 
Crocker, 2011; Fong, et al., 2014).  
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1.3 Sialic Acids 
The native ligands for Siglecs are Sialic acids (Sia), sugars with a nine-carbon 
backbone as shown in Figure 1.6.  
 
Figure 1.6. Backbone of Sialic Acids. 
They are relatively strong acids (pKa ~2.6) due to the C1 carboxylate adjacent 
to the C2 anomeric carbon. Over 50 forms of sialic acid have been identified to date, 
due to the number of locations available for structural modification as well as the core 
variation. The hydroxyl groups located at carbons 4, 7, 8 and 9 may undergo 
modifications such as acetylation, phosphorylation, sulfation or methylation. 
Furthermore, different substitutions may be made at carbon 5. The most common 
sialic acid in human body is the N-acetylneuraminic acid (NeuAc), shown in Figure 
1.7. Its exocyclic glycerol chain (C7, C8 and C9) provides opportunity for extensive 
hydrogen bonding and its N-acetyl group can participate in hydrophobic interactions. 
Thus, the different moieties and chemical groups play an important role in Sialic 
Acids binding specificity and function (Schauer, 2004). 
 
Figure 1.7. N-acetylneuraminic acid structure (NeuAc). 
 
1.4 Sialic acids’ role and location in the human body. 
All eukaryotic and several prokaryotic systems express Sialic Acids. In 
humans, they are normally part of glycan oligomers and appear most frequently as 
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terminal molecules of N-glycans, O-glycans and glycosylphosphatidylinositol 
anchored proteins (GPI), being able to take part in many intermolecular and 
intercellular reactions because of their acidic negatively charged nature. However, 
Sialic Acids are not commonly used as energy resources (Varki and Angata, 2006) 
and normally play an important role as ligands of protein receptors. Thus, through 
their very specific interactions they take part in vertebrates’ innate immune system 
signalling among other key physiological processes such as development, cellular 
recognition, cell-cell attachment and cell function regulation.  
Changes in cellular sialylation have been also associated with cancer, 
infection, diabetes and other illnesses, but many details of the events in which they 
take part in as well as their pathological states remain still ambiguous. There is a fast 
growing of knowledge of Sialic Acids and molecules that specifically bind to them 
and it supposes a research field of huge interest (Crocker, 2002; Varki and Angata, 
2006; Crocker, et al., 2007).  
For example, several bacteria, parasites and viruses like influenza possess 
receptors which recognize specifically cell surface Sialic Acids as ligands. Thus, 
pathogens can adhere to cells and infect them (Schauer, 2004; Crocker, et al., 2007). 
As a defence mechanism against pathogen attacks, Siglecs can bind to sialylated 
glycans displayed in the same cell surface, leading to Cis interactions (Macauley, et 
al., 2014). By attaching to these nearby endogenous sialic acids, they reduce the 
likelihood of viral attachment, protecting the sialylated glycans from external 
attachments to viral hemagglutinins. Contrarily, the loss of terminal human Sialic 
Acids through sialidase cleavage unmasks the Siglecs and makes them available for 
Trans binding to another host cell or to a pathogen that has a stronger affinity for the 
Siglec binding site (Varki and Angata, 2006). 
Cis interactions also enable identifying cells as ‘self’ to the immune system 
and preventing autoimmune attacks from macrophages and other immune system cells 
(Macauley, et al., 2014).  
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1.5 Sialic Acids Biosynthesis  
Sialic Acid synthesis in animals takes place mainly in the cellular cytosol and 
consists in a five-step process which involves four enzymes. NeuNAc is synthesised 
and activated in the nucleus; and subsequently transferred to the Golgi Apparatus 
where the molecule is attached to larger glycans. Then, glycans are transported to the 
location where they carry out their biological function (soluble or attached to 
glycoproteins). They also can undergo different modifications when substitutions are 
added or relocated (Altheide, et al., 2006). 
Figure 1.8 summarizes the cycle of Sialic Acids biosynthesis in the cellular 
cytosol starting by their precursor 5’-diphosphate-N-acetyl-D-glucosamine 
(UDPGlcNAc) which is transformed into N-acetyl-D-mannosamine (ManNAc) with 
removal of the UDP moiety and epimerization of the carbohydrate by means of the 
dual activity enzyme UDP-GlcNAc 2-epimerase/ManNAc-6-kinase. Then, the kinase 
function of the same enzyme phosphorylates the sugar to produce N-acetyl-d-
mannose-6-phosphate (ManNAc-6-P) which is transformed into N-acetylneuraminic 
acid 9-phosphate (Neu5Ac-9-P) by means of a condensation reaction with 
phosphoenolpyruvate (PEP) performed by the enzyme NeuAc-9-P-synthetase.  
Finally, this precursor is dephosphorylated by Neu5Ac-9-P-phosphatase to produce 
the Neu5Ac. After biosynthesis, Neu5Ac is transported to the cell nucleus and attached 
to cytidine 5’-triphosphate (CTP) to produce the donor substrate cytidine-5’-
monophospho-N-acetylneuraminic acid (CMP-Neu5Ac) for subsequent transfer to an 
oligosaccharide structure after the loss of pyrophosphate via catalysis by the enzyme 
CMP-NeuAc synthetase. The CMP-Neu5Ac substrate is transported back to the 
cytoplasm and then to the Golgi where the syaliltransferases attach Neu5Ac residues 
to oligosaccharides using CMP-Neu5Ac as a sugar donor. These transferases produce 
specific glycosidic linkages for sialic acids (α2→3, α2→6 or α2→8) determined by 
their preference for specific monosaccharide acceptors. Those specificities are 
indicated by the enzyme’s nomenclature. However, a lack of substrate selectivity was 
observed in some in vitro experiments using unnatural ManNAc structures. Figure 1.2 
shows again the different linkages which Sialic Acids can form with other glycans 
(Altheide, et al., 2006). 
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Figure 1.8. Summary of Sialic Acids synthesis, activation, transfer and transport (Altheide, et al., 2006). 
 
 
Figure 1.2. Neu5Ac and the possible linkages that it forms with other glycans (Schauer, 2004). 
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1.6 Types and Effects of Siglec-ligand Interactions  
Each Siglec family member has specificity for different types of sialylated 
glycans either found on the surface of mammalian cells or soluble in extracellular 
fluids. Thus, we talk about Cis interactions when both ligand and receptor are 
expressed on the surface of the same cell, and Trans interactions when ligand and 
receptor belong to different cell, or the ligand is a soluble glycoconjugate, both types 
of interactions are represented in Figure 1.9 (Crocker, et al., 2007; Pillai, et al., 2012; 
Macauley, et al., 2014). The binding can have a variety of effects on immune system 
cell functions such as the downregulation of cell signals triggered by other receptor-
ligand interactions, the induction of apoptosis and cell migration, or the internalization 
of a ligand into cellular cytoplasmic vesicles. Siglecs may also be sequestered by other 
non-activator carbohydrate ligands which can block their active site and avoid the 
interaction with sialic acids, influencing over cellular signalling (Macauley, et al., 
2014). All types of possible interactions are summarized in Figure 1.9. 
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Figure 1.9. Representation of all possible types of interactions that Siglecs can carry out according to the location 
of their sialylated ligand. Panel a): Cis interactions occur when the ligand or the inhibitor are attached to a 
glycoprotein expressed by the same cell, and lead to cellular signal modulation. Panel b): Trans interactions can 
happen with free ligands or inhibitors, leading as well to cellular signal modulation. Panel c): Trans interactions 
with ligands or inhibitors expressed by nearby cells leading to cellular events such as migration, apoptosis or 
endocytosis (Macauley, et al., 2014). 
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1.7 Siglecs and Human Disease 
Siglecs have been associated with different human diseases such as bacterial 
and viral infections, lung inflammation, autoimmune disease and cancer (Macauley, 
et al., 2014). Indeed, many studies have identified polymorphisms and mutations in 
Siglec genes linked to diseases: some Siglec3 (CD33) genetic variants are associated 
with a major risk factor for Alzheimer’s disease (Bertram, et al., 2008; Hollingworth, 
et al., 2011; Naj, et al., 2011) and Siglec8 polymorphisms are related to a higher 
susceptibility to asthma (Gao, et al., 2010). Furthermore, several human bacterial 
pathogens can display sialic acid-based ligands that bind Siglecs and suppress immune 
response, leading to pathogen survival (Crocker, et al., 2007; Pillai, et al., 2012; 
Macauley, et al., 2014), i.e. Group B Streptococcus (GBS) is classified into nine 
serotypes that display a capsular polysaccharide (CPS) and have in common a terminal 
sialic acid residue. Some studies hypothesise that GBS evolved to display that CPS 
Sia as a form of molecular mimicry to limit the activation of an effective innate 
immune response by interacting with certain human Siglecs expressed on neutrophils 
and monocytes, as Siglec5 and Siglec9 (Carlin, et al., 2007). Table 1.1 (showed 
before) summarizes all known Siglec family members as well as the cell types in 
which they are expressed, the number of extracellular Ig-like domains and cytoplasmic 
motifs they contain, and the human disease to which they are linked (Macauley, et al., 
2014).  
1.8 Siglecs as Interesting Pharmaceutical Targets 
Siglecs have been highlighted as interesting targets for the development of 
immunotherapeutics, due to their highly restricted expression in immune system cells 
and differential expression in specific cellular types which relate them to very specific 
diseases (Crocker, et al., 2007; Jellusova and Nitschke, 2012; Kawasaki, et al., 2013; 
Kiwamoto, et al., 2013; Muller and Nitschke, 2014). A good example of the successful 
development of an immunotherapeutic targeting a Siglec receptor is the humanized 
anti-CD33/Siglec3 monoclonal antibody covalently attached to a cytotoxic antitumor 
drug from Pfizer (commercial name Mylotarg®) for the treatment of acute myeloid 
leukaemia. The anti-tumour mechanism of Mylotarg® is represented in Figure 1.10: 
The non-cytotoxic antibody binds to the Siglec3 antigen of normal and leukemic 
myeloid cells (but not to their hematopoietic precursors) and is internalized into 
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lysosomes where acidification activates the cytotoxic conjugated drug calicheamicin 
by a spontaneous reaction with reduced glutathione (GSH). Then, calicheamicin 
targets and destroys DNA strains, killing the tumour cells (Laszlo, et al., 2014; Loke, 
et al., 2015; Garfin and Feldman, 2016).   
 
Figure 1.10. Summary of action mechanism of Mylotarg® to treat acute myeloid leukaemia. 1. The non-cytotoxic 
conjugated antibody binds specifically to Siglec3. 2. Antibody and receptor are internalised into lysosomes by 
endocytosis. 3. The acid pH activates the cytotoxic conjugated drug calicheamicin by spontaneous reaction with 
GSH 4. Calicheamicin is released into the cytoplasm. 5. Calicheamicin gets into the nucleus and destroys DNA, 
killing the leukemic cell. 
 
This drug was approved by the US Food and Drug Administration in 2000, but 
it was linked to a serious liver condition and the beneficial effects of its administration 
in combination with chemotherapy in acute myeloid leukaemia patients was not 
demonstrated in clinical trials. Mylotarg® was voluntarily withdrawn from the market 
by Pfizer in mid-2010. However, some regulatory authorities did not agree with that 
decision and more clinical trials have been performed showing Mylotarg benefits. 
Finally, in early 2017 Pfizer reapplied for US and EU approval for the treatment of 
myeloid acute leukaemia (Laszlo, et al., 2014). There are also clinical studies 
investigating antibody-drug conjugates that target CD-22 (Siglec2) to treat B-cell 
malignancies (Shor, et al., 2015; Jahn, et al., 2016). 
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1.9 Siglec8 as a Therapeutic Target to Treat Asthma 
Siglec8 is a transmembrane receptor (Floyd, et al., 2000; Foussias, et al., 2000) 
exclusively expressed on human eosinophils, basophils and mast cells, where it 
regulates their function and survival (Macauley, et al., 2014). It has also been 
associated with chronic respiratory diseases such as asthma. Asthma is a chronic 
inflammatory disease of the respiratory airways characterized by variable and 
recurring symptoms such as wheezing, coughing, chest tightness or shortness of 
breath, joined by reversible airflow obstruction and bronchospasm (Bochner, et al., 
2013). Siglec8 is a promising pharmaceutical target to treat asthma since eosinophils 
are important effectors in this human allergic disease (Kiwamoto, et al., 2013; 
Ilmarinen and Kankaanranta, 2014a; Kano, et al., 2014).  
Eosinophil numbers generally increase in tissues, blood and bone marrow in 
association with allergic reactions. There is a correlation between eosinophil levels 
and disease severity as they orchestrate inflammation, tissue damage and airway 
obstruction during an asthma crisis by releasing proteases (Ilmarinen and 
Kankaanranta, 2014a). Several studies have reported the induction of cytokine-
activated eosinophil apoptosis (programmed cell death) when Siglec8 is activated by 
its ligands. This would decrease protease production and lead to a reversion of 
inflammation and tissue damage during an asthma crisis. Thus, Siglec8 has therapeutic 
potential in treatment of allergic asthma (Farid, et al., 2012; Feng and Mao, 2012; 
Kiwamoto, et al., 2012a). 
Although the mechanisms by which Siglec8 receptor activation induces 
apoptosis still have not been completely elucidated, there are several studies that have 
contributed some information. Siglec8 has an intracellular immunoreceptor tyrosine-
based inhibitory motif (ITIM) and an immunoreceptor tyrosine-based switch motif 
(ITSM) responsible for signal transduction through association with the SHP-2 protein 
tyrosine phosphatase (Nutku, et al., 2005; Kano, et al., 2013; Janevska, et al., 2015; 
Kano, et al., 2017). The studies conclude that the main causes of eosinophils apoptosis 
are increased mitochondrial damage and reactive oxygen species (ROS) production. 
Both seem to be mediated by the MAPK (mitogen-activated protein kinase)/ERK 
(extracellular receptor-stimulated kinase) pathway, a chain of cytoplasmic and nuclear 
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protein kinases that communicate the signal from the receptor on the cell surface to 
the DNA in the nucleus (Kano, et al., 2017). 
 Genetic studies showed a significant association between genetic sequence 
variants or polymorphisms in the SIGLEC8 gene and susceptibility to asthma in 
diverse populations, supporting the role of Siglec8 in the disease (Gao, et al., 2010). 
Furthermore, Siglec8 could be a potential human serum biomarker to diagnose certain 
hyper eosinophilic diseases which are not tissue localized (Ilmarinen and 
Kankaanranta, 2014a). Figure 1.11 summarizes the relevance of Siglec8 in lung 
inflammatory diseases and the effect that a Siglec8 agonist could perform during a 
disease exacerbation. 
 
 
Figure 1.11. Summary of a normal and asthma situation in the lung and the effect that a Siglec8 agonist could make 
to treat the asthma. A. In a normal situation, there will be a basal concentration of immune system cells in the lung 
or eosinophils in this case. B. When an asthma crisis happens, the levels of eosinophils increase, and they release 
proteases that damage and produce tissue inflammation. C. and D. A Siglec8 agonist would induce eosinophils 
apoptosis and thus, decrease the proteases concentration and their effects on the lung tissue relieving the asthma 
symptoms. 
 
1.10 Identification of Siglec8 Sialylated Ligands  
Glycan microarrays are based on the simultaneous presentation of a library of 
known glycans arranged on a surface in a resolvable pattern for defining binding 
specificities of glycan binding proteins (Song, et al., 2014). The specificity of the 
interactions is determined by a quantitative signal that enables to compare binding of 
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a protein to all glycans in the microarray, including those cases where there is no 
interaction, and detecting the ones that associate with the highest affinity.  
It has been estimated that the human glycome is composed of more than 7,000 
glycan structures, encompassing penta- and hexa-saccharide sequences and their 
chemical modifications. Therefore, the full potential of defined glycan microarrays 
will only be covered when the libraries of glycans represent the complete glycome of 
an organism, tissue or cell (Song, et al., 2014). 
Glycan microarray analyses were employed to identify the unique known weak 
binders for Siglec8 (Bochner, et al., 2005; Campanero-Rhodes, et al., 2006). They 
revealed specific and low affinity binding for only one single sialylated glycan: 
NeuAcα2-3(6-O-Sulfo) Galβ1-4[Fucα1-3] GlcNAc or 6’-Sulpho-sialyl-LeX, whose 
structure is shown in Figure 1.12. 
 
Figure 1.12. NeuAcα2-3(6-O-Sulpho) Galβ1-4[Fucα1-3] GlcNAc or 6’-Sulpho-Sialyl-LeX structure. 
  
Initially, Floyd and co-workers showed Siglec8 binding to Sialic Acid forms 
linked to Galβ1-4GlcNAc through α2-3 or α2-6 bonds (Floyd, et al., 2000), but a 
subsequent study performed with 28 different carbohydrate molecules could not 
determine a clear binding preference of these molecules for Siglec8 (Blixt, et al., 
2003). Later, Siglec8 binding was tested again against 172 different glycan structures, 
40 of which were sialylated, resulting in the detection of the 6’-Sulpho-Sialyl-LewisX 
glycan Figure 1.12) as a selective Siglec8 ligand with high affinity for the receptor 
(Bochner, et al., 2005). In the same study, neither the Sialyl-LewisX nor the 6-Sulpho-
Sialyl-LewisX (sulphated on the 6-position of the GlcNAc) (Figure 1.13) showed 
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binding, indicating that the Sialyl-LewisX 6’-sulphation is important for the 
interaction (Bochner, et al., 2005). This result was corroborated in a different study 
and extended to identify another low affinity binder for Siglec8: the disulphated 6, 6’-
Sulpho-Sialyl-LewisX (Figure 1.13) (Campanero-Rhodes, et al., 2006).  
 
Figure 1.13. 6, 6’-DiSulpho-Sialyl-LeX structure. 
 
1.11 Precedents in Structural Characterization of Siglec-ligand Interactions 
There are several studies in which the 3D structures of the Ig-like V-type or 
carbohydrate binding domains of human Siglecs have been characterized alone and/or 
in complex with ligands. In 2003 the Ig-like V-type N-terminal domain of the Natural 
Killer cell inhibitory receptor Siglec7 was resolved for the first time by means of X-
ray Crystallography alone and in complex with the ligand (2,8)-linked disialic acid 
(pdb IDs 1O7S and 1O7V) (Alphey, et al., 2003). Siglec7 structure was resolved again 
by means of the same technique in 2004 (pdb ID 1NKO), (Dimasi, et al., 2004) and 
finally three more Siglec7 X-ray resolved crystal structures in complex with other 
three different ligands (α(2,3)-α(2,6)-Disialyl lactotetraosyl 2-(trimethylsilyl)ethyl, 
methyl-9-(aminooxalyl-amino)-9-deoxyNeu5Ac (oxamido-Neu5Ac) and the α(2,8)-
disialylated ganglioside GT1b) were published in 2006 (pdb IDs 2DF3, 2G5R and 
2HRL) (Attrill, et al., 2006b; Attrill, et al., 2006c). Figure 1.14 shows the structure of 
the Siglec7 Ig-like V-type carbohydrate binding domain in complex with the ligand 
α(2,3)-α(2,6)-Disialyl-lactotetraosyl-2-(trimethylsilyl) ethyl resolved by X-ray 
Crystallography as an example (pdb ID 2DF3). 
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Figure 1.14. Siglec7 Ig-like V-type domain in complex with α (2, 3)-α (2, 6)-Disialyl lactotetraosyl 2-
(trimethylsilyl) ethyl resolved by X-ray Crystallography (pdb ID 2ZG1). 
Later, in 2008, the structure of the two N-terminal domains of Siglec5 alone 
(pdb ID 2ZG2), and in complex with 6’-sialyllactose (pdb ID 2ZG1) and 3’-
sialyllactose (pdb ID 2ZG3) were resolved by means of X-ray Crystallography 
(Zhuravleva, et al., 2008a). Figure 1.15 shows the structure of the Siglec5 Ig-like V-
type carbohydrate binding domain in complex with 6’-Sialylactose resolved by X-ray 
Crystallography.  
 
Figure 1.15. Siglec5 Ig-like V-type domain in complex with 6’-Sialyllactose resolved by X-ray Crystallography 
(pdb ID 2ZG1). 
In July of 2016, the Siglec8 carbohydrate-binding domain structure was 
resolved in complex with the 6’-Sulpho-Sialyl-LewisX ligand by means of solution 
state NMR spectroscopy (Propster, et al., 2016) (Figure 1.16).  
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Figure 1.16. Siglec8 carbohydrate binding domain in complex with its ligand 6’-Sulpho-Sialyl-LewisX resolved 
by solution state NMR spectroscopy (Propster, et al., 2016). 
In that work, the Siglec8 Ig-like V-type carbohydrate binding domain was 
cloned, soluble expressed and purified (Propster, et al., 2015). Subsequently the 
dissociation constants (KD) for the interaction between the Siglec8 Ig-like V-type 
domain and four variants of the sialic acid Sialyl LewisX (SulphoSialyl-LewisX, 6’-
SulphoSialyl-LewisX, 6-SulphoSialyl-LewisX and 6, 6’-DisulphoSialyl-LewisX) 
were determined by solution state NMR. This work confirmed 6, 6’-DisulphoSyalil-
LewisX as the known weak ligand with strongest affinity (KD = 183±18 μM) followed 
by 6’-SulphoSialyl-Lewis X (KD = 295±26 μM), and distantly by 6-SulphoSialyl-
LewisX (KD = 2.7±0.8 mM) and Sialyl LewisX (KD = 8.3±1.9 mM) as summarized in 
Figure 1.17. 
 
Figure 1.17. From left to right, structures of the Disulphated Sialyl LewisX which binds Siglec8 with stronger 
affinity than the monosulphated 6’-Sulpho-Sialyl LewisX and 6-Sulpho-Sialyl LewisX which did not show any 
binding to Siglec8 in the glycan microarrays (Campanero-Rhodes, et al., 2006). 
Chapter 1 – Introduction 
35 
 
The molecular model proposed in this study is displayed in Figure 1.18, where 
the Siglec8 amino acids interacting with the 6’-Sulpho-Sialyl-LewisX as well as the 
nature of the interactions are indicated (Propster, et al., 2016). The model describes 
the essential arginine (Arg109) which is conserved in all Siglecs and plays an 
important role in their ligand binding, anchoring the carboxyl group of the terminal 
sialic acid inside the binding pocket. Mutations of this residue have been shown to 
result in loss of binding of most Siglecs including Siglec8 (Propster, et al., 2016). 
 
Figure 1.18. 6’-Sulpho-Sialyl-Lewis X and Siglec8 amino acids interacting with it. Amino acids and chemical 
groups carrying out hydrophobic interactions are represented in pink meanwhile the ones carrying out ionic 
interactions are shown in red and the ones forming hydrogen bonds in green (Propster, et al., 2016). 
 
1.12 Investigation of Siglecs ligands. 
Similarly to many lectins, the literature describes the binding between Siglecs 
and sialylated oligosaccharides as low affinity interactions, with dissociation constant 
values between 0.1 and 3 mM (Attrill, et al., 2006a), i.e. Siglec5 recognizes both 
α(2,3)- and α(2,6)-linked sialic acids with dissociation constants of KD = 8.7 mM and 
KD = 8.0 mM, respectively (Zhuravleva, et al., 2008b). Those dissociation constant 
values are high in comparison to other lectins such as the C-type lectin DC-SIGN 
which has been found to bind mannose and fucose containing glycans with a range of 
affinities between 3 and 48 nM (van Liempt, et al., 2006). Therefore, Siglecs high 
affinity binding relies on multivalent clustering (Attrill, et al., 2006a).  
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Although weak Siglec8 binders (6,6'-Disulpho-Sialyl-LewisX and the 6'-
sulpho-Sialyl-LewisX) have been found, the identity of the endogenous Siglec8 
ligand/s or any other stronger binders remains unknown.  
The discovery of those weak Siglec8 ligands as well as the molecular model 
which describes the chemical nature of the Siglec8 amino acids-ligand interactions 
provide the basis for the investigation and design of molecules with stronger affinity 
for the receptor Siglec8 with therapeutic proposes. The design of therapeutic 
molecules targeting Siglecs has already been done for the receptor Siglec7, expressed 
on the surface of natural killer (NK) cells which are able to directly lyse tumour cells. 
In that work, high affinity low molecular weight Siglec7 ligands (low μM KD) were 
synthetized to interfere with cancer cell immune system evasion mechanisms. The 
mission of those molecules is to block the NK Siglec7 receptor avoiding that malignant 
cells camouflage themselves by displaying Siglec7 ligands on their surface and are 
recognised by the NK cells as 'self' (Prescher, et al., 2017). 
1.13 Rational and aims of this project 
Apart from the 6,6'-Disulpho-Sialyl-LewisX and the 6'-sulpho-Sialyl-LewisX 
weak binders, at present, no more Siglec8 ligands are known. The aim of this project 
is the rational designing of molecules that can bind to the carbohydrate binding domain 
of the protein membrane receptor Siglec8 with stronger affinity, and test the binding 
using biophysical methods. The interest of investigating new Siglec8 agonists is to 
induce eosinophils apoptosis to treat hyper-eosinophilic diseases such as some 
subtypes of asthma (Nutku, et al., 2003; Farid, et al., 2012; Ilmarinen and 
Kankaanranta, 2014b). Furthermore, the involvement of eosinophils in another 
chronic lung disease, the Chronic Obstructive Pulmonary Disease (COPD), has been 
recently described in the literature. Those studies found increased levels of these cells 
in tissues and blood circulation during both stable and disease exacerbations in patients 
with COPD, indicating that Siglec8 may be a good biomarker for this disease 
(Bafadhel, et al., 2017).  
Asthma and COPD are phenotypically complex diseases in which different 
cases vary in the underlying pathogenesis. However, approximately half of the patients 
with asthma seem to belong to a phenotype associated with predominant eosinophilic 
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inflammation known as allergic asthma, where eosinophils are the main immune 
system effectors responsible for the symptoms (Woodruff, et al., 2009). Asthma is a 
long-term condition that affects the respiratory airways. It is triggered when the 
immune system, mainly the eosinophils, react in an anomalous way against one or 
several stimuli such as pollen, stress, pollution… This induces inflammation, irritation 
and obstruction of the airways, and complicates the breathing (AsthmaUK). Chronic 
Obstructive Pulmonary Disease (COPD) is a chronic progressive lung disease 
characterised by a non-reversible airflow obstruction. COPD exacerbations are a key 
cause of morbidity and mortality (Dretzke, et al., 2015). In England, both diseases 
suppose a huge economic burden for the NHS with the cost of COPD rising to £1.9 
billion, and £3 billion in case of asthma each year (British Lung Foundation, 2016). In 
some cases, especially in older people, asthma and COPD may overlap and converge 
in the asthma-chronic obstructive pulmonary disease overlap syndrome (ACOS) 
which shares some characteristics with asthma and COPD (Papaiwannou, et al., 2014).  
Currently, a lot of effort is put into the investigation of new therapies to treat 
those cases of chronic lung diseases where the symptoms cannot be kept under control 
with the usual preventing and relieving treatments. The development of Siglec8 
agonists which induce eosinophils apoptosis has been highlighted as a promising 
strategy to treat asthma (Ilmarinen and Kankaanranta, 2014b).  
No Siglec8 agonists have been developed before, and there are not more clues 
available in the literature about Siglec8 binders than its recently resolved structure in 
complex with the ligand 6’-Sulpho-Syalil Lewis X. Thus, that study provided some 
chemical basis for the investigation and designing of higher affinity molecules 
targeting Siglec8.  
In this work, several constructs of the Siglec8 carbohydrate binding protein 
domain were cloned, expressed and purified in a soluble way. Subsequently, the 
soluble domains were characterized by means of different biophysical techniques. 
Several low molecular weight carbohydrate and peptide ligands were designed using 
as a basis the solution state NMR Siglec8 resolved structure in complex with 6’-
Sulpho-Syalil Lewis X. Finally, the binding of those molecules to the Siglec8 Ig-like 
V-type domain was tested in solution, and dissociation constant (KD) values were 
estimated for some of the Siglec8-ligand interactions. The discovery of small 
molecules that bind the Siglec8 Ig-like V-type domains may lead to development of 
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stronger binders with therapeutic activity to treat asthma or other chronic diseases 
characterised by an anomalous eosinophilic proliferation.  
Apart from their well-known implication in asthma, eosinophils have recently 
been found in the airways, tissues, and circulation of patients with COPD, during both 
stable and disease exacerbations, and been pointed out as biomarkers and mediators 
of the COPD (Bafadhel, et al., 2017).  
This PhD project also encompassed an industrial collaboration with Mologic 
Ltd. (Bedford, UK). The protocol to produce and purify Siglec8 recombinant protein 
domains was developed at Warwick in collaboration with Mologic. Subsequently 
some of the material produced was used to generate antibodies anti-Siglec8 by 
boosting the immune response of immunised animals. Thus, those antibodies may be 
employed in the development of a diagnostic test for chronic lung disease 
exacerbations by detecting increased levels of eosinophils in patient's body fluids.
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2. Materials and methods. 
2.1 Cloning, expression and purification of Siglec8 Ig-like V-type domains. 
Strain, genotype, use and origin of all Escherichia coli bacterial strains are 
summarized in Table 2.1.  
Table 2.1. Description of all Escherichia coli strains used in this work. 
Strain Genotype Uses Reference Origin 
 
 
DH5alpha 
 
F- endA1 glnV44 thi-1 
recA1 relA1 gyrA96 deoR 
nupG Φ80dlacZΔM15 
Δ(lacZYA-argF)U169, 
hsdR17(rK- mK+), λ– 
 
General cloning and storage 
of common plasmids 
 
http://blog.addgene.or
g/plasmids-101-
common-lab-e-coli-
strains 
 
 
Laboratory stock 
(stored at   -80°C) 
 
 
BL21 (DE3) 
PlySs 
 
 
F- ompT hsdSB(rB- mB-) gal 
dcm (DE3) pLysS (CamR) 
 
BL21 host expression strain 
that expresses T7 RNA 
polymerase and also encode 
T7 lysozyme that suppresses 
basal expression of toxic 
target proteins prior to 
induction 
 
 
http://www.merckmill
ipore.com/ 
 
 
Laboratory stock 
(stored at   -80°C) 
 
Rosetta 
gami B 
(DE3) 
 
 
 
 
F– ompT hsdSB (rB– mB–) 
gal dcm lacY1 ahpC 
(DE3) gor522::Tn10 trxB 
pRARE (CamR, KanR, 
TetR) 
 
Rosetta-gami B strains 
combine the key features of 
BL21, Origami, and Rosetta 
to enhance both the 
expression of eukaryotic 
proteins and the formation 
of target protein disulfide 
bonds 
 
 
http://www.merckmill
ipore.com/ 
 
Purchased from 
Novagen (USA) 
 
A description of all cloning and expression vectors used in this work is 
included in Table 2.2. 
Table 2.2. Description of all cloning and expression vectors used in this work. 
Plasmid Features Reference Origin 
 
 
pUC-57 
 
General cloning and storage of genes vector in E. coli. It was 
purchased with the codon optimised Siglec8 synthetic gene.  
 
 
http://www.genscr
ipt.com/ 
 
Purchased from 
GeneScript 
(USA) 
 
 
 
 
pET-28a(+) 
 
 
T7 bacteriophage transcription system and expression induced 
by providing a source of T7 RNA polymerase in the host cell. N-
terminal His-Tag/thrombin cleavage site to enable removal of 
the tag after protein purification/T7-Tag configuration plus an 
optional C-terminal His-Tag sequence/kanamycin resistance 
 
 
http://www.merck
millipore.com/ 
 
 
Laboratory stock 
(stored at   -80°C) 
 
 
pET-
43.1a(+) 
 
 
 T7 bacteriophage transcription system and expression induced 
by providing a source of T7 RNA polymerase in the host cell. 
Optional N-terminal or C-terminal His-Tag/optional Nus-Tag 
for expression of peptide sequences fused/ampicillin resistance. 
 
 
http://www.merck
millipore.com/ 
 
 
Purchased from 
Novagen (USA) 
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pET151/D-
TOPO T 
 
 
T7 bacteriophage transcription system and expression 
induced by providing a source of T7 RNA polymerase in 
the host cell. N-terminal tag containing the V5 epitope and 
a 6xHis tag/TEV cleavage site to enable removal of the tag 
after protein purification/ampicillin resistance 
 
https://tools.thermofishe
r.com/content/sfs/manu
als/pettopo_man.pdf 
 
 
Purchased from 
Invitrogen (USA) 
 
All primers were supplied by Sigma Aldrich (UK) and are listed in Table 2.3, 
including the Siglec8 fragments that were amplified as well as the name of the 
restriction enzyme specific recognition sequences incorporated to ligate the PCR 
products into expression vectors. Those nucleotides complementary to the Siglec8 
gene are coloured in red, specific restriction enzyme recognition sequences and TOPO 
cloning sequences in fuchsia, spacers in grey, stop codons in black, TEV (tobacco etch 
virus protease) cleavage site in orange and non-specific extra final nucleotides in blue 
which are required for enzymatic digestion. The table also includes primers 
complementary to the T7 promoter and terminator sequences, the universal RNA 
polymerase starting and terminating sequences found in many plasmids and vectors. 
Table 2.3. All primers sequences used in this work, including incorporated restriction sites and amplified Siglec8 
fragments. Those nucleotides complementary to the Siglec8 gene are coloured in red, restriction enzymes specific 
recognition sequences and TOPO-cloning sequences in fuchsia, spacers in grey, stop codons in black, TEV 
cleavage site in orange and non-specific extra ending nucleotides in blue.  
 
Siglec8 
fragment 
 
Forward Primer  
(5’-3’) 
 
Forward 
restriction site 
 
Reverse primer  
(5’-3’) 
 
Reverse 
restriction site 
 
 
Gly40-Phe123 
 
 
 
GATATCCATATGGGC
CTGTGCGTCCATGT 
 
Nde I 
 
CTAGCTGGATCCTTA
AAAGTAAGAGCCTTT
GTCGCG 
 
Bam HI 
 
Met17-His155 
 
GATATCCATATGATG
GAAGGTGACCGCCAG
TAT 
 
Nde I 
 
ATCTAACTCGAGGCC
CTGAAAATACAGGTT
TTCGCTGCCATGGGT
CAGGGCCGTGA 
 
 
Xho I 
 
Met17-His155 
(Cys42>Ser42)  
mutagenesis  
 
 
 
 
GAAGGCCTGTCCGTC
CATGTG 
 
 
----- 
 
 
CTGAACGGTCACCAG
TTC 
 
 
----- 
 
Met17-His155 
(Cys42>Ser42) 
For TOPO 
cloning 
 
 
 
 
CACCATGGAAGGTGA
CCGCCAGTATGGT 
 
 
TOPO cloning 
sticky end 
 
 
ATGGGTCAGGGCCGT
GACGAA / 
TTAATGGGTCAGGGC
CGTGACGAA 
 
 
 
----- 
T7 Primers TAATACGACTCACTA
TAGGG 
 GCTAGTTATTGCTCA
GCGG 
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2.1.1. DNA manipulation and cloning techniques: 
Siglec 8 gene  
A codon optimised gene for expression in E. coli encoding full-length human 
Siglec8 within the cloning vector pUC57, was purchased from GenScript (USA), the 
protein sequence is shown in Figure 2.1. The gene was used as a template to amplify 
different versions of the Ig-like V-type domain by means of PCR. 
 
Figure 2.1. Siglec8 full-length protein sequence. 
Preparation of Siglec 8 DNA stocks 
E. coli DH5 alpha cells were transformed with the vector pUC57 containing 
the Siglec 8 gene. Plasmid DNA was isolated from 5 mL E. coli DH5 alpha strain 
overnight cultures using the geneJET Plasmid Miniprep kit (Thermo Scientific, 
Lithuania). The kit was used according to the manufacturer’s instructions and plasmid 
DNA was recovered in 50 μL of Elution Buffer and stored at -20°C. 
PCR 
 All PCR reactions were performed by mixing 10 μL of Phusion Buffer GC 5x, 
1 μL of 10 mM dNTPs mix and 0.5 μL of Phusion High-Fidelity DNA Polymerase 
(2,000 U/mL), all purchased from New England Biolabs (UK). Subsequently, 2.5 μL 
of both forward and reverse primers (shown in table 2.3) at a concentration of 10 mM, 
up to 10 ng of DNA plasmid template and deionised H2O were added until a total 
volume of 50 μL was reached. All reactions were performed in a Biometra T3 
Thermocycler with the following cycling conditions (Table 2.4): 
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Table 2.4. PCR programme used to amplify the Siglec8 Methionine 17-Histidine 155 fragment. 
PCR programme 
Initial Denaturalization 98 C, 30’’ 
 
32 cycles 
98 C, 10’’ 
Primers annealing Tre, 30’’ 
72 C, 30’’  
Final extension  72 C, 10’ 
Hold  4 C 
 
Agarose gel electrophoresis 
Agarose gels were prepared by dissolving 1% (w/v) agarose in TBE buffer (89 
mM Tris, 89 mM H3BO3, 20 mM EDTA, pH 8.0). 1:10,000 dilution of Safe DNA Gel 
Stain from Invitrogen (USA) was added to allow visualization of DNA. DNA samples 
were prepared by mixing 2 μL of Gel Loading Dye Purple (6x) from New England 
Biolabs (USA) and 10 μL of DNA solution. Gels were submerged in TBE buffer and 
electrophoresis was performed at 100-150 V until the dye front was at least half way 
through the gel. DNA was visualized using a UV transilluminator and photographs of 
gels were taken. 
Purification of DNA by gel extraction. 
DNA was excised from agarose gels and extracted using a QIAprep Gel 
Extraction kit from Qiagen (Germany). The kit was used according to the 
manufacturer’s instructions and DNA was recovered in 30 μL of elution buffer. 
Restriction endonuclease digestion of DNA 
 Restriction endonuclease digestion of DNA was performed according to the 
enzyme manufacturer’s instructions. Reactions were typically incubated at 37 °C for 
1 hour before being subjected to gel electrophoresis and purified with the DNA gel 
extraction kit described above. 
Ligation of fragments 
 Ligation reactions were performed using T4 DNA ligase according to the 
manufacturer’s instructions. Vector and insert were mixed in a 1:3 ratio, and typically 
incubated overnight into an ice bucket at room temperature, such that the temperature 
gradually increased from 0 degrees to room temperature. For the fragment cloned in 
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the TOPO cloning vector pET-151 (Invitrogen, USA), the TOPO cloning kit 
manufacturer’s instructions were followed. 
Sequencing of plasmid DNA  
Samples were sent for sequencing to GATC Biotech (Konstanz, Germany) 
using T7 promotor primers (shown in table 2.3). 
Mutagenesis of Siglec 8 domain Cys42 > Ser42  
 The substitution of the Siglec 8 Cys42 residue with serine (Ser42) was 
performed by making a one nucleotide mutation using the Q5 Site-Directed 
Mutagenesis Kit from New England Biolabs (USA) according to the manufacturer’s 
instructions. Primers used to introduce that mutation are shown in table 2.3. 
 
2.1.2. Growth and maintenance of E. coli: 
Media 
Luria-Bertami (LB), 2x Yeast extract and Triptone (2xYT) and minimal 9 
(M9) media were used for the aerobic growth of E. coli in liquid media.  
LB (10 g/L bacto-tryptone, 5 g/L yeast extract, 10 g/L sodium chloride, pH 
7.4) was used as a standard media and 2xYT (16 g/L tryptone, 10 g/L yeast extract, 5 
g/L sodium chloride, pH 7.4)  as well as M9 media (6 g/L Na2HPO4, 3 g/L KH2PO4, 
0.5 g/L NaCl, 1 g/L NH4Cl, 2.5 g/L glucose, 240 mg/L MgSO4, 11.2 mg/L CaCl2, 15 
mg/L ZnCl2, 15 mg/L FeCl2, 200 mg/L yeast extract and 10 mL of BME Vitamins 
Solution 100x from Sigma (USA), pH 7.4) were used to optimise the bacterial growing 
conditions and protein expression levels. LB medium with 16 % (w/v) agar was used 
for the aerobic growth of E. coli on plates.  Antibiotics were added, when necessary, 
to the following concentrations: Ampicillin 100 μg/mL, Kanamycin 50 μg/mL and 
Chloramphenicol (35 μg/mL).  
Maintenance  
For long term storage of E. coli strains and constructs generated in this study, 
glycerol stocks were prepared by adding 1 mL of 50 % glycerol to 1 mL of overnight 
culture. These were frozen immediately on dry ice and stored at -80°C. 
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Preparation of E. coli competent cells 
 A starter culture was prepared by inoculating 5 mL of LB with E. coli cells and 
incubating overnight at 37°C with shaking at 180 rpm. The next morning, 1 mL of the 
overnight culture was used to inoculate 100 mL of LB and was incubated for 1.5-3 
hours at 37°C with 180 rpm shaking. Subsequently cells were put on ice for 10 
minutes, collected by centrifugation for 3 minutes at 2,500 x g re-suspended in 10 mL 
of cold 0.1 M CaCl2 and left on ice for 20 minutes. Another centrifugation step was 
carried out for 10 minutes at 2,500 x g and the pellet was re-suspended again in 5 mL 
of cold 0.1 CaCl2 containing 15% glycerol, aliquoted in cryotubes (100 μL/tube) and 
frozen at -80°C. 
Transformation of competent E. coli cells 
 1μL of DNA plasmid solution (80-100 ng/μL) was added to 100 μL of 
competent cells and incubated on ice for 30 minutes. Subsequently a heat shock was 
applied by leaving them in a 42°C water bath for 45 seconds followed by 2 minutes 
on ice again. Then they were re-suspended in 1 mL of LB media and incubated for 1 
hour at 37°C with shaking at 180 rpm. Finally, cells were spun down, re-suspended in 
200 μL of LB, and spread on LB-agar plates supplemented with the corresponding 
selective antibiotic and incubated overnight at 37°C.   
2.1.3. Protein preparation for characterization and binding studies: 
Expression of non-isotopically labelled Siglec8 Ig-like V-type domains 
When LB media was used, 2 liters were inoculated with a 10 mL LB overnight 
culture of either E. coli BL21 PlySs or Rosetta gami B (DE3) and incubated at 37°C 
and 180 rpm shaking until an OD600 of 0.6 was reached. When 2xYT or M9 media 
were used, 2 liters were inoculated with a 10 mL LB overnight culture and incubated 
at 37°C and 180 rpm shaking until an OD600 of 2 was reached. At this stage, expression 
was induced by adding β-D-1-thiogalactopyranoside (IPTG) to a final concentration 
of 1.0 mM and cells were grown for a further 40 hours at an incubation temperature 
of 15°C. Cultures were taken then and centrifuged at 14,000 x g. 500 μL samples were 
removed before and after induction to monitor the expression by means of SDS-PAGE 
electrophoresis. 
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Optical density of culture samples 
Absorbance of cell culture samples was measured at 600 nm using a UV-vis 
spectrometer. If required, samples were diluted to an OD600 between 0.1 and 0.8 with 
the same media used for growth. Media was used as a blank for all measurements. 
Cell lysis by cell disruption 
After 40 hours of expression, cell cultures were centrifuged for 15 minutes at 
4,000xg, re-suspended in 5 mL of BugBuster Protein Extraction Reagent (Merck 
Millipore, USA) per gram of wet cells supplemented with EDTA-free protease 
cocktail inhibitor (Roche, Germany) at the manufacturer’s recommended 
concentration, and frozen at - 20°C. The same day or days after, the cell suspension 
was thawed at room temperature and passed 3 times through a cell disruptor (One 
Shot, Constant Systems Ltd., UK) at 24 poises pressure. Subsequently soluble and 
insoluble material were separated by centrifugation at 30,000 x g for 30 minutes, and 
samples of both were removed in order to determine the solubility of the protein by 
running an SDS-PAGE gel.  
SDS poly-acrylamide gel electrophoresis (SDS-PAGE) 
Acrylamide sodium dodecyl sulphate-polyacrylamide gel electrophoresis 
(SDS-PAGE) was used for the separation of proteins based on their molecular weight 
and charge. All SDS-PAGE gels were made of one stacking and one resolving layer 
which contained 4 and 12 % (v/v) of acrylamide respectively and were prepared using 
the standard Laemmli Method (Laemmli 1970). Standard running buffer (3 g/L Tris 
Base, 14.4 g/L glycine and 1 g/L SDS in H2O) provided by the Chemical Biology 
Research Facility was used. Gels were run at 125 V for 15 minutes and later at 200 V 
for 35 minutes. 
SDS-PAGE sample preparation 
 All cell culture samples were normalised with respect to the concentration of 
cells in the pre-induction sample according to their OD600 by applying the following 
relationship: 
𝑉𝑜𝑙𝑢𝑚𝑒 𝑜𝑓 𝑆𝐷𝑆 − 𝑆𝐷𝑆𝑃𝐴𝐺𝐸 𝑙𝑜𝑎𝑑𝑖𝑛𝑔 𝑏𝑢𝑓𝑓𝑒𝑟 =
𝑉𝑜𝑙𝑢𝑚𝑒 𝑜𝑓 𝑠𝑎𝑚𝑝𝑙𝑒 − 𝑂𝐷
6
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Thus, samples were diluted in the suitable volume of SDS-PAGE loading 
buffer (50 mM Tris-HCl, 100 mM dithiothreitol (DTT), 2 % (w/v) SDS, 0.1 % 
bromophenol blue and 10 % (v/v) glycerol, pH 6.8), boiled at 90°C for 5 minutes, and 
10 μL loaded per well in the gels. All cellular protein samples were prepared by means 
of the same procedure, mixing 5 μL of loading buffer and 15 μL of sample. 
SDS-PAGE gel staining 
Coomassie stained gels were immersed in 20 mL of fixing solution for 10 
minutes (50% (v/v) MeOH, 10% (v/v) Acetic Acid) and then stained in 20 mL of 
Coomassie solution (0.025% (w/v) Coomassie blue R250, 10% (v/v) MeOH) for 2 to 
4 hours. Subsequently, they were destained in a 10% (v/v) acetic acid solution until 
the bands were clearly visible. Alternatively, gels were immersed for 1 hour in 10 mL 
of the pre-made dye Instant Blue from Expedeon (UK) and distained in water.  
Western Blotting 
SDS-PAGE gels were electro-blotted onto a 0.45 nm pore size nitrocellulose 
membrane immersed in transfer buffer (25 mM Tris Base, 190 mM glycine and 20% 
methanol, pH 8.3) at 25 V for 1 hour and 30 minutes. After the transfer, the membrane 
was blocked in 5% (w/v) powdered skimmed milk dissolved in Tris-Buffered Saline 
and Tween-20 (TBST) (30mM Tris-HCl, 140mM NaCl, 3mM KCl and 0.1 % Tween-
20, pH 7.4) for 30 minutes at room temperature and subsequently washed several times 
with TBST. Later, the membrane was incubated overnight at 4°C in the same milk 
solution supplemented with 2 μL of mouse monoclonal anti-6x C-terminal His Tag 
antibody (Abcam, UK), washed again the next morning and incubated for 1 hour at 
room temperature in the milk solution supplemented with 2 μL of Goat Anti-Mouse 
IgG2c antibody with pre-adsorbed alkaline phosphatase. After several washes the 
membrane was incubated for a maximum of 15 minutes with Novex Alkaline 
Phosphatase Chromogenic Substrate (Invitrogen, USA). 
Insoluble material treatment and protein preparation for refolding 
 Insoluble material was washed several times to isolate the protein inclusion 
bodies from other cellular material. Three repeated washes were carried out by re-
suspending the insoluble material in 5 mL of wash buffer (100 mM Tris-HCl, 5 mM 
EDTA, 5 mM DTT, 2 M urea and 2 % (w/v) Triton X-100, pH 7.0) per gram of original 
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wet cells and centrifuging for 20 minutes at 30,000 x g. The fourth wash was 
performed with the same buffer prepared without Triton X-100. At this point, 
inclusion bodies were aliquoted in individual tubes containing 10 mg of dry material 
which were freeze-dried and kept at – 80 °C for further refolding. 
Refolding of Siglec8 Ig-like V-type protein domains using a drop-wise method 
Two aliquots of 10 mg washed inclusion bodies were defrosted and solubilized 
in 10 mL of protein extraction buffer (50 mM Tris-HCl, 8 M guanidine hydrochloride, 
5 mM DTT, 5 mM EDTA, pH 7.5), giving a concentration of 2 mg/mL. Subsequently, 
the solution was added drop by drop to 1 L of refolding buffer (6.05 g/L TRIS-HCl, 
43 g/L guanidine hydrochloride, 0.5 g/L reduced glutathione and 0.5 g/L oxidized 
glutathione, pH 8.5) and kept 2 hours under slow shaking with a magnetic stirrer at 
room temperature. After 2 hours, the solution was transferred to the cold room and 
kept overnight under slow shaking at 4°C.  
Purification of refolded Siglec 8 Ig-like V-type protein domains  
 After overnight refolding, the 1 L of refolding solution was centrifuged at 
2,500 x g for 10 minutes to remove any unfolded protein and other insoluble material. 
The soluble fraction was passed overnight through a 1 mL HisTrap HP nickel column 
(GE Healthcare Life Sciences, UK) using a peristaltic pump. The next day, the column 
was washed with 5 column volumes of 20 mM NaPi, 500 mM NaCl, 20 mM 
imidazole, pH 7.5 buffer, and the protein was eluted in 5 mL of 20 mM NaPi, 500 mM 
NaCl, 500 mM imidazole, pH 7.5 buffer. Subsequently, the protein solution was 
washed with a 20x volume excess of 20 mM NaPi, 500 mM NaCl, pH 7.5 buffer using 
10 kDa MWCO centrifugal concentrators (Merckmillipore, UK) to get rid of the 
imidazole.  
2.2 Biophysical characterization of the Siglec 8 Ig-like V-type domain. 
Siglec8 construct composition and physicochemical characteristics 
 The Siglec8 amino acid sequence in FASTA format was introduced as an input 
in the online software ProtParam from ExPASy (SIB). The analysis provided domain’s 
amino acid composition, molecular weight, isoelectric point, extinction coefficient and 
hydrophobicity.  
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 The Siglec8 3D-structure illustrating the distribution of different amino acid 
types was downloaded from the Protein Data Bank (Propster, et al., 2016) and loaded 
into Pymol (Pymol), where hydrophobic, hydrophilic and charged amino acids where 
manually highlighted in different colours.  
Siglec8 identity confirmation by means of tandem mass spectrometry (nano-LC-ESI-
MS/MS) 
A SDS-PAGE gel with 10 μL of pure Siglec 8 protein was run and the protein 
band was excised and sent to the Proteomics facility in the School of Life Sciences at 
Warwick for analysis. The protein was extracted from the poly-acrylamide gel band 
and enzymatically digested with trypsin. An aliquot containing 20 µL of extracted 
peptides (total sample volume 50 µl) was analysed by means of nano LC-ESI-MS/MS 
with the Ultimate 3000/Orbitrap Fusion instrumentation (Thermo Scientific) using a 
30-minute LC separation on a 25-cm column. The data were used to interrogate the 
Homo sapiens and Escherichia coli databases and the common contaminant database 
from MaxQuant. MaxQuant software was used for protein identification and Scaffold 
software for data analysis and visualise the results.  
Quantification of Siglec 8 Ig-like V-type domain concentration by UV-vis absorbance 
 After refolding and purification, the UV-vis absorbance of 50 μL of the 
resulting solution of Siglec 8 Ig-like V-type constructs in 20 mM NaPi, 500 mM NaCl, 
pH 7.5 buffer was measured between 230 and 330 nm using a Jasco V-660 
spectrophotometer. After subtracting the buffer absorbance from the protein solution, 
the intensity at 280 nm was used to calculate the domain concentration by means of 
the Beer-Lambert law using a calculated extinction coefficient of 35,535 L·mol-¹·cm-
¹.  
Siglec 8 Ig-like V-type domain fold monitored by Circular Dichroism (CD)  
A CD spectrum was recorded for a 200 μL fresh Siglec 8 Ig-like V-type domain 
sample after refolding, purification and buffer exchange into 50 mM Tris, pH 7.5, 
between 180 and 300 nm. The protein concentration was approximately 1 mg/mL. The 
instrument was a Jasco J-1500 CD Spectrometer and the measurement parameters 
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were: data pitch 0.2 nm, CD and FL scales 200 mdeg/1.0 dOD, D.I.T. 2 s, bandwidth 
2.0 nm, scanning speed 100 nm/min and 32 accumulations. 
Siglec 8 Ig-like V-type domain folding monitored by means of fluorescence 
 1 mg/mL Siglec 8 Ig-like V-type domains and lysozyme samples in 20 mM 
NaPi, 500 mM, and pH 7.5 buffer were solubilised with increasing concentrations of 
denaturing agent GdnHCl (between 0 and 2.0 M for Siglec 8 and between 0 and 3.5 
M for lysozyme). Samples were left to equilibrate for 24 h at 4°C, and the next day 
fluorescence measurements were performed for all samples using a JASCO FP-6500 
Spectro fluorometer. Samples were excited at 280 nm (Trp and Tyr excitation 
wavelength) and the emission spectra were collected between 320 and 380 nm.  
Siglec8 Ig-like V-type domain size characterization by small angle X-Ray scattering 
(SAXS) 
 Small-angle X-ray scattering (SAXS) measurements were made using a 
Xenocs Xeuss 2.0 equipped with a micro-focus Cu Kα source collimated with 
Scatterless slits. The scattering was measured using a Pilatus 300k detector with a 
pixel size of 0.172 μm x 0.172 μm. The distance between the detector and the sample 
was calibrated using silver behenate (AgC22H43O2), giving a value of 1.195(5) m. The 
magnitude of the scattering vector (q) is given by 𝑞=4𝜋sin𝜃𝜆⁄, where 2θ is the angle 
between the incident and scattered X-rays and λ is the wavelength of the incident X-
rays. This gave a q range for the detector of 0.01 Å-1 and 0.33 Å-1. Samples were 
injected into a Xenocs Low Noise Flow Cell giving a sample thickness of 1.1 mm. A 
radial integration of the 2D scattering profile was performed and the resulting data 
corrected for the absorption, sample thickness and background from the sample 
holder. Finally, the scattering intensity was then rescaled to absolute intensity using 
glassy carbon as a standard.   
The radius of gyration prediction was performed using the downloaded Siglec 
8 Ig-like V-type solution state NMR resolved structure from the Protein Data Bank 
(pdb ID 7N2A) and the software Gromacs (Gromacs). An energy minimisation setting 
water as the solvent, followed by two equilibrium simulations and a 1 ns molecular 
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dynamics simulation without position restraints were run. Subsequently, the radius 
gyration (Rg) was measured across a 1 ns trajectory.  
2.3 Exploring Siglec 8 as a therapeutic and diagnostic target. 
Design of small molecules targeting Siglec 8 Ig-like V-type domains 
Small molecules targeting Siglec 8 Ig-like V-type domains were designed 
using the chemical model of a Siglec 8-binding glycan described in the literature as a 
starting point (Propster, et al., 2016). Dry de-salted di-peptides Glu-Val, Glu-Asp, 
Glu-Leu and Glu-Phe and Glu-Pro were synthesised using FMOC chemistry and 
purified by Insight Biotechnology (UK). Both L-Phospho-Tyrosine and N-
Acetylneuraminic Acid were purchased from Sigma Aldrich (UK). Glucuronic Acid 
and D-Galactose-6-Sulphate were purchased from Carbosynth (UK). 
Siglec 8 Ig-like V-type domain biotinylation  
 Siglec 8 Ig-like V-type domain biotinylation was performed using an EZ-
LinkSulfo-NHS-LC-Biotinylation Kit with a 1:1 ratio, according to Thermo Fisher 
Scientific instructions. The total length added to the protein chain (Biotin + spacer 
arm) was 22.4 Å.  
Siglec 8-small molecule binding measurements using the Octet technology 
 Ligands were solubilised in 20 mM NaPi, 500 mM NaCl, pH 7.5 and different 
dilutions were made to achieve a range of experimental concentrations. The 
concentration of biotinylated Siglec 8 protein domain was maintained at a constant 20 
μM in the same buffer. A total volume of 250 μL per well of either protein or ligand 
were added to the Octet plate according to the experimental design described in 
Chapter 5 and the experiment was carried out using Dip and Read Streptavidin 
Biosensors (Pall ForteBio, Europe). 
 The experiment was programmed setting the following times according to 
ForteBio instructions: 60 s for the baseline, 60 s of loading, 60 s of custom (washing) 
step, 60 s for a second baseline, between 300 and 600 s for association and between 
300 and 600 s for dissociation. Data were processed by subtracting the blank spectra 
(experiment without protein and experiment without ligand) from the sample spectra 
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according to manufacturer's instructions and curves were fitted using a heterogeneous, 
local and partial model.  
Siglec 8-small molecule binding measurements using equilibrium dialysis. 
 One equilibrium dialysis device was used to test the protein-ligand binding at 
each ligand concentration. Each device has two chambers separated by a dialysis 
membrane of 5,000 kDa MWCO which allows the ligand molecules to pass from one 
compartment to the other but not the protein molecules. Ligands were solubilised in 
20 mM NaPi, 500 mM NaCl, pH 7.5 and different dilutions were made to achieve a 
range of experimental concentrations between 50 and 500 µM. The concentration of 
Siglec8 protein domains in the same buffer was maintained at a constant 50 μM 
concentration. 50 μL of 50 μM protein solution were added to one of the equilibrium 
dialysis device chambers and 50 μL of a specific concentration of ligand solution to 
the other. Each device was left to equilibrate for 2 hours at room temperature under 
gentle shaking. After equilibration, 50 μL of solution from the ligand were recovered 
to measure the ligand concentration. For each ligand concentration, another 
experiment with protein but no ligand was set up as a control. Each experiment was 
repeated for each ligand concentration at a fixed protein concentration plus a blank.
  
Quantitative solution state NMR after Siglec8-Phospho-Tyrosine equilibrium dialysis 
A volume of 50 μL was taken from each equilibrium dialysis device's ligand 
chamber and diluted with 85 μL of HPLC quality H2O and 15 μL of D2O (10% v/v) 
to reach a volume of 150 μL for solution state NMR measurements. The DDS (4,4-
dimethyl-4-silapentane-1-sulfonic acid) standard was prepared in the same way by 
diluting 50 μL of a 100 μM DDS solution with 85 μL of HPLC quality H2O and 15 
μL of D2O (10% v/v).  
One dimensional 1H NMR spectra of all samples were measured in the 700 
MHz Bruker Avance NMR spectrometer at the University of Warwick.  All spectra 
were measured using an offset (O1) of 4.719 ppm, a spectral window of 14 ppm, a 
receiver gain of 912, a 90-degree pulse of 9.00 μs, 4 dummy scans and 256 scans. 
Spectra were processed using the Topspin 3.2 software. First, a baseline 
correction was applied, subsequently all peaks were integrated using identical integral 
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regions to compare their intensities. For each concentration, the intensity of the sample 
was subtracted from the intensity of the control, ∆I (Icontrol – Isample). The ʹsampleʼ was 
the ligand solution taken from the equilibrium dialysis experiment with protein and 
the ʼcontrolʹ the ligand solution at the same concentration as the sample taken from the 
equilibrium dialysis experiment without protein. The integral of the peak belonging to 
the three DSS methyl groups was used as standard to convert ∆I into ∆C (Ccontrol – 
Csample). ∆C was used to calculate the amount of ligand bound to the protein receptor 
(Cbound = (Ccontrol – Csample) *2) and a dissociation curve was built by representing the 
initial concentration of ligand added to the chamber versus the fraction of ligand bound 
to the protein receptor (B = Cbound / Creceptor).   
Different values of the fraction of Phospho-Tyrosine bound to Siglec8 were 
represented against the different initial concentrations of Phospho-Tyrosine added to 
the equilibrium dialysis device and curves were fitted according to the Hill equation 
using the software Origin (Origin) and information about binding cooperativity and 
affinity were extracted from the obtained equation. 
Quantitative fluorescence after Siglec8-Phospho-Tyrosine equilibrium dialysis 
A volume of 50 μL was taken from each equilibrium dialysis device's ligand 
chamber and a fluorescence spectrum measured between 250 and 500 nm using a 
JASCO FP-6500 Spectro fluorometer. Samples were excited at 268 nm, which is the 
maximum absorbance wavelength of Phospho-Tyrosine. The maximum emission 
fluorescence wavelength was 297 nm and the values of fluorescence intensity at this 
wavelength were used to calculate the difference in fluorescence emission between 
sample and control (Fcontrol – Fsample). A standard solution of Phospho-Tyrosine was 
used to convert ∆F into ∆C (Ccontrol – Csample). ∆C was used to calculate the amount of 
ligand bound to the protein receptor (Cbound = (Ccontrol – Csample) *2) and a dissociation 
curve was built by representing the initial concentration of ligand added to the chamber 
versus the fraction of ligand bound to the protein receptor (B = Cbound / Creceptor). Data 
were fitted to the Hill equation using the software Origin.  
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3. Cloning, expression and purification of 
Siglec8 Ig-like V-type domains. 
3.1 Introduction to recombinant protein expression.  
A recombinant protein is a protein encoded by a gene that has been cloned in 
a cell (bacterial, yeast, mammalian cell) that supports expression of the gene, and 
translation of messenger RNA. The production of recombinant proteins in 
heterologous organisms has represented a huge advancement to produce desired 
proteins of medical or industrial interest, avoiding use of large amounts of animal or 
plant tissue otherwise required to obtain sufficient quantities of protein. Production of 
recombinant proteins first involves (Rosano and Ceccarelli, 2014; Lyons, et al., 2016) 
cloning of the gene of interest into an expression vector. A vector is a fragment of 
circular DNA provided with specific regulatory sequences that act as enhancer and 
promoter regions, leading to efficient production of the protein encoded by the inserted 
gene. This is achieved by the production of significant amount of stable messenger 
RNA, which can be translated into the protein. The vector is introduced into a suitable 
expression host, which can be prokaryotic such as bacteria, or eukaryotic as 
mammalian cells. Prokaryotic cells have a simpler structure than eukaryotic cells; their 
main differences reside in the presence of membrane-bound organelles, cell wall, 
DNA structure and the energy producer organelles, chloroplasts and mitochondria. 
The host cell is then grown to cell densities of 0.6-0.8, at which point protein 
expression is induced with a molecule that triggers transcription, typically Isopropyl 
β-D-1-thiogalactopyranoside (IPTG) if a gene is under the control of the lac operator. 
This compound mimics allolactose, a lactose metabolite which binds to the lac 
repressor sequence, taking its place and triggering gene transcription. Furthermore, 
unlike allolactose, IPTG cannot be hydrolysed by the cell and the expression of lac-
controlled genes is not inhibited during the experiment.  Once expressed, the cells are 
harvested, and the desired protein is purified.  Protein purification is required to get as 
much soluble, folded and functional protein as possible. The complexity of this step 
varies depending on whether high amounts of soluble protein are produced in the cell 
cytoplasm, if the protein levels are low, or if the protein is insoluble and aggregates 
forming inclusion bodies.   
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Many challenges can occur throughout the different steps of recombinant 
protein production, and therefore it is very important to choose the appropriate 
combination of host, vector, media and culture conditions. One of the first 
considerations is whether there are any features of the protein sequence and structure 
that could adversely affect expression and solubility (Lyons, et al., 2016). This could 
include post translational modifications, enzymatic modification of proteins during or 
after protein biosynthesis which modify an existing functional group or introduce a 
new one. Some modifications such as phosphorylation commonly regulate the activity 
of enzymes, and others like glycosylation can promote protein folding and improve 
stability. Prokaryotic cells lack the required machineries to perform them. Another 
modification is formation of disulphide bonds, established through the thiol groups of 
two cysteines, which are key protein folding features. The presence of signal peptide 
sequences should also be considered. These sequences are usually 16-30 amino acids 
in length and are present at the N-terminus of newly synthesized proteins. In 
eukaryotes, they direct the insertion of proteins into the membrane of the endoplasmic 
reticulum and subsequently, they are cleaved off. When expressing eukaryotic proteins 
in bacteria, they must not be included as they cannot be recognized and lead to 
insolubility. 
Careful consideration must also be given to the choice of expression host.   
Prokaryotic hosts (bacteria) and eukaryotic hosts (e.g. yeast, unicellular algae, 
filamentous fungi, or tumoral mammalian cell lines) have strengths and weaknesses. 
Bacteria are a very convenient option because of their easy production of large 
amounts of protein in very short times using relatively cheap and simple media, 
molecular tools and reagents. However, prokaryotes lack the enzymatic machinery to 
carry out post-translational modifications or molecular folding, thus multi-domain 
eukaryotic proteins expressed in bacteria often are non-functional or become insoluble 
as inclusion bodies. Inclusion bodies are difficult to recover and require several 
extraction steps with denaturing agents followed by protein refolding methods that 
aim to yield protein in its native conformation (often at much lower yield). Therefore, 
in those cases, yeast may be a better choice as expression hosts. Moreover, when 
human-like splicing of mRNA is required, insect or mammalian cell lines are the best 
alternative (Lyons, et al., 2016). 
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3.2 Cloning and expression of protein domains 
A protein domain is a conserved part of a given protein sequence which has a 
tertiary structure that can evolve, function and exist independently of the rest of the 
protein chain (Lyons, et al., 2016). Each domain forms a compact three-dimensional 
structure that often can be independently stable and folded. The expression of a single 
protein domain of interest as opposed to the larger, full-length protein has the 
advantages of simplified data interpretation and (potentially) simpler expression.  
However, the protein sequence must be carefully analysed for the presence of post-
translational modifications as well as inter-domain disulphide bonds. In addition, it is 
important to carefully select the sequence to be cloned to ensure that the entire domain 
is present, with no residues missing and no extra amino acids included that belong to 
the next domain. In this work the Immunoglobulin-like (Ig-like) V-type carbohydrate 
binding domain of the human membrane protein receptor Siglec8 was amplified by 
PCR using the full length SIGLEC8 synthetic gene, and subsequently cloned and 
expressed to perform ligand binding studies. 
3.3 Analysis of Siglec8 structural features 
The protein sequence and reported Siglec8 receptor structural features were 
found in the protein database ‘Uniprot’. All well delimited and characterized domains 
are shown in Figure 3.1. The receptor contains three extracellular immunoglobulin-
like domains and one cytoplasmic immunoreceptor tyrosine-based inhibitor involved 
in modulation of cellular responses (Foussias, et al., 2000). The Ig-like, V-type 
carbohydrate binding domain spans from glycine 40 to phenylalanine 123 and forms 
an inter-domain disulphide bond between the cysteines 42 and 181, and an intra-
domain disulphide bond between the cysteines 47 and 107 (Foussias, et al., 2000).  
 
Figure 3.1. Representation of Siglec8 amino acid sequence, highlighting the location of the different domains and 
disulphide bonds (Foussias, et al., 2000). 
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Classical Ig-like domains are well conserved, but they can be composed of 7-
10 β strands and differ significantly in size due to the high variability in the length of 
their loops (Smith and Xue, 1997). Thus, Ig-like domains are classified according to 
their number of β strands: C2-type domains are composed of two sheets with three 
and four antiparallel β-strands and V-type is formed of two sheets with four and five 
antiparallel β-strands (Smith and Xue, 1997) (Figure 3.2). 
 
Figure 3.2. Ig-like C2-type and Ig-like V-type domains schematic structure (Smith and Xue, 1997). 
Regarding post translational modifications, the Siglec8 receptor is 
glycosylated at asparagines 172, 249 and 267. Figure 3.3 shows a schematic 
representation of the primary, secondary and tertiary structure of Siglec8, as well as 
disulphide bonds and glycosylation positions. 
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Figure 3.3. Schematic representation of the primary, secondary and tertiary structure of Siglec8 (Foussias, et al., 
2000). 
3.4 Optimization of the production of soluble Siglec8 Ig-like V-type domain 
A codon optimised gene encoding full-length human Siglec8 protein for 
expression in E. coli within the cloning vector pUC57 was purchased, and 
complementary primers were designed to amplify the fragment corresponding to the 
Ig-like V-type ligand binding domain by means of PCR. Codon optimization is 
required to improve the efficiency of the protein translation as not all tRNAs (adaptor 
molecules that serves as physical link between mRNA and the amino acid sequence) 
coding for a specific amino acid are expressed at the same level across species. 
However, some E. coli expression strains are available with extra tRNAs that the wild-
type strains do not produce abundantly, and in some cases the optimization may not 
be required.  
In this work, three different vectors were used in order to try to improve the 
solubility and expression levels of the Siglec8 Ig-like V-type protein domain: pET-
28a(+), pET-43a(+) and pET151/D-TOPO T (pictures of the vectors sequences in 
Materials and Methods). For pET-28a(+) and pET-43a(+), primers were designed with 
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hanging non-complementary 5’-ends which introduced appropriate restriction sites 
and a stop codon (TAA), or the TEV protease cut site (ENLYFQG) when necessary. 
Figure 3.4 summarizes the Siglec8 Ig-like V-type domain cloning steps for pET 
vectors which do not belong to the TOPO cloning technology.  
 
Figure 3.4. Siglec8 Ig-like V-type domain cloning steps. A. Amplification of Siglec8 Ig-like V-type domains by 
PCR followed by double digestion with restriction enzymes. B. Double digestion of the expression vector pET 
with the same enzymes. C. Ligation reaction of the pET expression vector and the PCR products coding for the Ig-
like V-type Siglec8 domain. 
 
As mentioned above, different constructs of the Siglec8 Ig-like V-type domain 
were cloned in three different vectors in order to try to optimise expression levels 
and/or solubility. Initially, the amino acid sequence encoding only the Siglec8 Ig-like 
V-type domain from Gly40 to Phe123 was amplified and cloned into pET-28(a+), but 
no overexpression was achieved. A literature search of all members of the human 
Siglec family whose Ig-like V-type domains have been overexpressed in bacteria 
(Siglecs5, 7, 8 and 9) revealed that all constructs encompassed an equivalent region of 
the receptors and included some extra inter-domain amino acids (Barb, et al., 2013; 
Propster, et al., 2015). A further BLAST sequence alignment of Siglecs5, 7, 8 and 9 
revealed high amino acid sequence conservation (Figure 3.5).  
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Figure 3.5. Siglecs5, 7, 8 and 9 BLAST alignments of the previously cloned and expressed domains highlighted in 
different colours. The BLAST was performed with UniProt (Barb, et al., 2013; Propster, et al., 2015). 
Therefore, the region encoding Siglec8 Ig-like V-type domain residues from 
Met17 to His155, the Siglec8 region that was successfully expressed by Propster and 
co-workers (Propster, et al., 2015), was amplified and cloned into pET-43(a+) and 
pET-151 TOPO. Different combinations of E. coli bacterial strains, culture media, 
IPTG concentrations, additives, temperatures and growth times were tested to try to 
optimise expression levels and/or solubility of the different constructs. 
An overview of all trials and optimization steps, in chronological order, is 
summarized below in Table 3.1, and discussed in more detail in the following sections. 
Table 3.1. Different steps followed to clone and express Siglec8 Ig-like V-type domain chronologically ordered. 
Siglec8 fragment Vector Experiment Outcome 
Gly40-Phe123 pET-28(a+) Cloning Domain was cloned.  
Gly40-Phe123 pET-28(a+) Expression Domain did not express. 
Met17-His155 pET-43(a+) Cloning Domain was cloned. 
Met17-His155 pET-43(a+) Expression and 
solubility 
Domain was expressed at low levels. 
It was soluble but formed oligomers. 
Met17-His155 pET-43(a+) Mutagenesis Unpaired Cys42 was substituted by Ser42 to 
avoid oligomerization. 
Met17-His155 
(Cys42>Ser42) 
pET-43(a+) Expression and 
solubility 
Domain was expressed at low levels. 
It became insoluble. 
Met17-His155 
(Cys42>Ser42) 
pET-43(a+) Solubility 
optimization 
Domain remained been insoluble. 
 
Met17-His155 
(Cys42>Ser42) 
pET151/D-
TOPO T  
Cloning Domain was cloned. 
 
Met17-His155 
(Cys42>Ser42) 
pET151/D-
TOPO T  
Expression and 
solubility 
Domain was expressed at high levels with 
some extra amino acids at the end (a Cys 
included). 
It was still insoluble. 
Met17-His155 
(Cys42>Ser42) 
pET151/D-
TOPO T  
Mutagenesis Stop codon (TAA) was introduced after 
His155 to remove extra amino acids. 
Met17-His155 
(Cys42>Ser42) 
pET151/D-
TOPO T  
Expression and 
solubility 
Domain was expressed at high levels. 
It was still insoluble. 
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Siglec 8 Gly40-Phe123 cloning into pET-28(a+) 
Figure 3.6 shows the agarose gel (1% w/v) for the amplified DNA fragment 
encoding residues Gly40 to Phe123. Lane 1 contains the standard DNA ladder, lanes 
2 and 3 contain the 279bps blunt ended DNA fragment, and lanes 4 and 5 contain the 
same fragment after Bam HI and Nde I double digestion (265 bps), before and after 
purification ready for cloning. 
                                                   
Figure 3.6. Amplified 279 bps blunt ended DNA fragment encoding Gly40-Phe123 (lanes 2 and 3) and same 
fragment of 265 bps after double digestion with Nde I and Bam HI (lanes 4 and 5). The first lane corresponds to 
the ladder Middle Range (Life Technologies) with 5000-2000-850-400-100 bps long fragments from top to bottom. 
Figure 3.7 displays the 1% (w/v) agarose gel of the pET-28(a+) vector (6,829 
bps long) after single and double digestion. Lane 3 corresponds to the 6,829bps 
linearized vector after single digestion with Bam HI. Lane 2 shows the two fragments 
of 1,500 and 5,329 bps with cohesive ends after Nde I and Bam HI double digestion. 
The longer fragment (5,329 bps) with all sequences required for expression was 
subsequently purified before insertion of the Siglec8 domain. 
 
Figure 3.7. 1% (w/v) agarose gel demonstrating single (Bam HI, lane 3) and double digestion (Bam HI, Nde I, lane 
2) of pET-28(a+). The first lane corresponds to the ladder Middle Range (Life Technologies) with 5000-2000-850-
400-100 bps long fragments from top to bottom.  
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The gene encoding the Siglec8 fragment Gly40 – Phe123 (279 bps) was ligated 
into pET-28(a+) and resulting colonies were screened for the presence of the inserted 
gene by means of colony PCR. Figure 3.8 shows the agarose gel containing the 
different PCR reactions after ligation into pET-28(a+). Lanes 2, 4, 6, 7 and 14 
confirmed the insertion of the 279bps domain into the plasmid pET-28(a+). Those 
plasmids which gave a positive result in the colony PCR were sequenced to check that 
frame, sequence and genetic construction were all correct. All PCR positive plasmids 
contained the correct genetic construction. An example of the sequencing data is 
shown in Figure 3.9. The fragment contained an N-terminal 6 x His-tag followed by a 
thrombin protease site. The starting methionine was introduced by the Nde I restriction 
site and the stop codon was introduced with the PCR primer immediately following 
the last amino acid Phe123. 
 
Figure 3.8. PCR colonies. The first lane corresponds to the ladder Middle Range (Life Technologies) with 5000-
2000-850-400-100 bps long fragments from top to bottom. The rest are PCRs carried out using plasmid preps 
which came from different bacterial colonies transformed with ligation reaction of pET-28(a+) and the fragment 
Gly40-Phe123. Colonies from lanes 2, 4, 6 and 14 were positive for the 279 bps insert.                                                      
 
Figure 3.9. Sequencing result for one of the positive PCR colonies of Siglec8 Gly40-Phe123 cloned into pET-
28(a+). The N-terminal 6xHis-Tag and the thrombin site as well as the Nde I and Bam HI cloning sites are 
highlighted.  
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Expression of Siglec8 Gly40 - Phe123 cloned into pET-28(a+) 
Figure 3.10 shows the SDS-PAGE analyses of E. coli BL21 PlySs cell cultures 
transformed with the Siglec8 Gly40-Phe123 Ig-like V-type domain in the vector pET-
28(a+). Four different IPTG concentrations and growth temperatures were tested: 
37°C and 0.1 mM IPTG, 37°C and 0.5 mM IPTG, 15°C and 0.1 mM IPTG; and 15°C 
and 0.5 mM IPTG; samples were collected immediately prior to induction and 2, 4, 5, 
22 and 24 hours after induction. No expression of the 11.86 kDa Ig-like V-type domain 
was observed at any of those conditions. 
 
Figure 3.10. SDS-PAGE gels belonging to the BL21 PlySs cultures grown in LB and transformed with pET-28a 
(+) and the insert Siglec8 Gly40-Phe123. From left to right cultures were performed at 37°C induced with 0.1mM 
IPTG, 37°C induced with 0.5mM IPTG, 15°C induced with 0.1mM IPTG and 15°C induced with 0.5mM IPTG. 
For each condition samples were taken out before and 2, 4, 5, 22 and 24 hours after induction. All samples contained 
100mM DTT. 
At this stage, the expression and purification of the Siglec 8 Ig-like V-type 
domain was published (Propster, et al., 2015). Based on that paper, together with a 
literature search and a sequence BLAST of all Siglec Ig-like V-type domains cloned 
and expressed in bacteria until that time (5, 7, 8 and 9), I decided to clone the same 
fragment and use the same vector as the authors used. An alignment of the Siglec5, 7, 
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8 and 9 Ig-like V-type domains sequences is shown in Figure 3.9 and revealed high 
amino acid sequence conservation and that all authors produced equivalent regions of 
the domain (Barb, et al., 2013; Propster, et al., 2015)Therefore, this new study 
(Propster, et al., 2015) was taken as reference, and the amino acid sequence encoding 
the Siglec8 Ig-like V-type domain from Met17 to His155 was amplified and cloned 
into pET-43(a+).  
Siglec8 Met17-His155 cloning into pET-43(a+) 
Figure 3.11 shows the agarose gel (1% w/v) for the amplified, blunt ended 
468bps DNA fragment which encodes for the Siglec8 Ig-like V-type domain from 
Met17 to His155 (lane 2). The second band in lane 2 below 100 bps corresponds to 
the primers used for PCR amplification. The same fragment of 454 bps with cohesive 
ends after Nde I and Xho I double digestion is shown in lane 3 and after purification 
ready for cloning in lane 4. 
 
Figure 3.11. Amplification of DNA fragment encoding Met17-His155, and subsequent double digestion. Lane 1: 
Middle Range DNA ladder (Life Technologies) whose fragments of known sizes are 5000-2000-850-400-100 base 
pairs. Lane 2: PCR amplified blunt ended product, with a theoretical size of 468 bps. Lanes 3 and 4: product after 
double digestion with Nde I and Xho I restriction enzymes (theoretical size of 454 bps). 
The 7,275bps pET-43(a+) vector singly digested with Nde I (Figure 3.12, lane 
1) and doubly digested with Nde I and Xho I (lanes 2 and 3) giving rise to two 
fragments of 1,787 and 5,488 bps and cohesive ends. The longer fragment was 
subsequently purified ready for ligation of the gene encoding the Siglec8 domain. 
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Figure 3.12. 1% agarose gel demonstrating pET-43(a+) single Nde I digestion of 7,275 bps long (lane 1) and the 
two fragments of 1,787 and 5,488 bps long after double digestion with Nde I and Xho I (Lanes 2 and 3). 
The gene encoding the Siglec8 fragment Met17-His155 (454 bps) was ligated 
into pET-43(a+) and resulting colonies were screened for the presence of the inserted 
gene by means of colony PCR. Figure 3.13 shows the agarose gel containing the 
different PCR reactions after ligation into pET-43(a+). Lanes 8, 11 and 13 confirmed 
the insertion of the 454bps fragment into the plasmid pET-43(a+). Those plasmids 
which gave a positive result in the colony PCR were sequenced to check that frame, 
sequence and genetic construction were all correct. All positive plasmids contained 
the correct genetic construction. An example of the sequencing data is shown in Figure 
3.14. The fragment contained a C-terminal 6 x His-tag preceded by a TEV protease 
site.  
 
Figure 3.13. PCR colonies. From left to right the first lane corresponds to the Middle Range ladder and the rest are 
PCRs carried out using plasmid preps which came from different bacterial colonies transformed with ligation 
reaction of pET-43 a(+) and the fragment Met17-His155. Colonies from lanes 8, 11 and 13 showed the presence 
of the 444bps fragment. 
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Figure 3.14. Sequencing results pET-43(a+) with Met17-His155 Siglec8 insert and TEV site between Nde I and 
Xho I. 
Expression and solubility of Siglec8 Met17-His155 cloned in pET-43(a+) 
Figures 3.15, 3.16, 3.17 and 3.18 show the SDS-PAGE and Western Blot 
analyses of E. coli BL21 PlySs cell cultures transformed with the Siglec8 Met17-
His155 Ig-like V-type domain in the vector pET-43(a+). Western Blot was carried out 
in two steps using a mouse anti-C-terminal 6x-HisTag primary monoclonal antibody 
and a goat anti-mouse IgG2c (immunoglobulin G2c) secondary antibody with the 
alkaline phosphatase (AP) enzyme pre-adsorbed. The presence of antibody attached 
to the protein was revealed using an AP chromogenic substrate.  
Four different IPTG concentrations and growth temperatures were tested: 37°C 
and 0.1 mM IPTG, 37°C and 0.5 mM IPTG, 15°C and 0.1 mM IPTG; and 15°C and 
0.5 mM IPTG; and samples were removed before, 2, 4 and 6 hours after induction 
when cultures were performed at 37°C, and before, 2, 4, 7, 22, 30 and 34 hours after 
induction when cultures were performed at 15°C.  
At 37°C and 2 hours post-induction, a band migrating at an approximate 
molecular weight of 72 kDa was observed in both SDS-PAGE and Western Blot 
(Figures 3.15 and 3.16). However, this size was much larger than the expected 18.24 
kDa molecular weight, suggesting strong aggregation into tetramers or even larger 
aggregates, despite of the addition of 100 mM DTT to the SDS-PAGE sample. At 
15°C and 2 hours post-induction with 0.5 mM IPTG, a faint band migrating between 
the 17 and 20 kDa markers was observed (Figure 3.17). This is in good agreement 
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with the expected molecular weight of 18.24 kDa for the Ig-like V-type domain, and 
the band became more intense at longer expression times but was still very faint after 
34 hours of expression, and the band was not observed in the Western Blot (Figure 
3.18). 
 
Figure 3.15. SDS-PAGE gels belonging to the BL21 PlySs cultures grown in LB and transformed with pET-43a 
(+) and the insert Siglec8 Met17-His155. From left to right cultures were performed at 37°C induced with 0.1mM 
IPTG and 37°C induced with 0.5mM IPTG. For each condition samples were taken out before and 2, 4 and 6 hours 
after induction. All samples contained 100mM DTT. 
 
 
Figure 3.16. Western Blot belonging to the BL21 PlySs cultures grown in LB and transformed with pET-43a (+) 
and the insert Siglec8 Met17-His155. From left to right cultures were performed at 37°C induced with 0.1mM 
IPTG and 37°C induced with 0.5mM IPTG. For each condition samples were taken out before and 2, 4 and 6 hours 
after induction. All samples contained 100mM DTT. 
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Figure 3.17. SDS-PAGE gels belonging to the BL21 PlySs cultures grown in LB and transformed with pET-43a 
(+) and the insert Siglec8 Met17-His155. From left to right cultures were performed at 15°C induced with 0.1mM 
IPTG and 15°C induced with 0.5mM IPTG. For each condition samples were taken out before and 2, 4, 7, 22, 30 
and 34 hours after induction. All samples contained 100mM DTT. 
 
Figure 3.18. Western Blot belonging to the BL21 PlySs cultures grown in LB and transformed with pET-43a (+) 
and the insert Siglec8 Met17-His155. From left to right cultures were performed at 15°C induced with 0.1mM 
IPTG and 15°C induced with 0.5mM IPTG. For each condition samples were taken out before and 2, 4, 7, 22, 30 
and 34 hours after induction. All samples contained 100mM DTT. 
At this stage, the strain E. coli Rosetta gami B (DE3) was purchased taking 
reference from previous published work (Propster, et al., 2015). The strain’s genotype 
is described in detail in the Bacterial strains section (Materials and Methods). In brief, 
mutations in enzymes Glutathione and Thioredoxin reductases facilitate the formation 
of disulphide bonds between cysteines in the bacterial cytoplasm and thus, protein 
folding. Furthermore, the strain is provided with those genes encoding E. coli rare 
codon tRNAs, which enhances translation of mRNA transcribed from genes belonging 
to other species.  
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Figures 3.19 and 3.20 show the SDS-PAGE gels analyses performed using E. 
coli Rosetta gami B (DE3) cell cultures transformed with the Siglec8 Met17-His155 
Ig-like V-type domain cloned in the vector pET-43(a+). Four different IPTG 
concentrations and growth temperatures were tested in LB media: 37°C and 0.1 mM 
IPTG, 37°C and 0.5 mM IPTG, 15°C and 0.1 mM IPTG; and 15°C and 0.5 mM IPTG. 
Samples were collected before and 2, 4, 24, 30 and 38 hours after induction. In all 
cases, a band migrating between the 16.6 and 25 kDa markers was observed, in good 
agreement with the expected mass of 18.24 kDa for the Siglec8 Ig-like V-type domain. 
However, the band was still very faint, suggesting low expression levels. 
 
 
Figure 3.19. SDS-PAGE gels belonging to the E. coli Rosetta gami B (DE3) cultures grown in LB and transformed 
with pET-43a (+) and the insert Siglec8 Met17-His155. From left to right cultures were performed at 37°C induced 
with 0.1mM IPTG and 37°C induced with 1.0mM IPTG. For each condition samples were taken out before and 2, 
4, 24, 30 and 38 hours after induction. All samples contained 100mM DTT. 
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Figure 3.20. SDS-PAGE gels belonging to the E. coli Rosetta gami B (DE3) cultures grown in LB and transformed 
with pET-43a(+) and the insert Siglec8 Met17-His155. From left to right cultures were performed at 15°C induced 
with 0.1mM IPTG and 15°C induced with 1.0mM IPTG. For each condition samples were taken out before and 2, 
4, 24, 30 and 38 hours after induction. All samples contained 100mM DTT. 
Since NMR studies require large quantities of stable 15N, 13C and/or 2H isotope 
labelled proteins, expression in minimal media (M9) was also checked and four 
different 1 L cultures of E. coli Rosetta gami B (DE3) transformed with the construct 
were grown under a variety of conditions: 37°C and 0.1 mM IPTG; 37°C and 1.0 mM 
IPTG; 15°C and 0.1 mM IPTG; and 15°C and 1.0 mM IPTG. Both SDS-PAGE and 
Western Blot analyses were carried out with samples removed before and 2, 4 and 24 
hours after induction, and these results are shown in Figures 3.21 and 3.22. In all cases 
apart from the culture grown at 15°C and induced with 0.1 mM IPTG, a band migrating 
between the 17 and 25 kDa standards was observed in both SDS-PAGE and in the 
Western blot strongly suggesting this band belonged to the 18.24 kDa Siglec8 Ig-like 
V-type domain. Low expression levels were still observed and indicated that the yield 
is similar in both LB and M9 media.  
Chapter 3 – Cloning, expression and purification 
72 
 
 
Figure 3.21. SDS-PAGE gels belonging to the E. coli Rosetta gami B (DE3) cultures grown in M9 media and 
transformed with pET-43a(+) and the insert Siglec8 Met17-His155. From left to right cultures were performed at 
37°C induced with 0.1mM IPTG, 37°C induced with 1.0mM IPTG, 15°C induced with 0.1mM IPTG and 15°C 
induced with 1.0mM IPTG. For each condition samples were taken out before and 2, 4, and 24, 30 hours after 
induction. All samples contained 100mM DTT. 
 
 
Figure 3.22. Western Blot belonging to the E. coli Rosetta gami B (DE3) cultures grown in M9 media and 
transformed with pET-43a(+) and the insert Siglec8 Met17-His155. From left to right cultures were performed at 
37°C induced with 0.1mM IPTG, 37°C induced with 1.0mM IPTG, 15°C induced with 0.1mM IPTG and 15°C 
induced with 1.0mM IPTG. For each condition samples were taken out before and 2, 4, and 24, 30 hours after 
induction. All samples contained 100mM DTT. 
 
After 30 hours, the culture grown at 15°C and induced with 1.0 mM IPTG was 
spun down and cells were lysed using a cell disruptor. Soluble and insoluble materials 
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were separated by centrifugation, and the soluble fraction was passed through a Nickel 
NTA column. Figure 3.23 shows the SDS-PAGE and the Western Blot analyses of the 
different elution fractions collected from the Nickel column (flow through, washes 
and elution steps with increasing concentration of imidazole). A very faint band above 
46 kDa was observed in the elution steps containing 332-500 mM imidazole (lanes 9 
to 14), indicating a low concentration of soluble protein and oligomerization of the 
domains, probably into trimers (54.72 kDa).  
 
 
Figure 3.23. Lane 1 belongs to the protein ladder. Lane 2 consists in just binding buffer. Lanes 3 and 4 
belong to washes with binding buffer. Lanes from 5 to 25 belong to the flow through with a linear 
increasing imidazole concentration: 20, 44, 68, 92, 116, 140, 164, 188, 212, 236, 260, 284, 308, 332, 
356, 380, 404, 428, 452, 476 and 500 mM respectively. 
To eliminate oligomer formation, the Siglec8 Cysteine residue located in 
position 42 (Cys42) which forms an inter-domain disulphide bond with Cys181 (not 
Chapter 3 – Cloning, expression and purification 
74 
 
included in the cloned construct), was substituted by a Serine (Ser42) in order to avoid 
the formation of incorrect disulphide bonds and/or oligomers via this unpaired Cys 
(Propster, et al., 2015). 
Siglec8 Met17-His155 (Cys42 > Ser42) mutagenesis 
 Primers were designed to mutate Cys42 to a serine within the Siglec8 Met17-
His155 Ig-like V-type domain using a Site-Directed Mutagenesis Kit. The pET-43 
(a+) plasmid containing the wild-type domain sequence was used as a template. Figure 
3.24 shows the sequencing results for the Siglec8 Met17-His155 domain mutated at 
position 42 with the substitution Cys42>Ser42. The fragment still contained the same 
features: A C-terminal 6 x His-tag coming after a TEV protease cutting site. 
 
Figure 3.24. Sequencing results for the Siglec8 Met17-His155 mutated domain with a Cys42>Ser42 substitution 
cloned into pET-43(a+). 
 
Expression and solubility of Siglec8 Met17-His155 (Cys42>Ser42) mutated domain 
cloned into pET-43(a+) 
Figures 3.25 and 3.26 show the SDS-PAGE and Western Blot performed for 
four different M9 cultures of E. coli Rosetta gami B (DE3) transformed with the 
construct pET-43(a+), Siglec8 Met17-His155 (Cys42>Ser42). Samples were removed 
before and 2 and 7 hours after induction in case of both cultures grown at 37ºC and 
induced with 0.1 and 1.0 mM IPTG; samples were removed before, 2 and 24 hours 
after induction for cultures grown at 15 ºC and induced with 0.1 and 1.0 mM IPTG. A 
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band migrating just above the 17 kDa marker, belonging to the 18.19 kDa mutated 
protein domain, was observed in all cases, even in the pre-induction samples. 
However, the expression levels still were not high.  
 
Figure 3.25. SDS-PAGE gel of samples from four E. coli Rosetta gami B (DE3) cultures performed in M9 media 
at 37ºC and induced with 0.1 mM IPTG, 37ºC and 1.0 mM IPTG, 15ºC and 0.1 mM IPTG; and 15ºC and 1.0 mM 
IPTG. Samples were taken out before and at different times after induction. All of them contained 100 mM DTT. 
 
Figure 3.26.  Western Blot of samples from four E. coli Rosetta gami B (DE3) cultures performed in M9 media at 
37ºC and induced with 0.1 mM IPTG, 37ºC and 1.0 mM IPTG, 15ºC and 0.1 mM IPTG; and 15ºC and 1.0 mM 
IPTG. Samples were taken out before and at different times after induction. All of them contained 100 mM DTT. 
 
After expression, cell cultures were spun down, re-suspended in lysis buffer 
and lysed using a cell disruptor to break the cells and release all their contents. Protease 
cocktail inhibitor was added to minimise protein degradation. Subsequently, the 
suspension was spun down to separate soluble and insoluble material. The lanes 
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labelled as “Sup” and “Pellet”, correspond to the soluble and insoluble material 
respectively, obtained after cell disruption and centrifugation. Soluble proteins stayed 
solubilised in the supernatant and the insoluble proteins formed part of the pellet. 
Figure 3.27 shows the SDS-PAGE and Western Blot analyses for E. coli Rosetta gami 
B (DE3) cells grown in LB at 15°C and induced with 1.0 mM IPTG. Along with the 
pre-induction and post-induction samples, supernatant and pellet samples were 
included and showed that most of the protein was in the pellet and insoluble, likely 
forming inclusion bodies. A very small amount of protein was soluble but could not 
be seen in the SDS-PAGE gel. The Western Blot also revealed some basal expression 
before induction, which could be interfering with the production of soluble post-
induction protein. 
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Figure 3.27. SDS-PAGE gel and Western Blot of samples from an E. coli Rosetta gami B (DE3) LB culture 
overexpressing Siglec8 Met17-His155 (Cys42 > Ser42) in pET-43(a+) performed at 15ºC and induced with 1.0 
mM IPTG. The first three lanes correspond to the Protein Ladder, supernatant and pellet respectively, after 
expression and disruption. The last three samples were taken out before and at different times after induction. All 
of them contained 100 mM DTT. 
 
Optimization of the solubility of Siglec8 Met17-His155 (Cys42>Ser42) mutated 
domain cloned into pET-43(a+) 
The addition of 1% (w/v) of glucose sometimes can eliminate the basal 
expression before induction, by lowering the cellular cAMP levels, which stimulates 
the lacUV5 promoter in DE3 strains. Thus, cellular collapse due to accumulation of 
protein in the cytoplasm is avoided.  To see if this had an impact on expression levels, 
three cultures were grown at 15, 25 and 37°C with the addition of 1% (w/v) glucose 
to the LB before transferring the cells to M9 media and inducing expression. Figure 
Chapter 3 – Cloning, expression and purification 
78 
 
3.28 displays the SDS-PAGE gel and Western Blot analyses of the soluble and 
insoluble material from those cultures. Although the basal expression in the pre-
induction sample was eliminated, the Siglec8 Ig-like V-type domain was still in the 
pellet after expression and cell disruption. In the Western Blot, only at 15°C, a very 
faded band could be observed in the lane belonging to the supernatant, suggesting a 
very small improvement in the solubility. This improvement may be due to the fact 
that, at low temperatures, the speed of cell metabolism is slower and protein 
aggregation is less likely. Although the expression levels improved, the protein 
domain solubility remained very low. 
 
Figure 3.28. SDS-PAGE gel and Western Blot of pellet and supernatant samples from three E. coli Rosetta gami 
B (DE3) M9 cultures overexpressing Siglec8 Met17-His155 (Cys42 > Ser42) domain performed at 15, 25 and 
37C°. All cultures were supplemented with 1% (w/v) of glucose before expression induction.  
 
A second attempt to improve the domain solubility was carried out using the 
GroEL/ES chaperone system (Houry, 2001). Chaperones are protein systems which 
assist the proper folding of target proteins, when they are synthesized on the ribosome, 
as well as the maintenance of pre-existing ones in a stable conformation. They are 
necessary for cell viability under both normal and stress conditions. The E. coli Hsp 
60 chaperone system assists in the folding of folding intermediates with exposed 
hydrophobic surfaces, avoiding their aggregation and the formation of inclusion 
bodies. It consists of GroEL and its cofactor GroES. GroEL is an oligomer composed 
of two rings with seven 57 kDa subunits each, which has an inner cavity were the 
protein intermediates are folded. GroES is a complex of seven units of a 10 kDa 
monomer. The system is used in molecular biology to assist folding of recombinant 
proteins by co-expressing both GroEL/ES system and the recombinant protein. Figure 
3.29 summarizes the GroEL/ES reaction cycle, where initially one GroEL ring in 
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‘open’ or trans conformation, captures a non-native substrate protein. Subsequently, 
ATP binding induces that GroEL ring conformational change into cis, enabling GroES 
to bind. This releases the substrate into the cavity, and the ATP molecule is hydrolysed 
leading to the binding of another ATP to the other unoccupied, trans GroEL ring. 
Finally, the binding induces the releasing of GroES from the complex, and the 
substrate into the cell. 
 
Figure 3.29. Schematic summary of GroEL/ES reaction cycle, assisting protein folding. 
Two E. coli Rosetta gami B (DE3) 1L LB cultures were transformed with both 
Siglec8 domain Met17-His155 (Cys42>Ser42) cloned into pET-43(a+), and 
GroEL/ES system cloned into pET-28(a). All gene expression was under the control 
of the lac operon. Cultures were grown at 37ºC and 15 ºC respectively, and both 
induced with 1.0 mM IPTG. Samples were removed before and 4 hours after induction 
for cells grown at 37ºC, and before, 4 and 40 hours after induction for cells grown at 
15ºC. Cell cultures were spun down, cells were lysed, and soluble and insoluble 
material was separated by centrifugation. Figures 3.30 and 3.31 show the SDS-PAGE 
gel and Western Blot analyses corresponding to those samples. In the SDS-PAGE gel, 
insoluble GroEL 57 kDa subunits (highlighted with a red arrow) were seen in the 
pellet, and soluble GroES 10 kDa subunits were observed in the supernatant. However, 
neither the SDS-PAGE gel nor the Western Blot show any trace of Siglec8 Met17-
His155 (Cys42>Ser42) expression. 
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Figure 3.30. SDS-PAGE gel of E. coli Rosetta gami B (DE3) cell cultures transformed with both pET43-a(+) vector 
with the Siglec8 Ig-like V-type domain (18.10 kDa) and GroEL/ES (57 and 10 kDa subunits) cloned into pET28(a). 
Cells were grown in 1L of LB at 15 and 37ºC respectively, and expression was induced with 1.0 mM IPTG. Samples 
were taken out before, 4 (and 40) hours after expression induction; soluble and insoluble materials were also 
included. 100 mM DTT was added to all samples. 
 
Figure 3.31. Western Blot of E. coli Rosetta gami B (DE3) cell cultures transformed with both pET43-a(+) vector 
with the Siglec8 Ig-like V-type domain (18.10 kDa) and GroEL/ES (57 and 10 kDa subunits) cloned into pET28(a). 
Cells were grown in 1L of LB at 15 and 37ºC respectively, and expression was induced with 1.0 mM IPTG. Samples 
were taken out before, 4 (and 40) hours after expression induction; soluble and insoluble materials were also 
included. 100 mM DTT was added to all samples. 
The same mutated domain, Siglec8 Met17-His155 (Cys42 > Ser42), was 
cloned into a new vector, pET151/D-TOPO T, aiming to improve both yield and 
solubility. 
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Siglec8 Met17-His155 cloning (Cys42>Ser42) mutated domain cloning into 
pET151/D-TOPO  
Figure 3.32 shows the agarose gel (1% w/v) for the amplified DNA fragment 
which encodes the blunt ended 421 bps Siglec8 Ig-like V-type domain from Met17 to 
His155 (Cys42>Ser42) (lanes 1, 2 and 3), ready to clone using the pET151/ 
Directional TOPO cloning vector. The domain was amplified by means of PCR using 
the pET-43a (+) vector as template and complementary primers. 
 
Figure 3.32. Siglec8 Ig-like V-type domain from Met17 to His155 blunt ended DNA fragment amplified by PCR 
ready to clone into the pET151/D-TOPO T kit. 
 
Figure 3.33 shows the sequencing results for the domain cloned into the 
pET151/D-TOPO vector. The fragment contained an N-terminal 6  His-Tag followed 
by a TEV site and eight extra amino acids at the C-terminus: KGELRSGC. The C-
terminal amino acid was a cysteine which could be used for protein immobilization by 
means of thiol coupling. However, in this case it may take part in the formation of 
undesirable disulphide bonds and enhance protein domain aggregation. 
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Figure 3.33. Sequencing results for the Siglec8 Met17-His155 Cys42>Ser42 domain cloned into the 
pET151/D-TOPO vector with some extra amino acids at the end (KGELRSGC). 
 
Expression and solubility of Siglec 8 Met17-His155 (Cys42>Ser42) mutated domain 
cloned into pET151/D-TOPO T with the extra C-terminal amino acids (KGELRSGC) 
Figure 3.34 shows the SDS-PAGE gel performed to two different 1 L E.  coli 
Rosetta gami B (DE3) cultures transformed with the construct pET151/D-TOPO T, 
Siglec8 Met17-His155 (Cys42>Ser42) with extra C-terminal amino acids 
(KGELRSGC). Both were performed at 15° C and induced with 1.0 mM IPTG. The 
first one was performed in 2xYT media, and the second one in M9 media. Samples 
were taken out before, and 40 hours after expression induction. At 40 hours post-
induction, a thick band migrating between the 15 and 25 kDa markers was observed 
and is in good agreement with the mass of the new construct (20.61 kDa). The 
expression levels of the domain cloned in the pET151/D-TOPO T vector improved 
significantly in both media in comparison with the other constructs. However, the 
protein domain was still insoluble. 
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Figure 3.34. SDS-PAGE performed to E. coli Rosetta gami B (DE3) cell cultures grown in M9 and 2xYT media at 
15°C for 40 hours. Samples were taken out before expression induction, 40 hours after and to both soluble and 
insoluble fractions after cell disruption and centrifugation. 
 
 Considering the possibility that the non-native, C-terminal cysteine could 
affect the domain folding and/or aggregation, a STOP codon was introduced 
immediately following His155. 
Introduction of a STOP codon (TAA) following His155 of Siglec8 Met17-His155 
(Cys42>Ser42) cloned into pET151/D-TOPO 
Figure 3.35 shows the sequencing results for the domain cloned into the 
pET151/D-TOPO vector with a STOP codon introduced after His155 using the Q5 
Site-Directed Mutagenesis Kit. The fragment still contained an N-terminal 6  His-
Tag followed by a TEV site. 
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Figure 3.35. Sequencing results for the Siglec8 Met17-His155 Cys42>Ser42 domain cloned into the pET151/D-
TOPO vector. 
Expression and solubility of Siglec8 Met17-His155 (Cys42>Ser42) domain cloned 
into pET151/D-TOPO T  
Figure 3.36 shows the SDS-PAGE analysis of a 1 L E. coli Rosetta gami B 
(DE3) LB culture, grown at 15° C and induced with 1.0 mM IPTG. Samples were 
taken out before, 40 hours after expression induction and from different dilutions of 
soluble and insoluble material. At 40 hours, a thick band migrating just below the 20 
kDa standard was clearly distinguished, and likely to belong to the 19.82 kDa Met17-
His155 (Cys42>Ser42) construct. The expression levels of the Siglec8 Ig-like V-type 
Met17-His155 (Cys42>Ser42) domain remained constant after the deletion of the 
eight extra amino acids (KGELRSGC), and there was no improvement in the domain’s 
solubility. 
Chapter 3 – Cloning, expression and purification 
85 
 
 
Figure 3.36. SDS-PAGE performed to E. coli Rosetta gami B (DE3) cell cultures grown in LB media at 15°C for 
40 hours. Samples were taken out before expression induction, 40 hours after and to both soluble and insoluble 
fractions after cell disruption and centrifugation. 
After all the above attempts to produce soluble protein had shown little 
success, it was decided to pursue a strategy of refolding Siglec8 Ig-like V-type domain 
from the insoluble fraction (i.e. from the inclusion bodies). 
3.5 Refolding insoluble proteins from inclusion bodies.     
The choice between working with insoluble recombinant protein or optimising 
the expression conditions to try to increase solubility relies on the nature of the protein 
and the amount required to perform an analysis. Strategies such as changing 
expression vector, fusion tag, host strain, growth conditions or co-expression with 
chaperones can really make a difference in achieving expression of soluble protein 
molecules. In contrast, a small protein (10-17 kDa) containing one  two cysteine 
residues might be expected to re-fold in a reasonable yield from inclusion bodies, 
while larger proteins with many Cys residues are the most problematic to refold 
(Palmer and Wingfield, 2012). In our case, the 19.82 kDa protein domain containing 
a single disulphide bond is a reasonable candidate for refolding.     
 Inclusion bodies are non-crystalline, amorphous structures formed by a 
mixture of unfolded and partially folded proteins, and perhaps native secondary 
structures densely packed (Palmer and Wingfield, 2012). 
In vitro folding studies with a mixture of proteins suggested that aggregation 
occurs between folded subdomains or intermediates which associate with 
complementary binding surfaces from other molecules to form oligomers and 
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eventually aggregates, therefore those interactions are not random or unspecific 
(Palmer and Wingfield, 2012). The propensity of a protein to form inclusion bodies 
does not seem to be directly related to the presence of cysteines and their sulfhydryl 
groups, as proteins without cysteines have been found to form inclusion bodies. 
However, the reducing environment of the E. coli cytoplasm may contribute to the 
instability and low solubility of these types of protein. Some other factors that may 
contribute to aggregate formation are the lack of post-translational modifications as 
glycosylation, and chaperones or enzymes catalysing folding such as the cis-trans 
isomerise. Furthermore, the high levels of protein concentration together with the 
limited solubility of their intermediates can also contribute (Palmer and Wingfield, 
2012). 
3.6 Refolding methods 
Refolding methods require the disruption of pure inclusion bodies into 
individual unfolded protein molecules in solution (Yamaguchi and Miyazaki, 2014). 
Initially, several washes must be carried out to remove other components in the pellet 
such as unbroken cells, membrane and cell material, or any other sources of 
contamination. Wash buffers contain a mixture of the non-ionic chaotropic agent urea 
at low concentrations, a reducing agent as DTT, detergent to help to remove cell 
membranes, and protease inhibitors to avoid proteolysis. Washes must be performed 
with the same buffer free of detergent to remove any excess which may influence the 
folding later. Once inclusion bodies are clean, they must be mechanically disrupted 
with extraction buffer containing high concentrations (5-8 M) of the strong chaotropic 
agent guanidine hydrochloride (GdnHCl) combined with a reducing agent (DTT). 
Thus, individual unfolded molecules are solubilised and ready for refolding 
(Yamaguchi and Miyazaki, 2014).  
The procedure for the removal of the denaturant from denatured proteins is a 
key step in their efficient recovery and refolding (Yamaguchi and Miyazaki, 2014). 
There are several approaches that have been reported to refold an inactive protein into 
an active one such as size-exclusion chromatography, reversed micelles, zeolite 
absorbing systems and the natural GroEL-GroES chaperones. However, in most cases 
there is a significant amount of protein precipitation due to the presence of high 
numbers of aromatic and aliphatic residues which decrease the solubility of proteins 
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during refolding and contribute to the aggregation of protein folding intermediates 
(Yamaguchi and Miyazaki, 2014). 
3.7 Description of the refolding methods tested in this work  
The most conventional refolding methods are dialysis and dilution, which can 
yield as much as 40% and 80% refolding of the total protein, respectively, at 
concentrations of 1-10 mg/mL (Yamaguchi and Miyazaki, 2014). Dialysis is based on 
the removal of denaturant by buffer exchange through a membrane with a molecular 
weight cut off (MWCO) of up to half of the protein molecular weight, present in 
refolding buffer of at least 50x the volume of the protein solution. Additives that 
inhibit aggregation are typically included when the target protein is refolded at 
intermediate to high concentration (0.1 to 10 mg/mL) (Yamaguchi and Miyazaki, 
2014). Figure 3.37 summarizes the basis of dialysis, where the membrane’s molecular 
weight cut off enables the small molecules, but not the protein, to pass through the 
membrane led by osmosis. 
 
Figure 3.37. Schematic representation of a dialysis, where the membrane’s molecular weight cut off enables the 
small molecules to pass through the membrane but not the protein molecules. 
However, the rapid decrease in denaturant concentration can initiate the re-
formation of aggregates, possibly because of the contact between exposed 
hydrophobic surfaces. The dialysis method can be optimised by removing the 
denaturant in a step-wise fashion, in which the protein is brought to equilibrium with 
gradually decreasing concentrations of denaturant (Yamaguchi and Miyazaki, 2014). 
This strategy helps to avoid aggregation of improperly folded protein and denaturing 
of properly folded molecules. Figure 3.38 summarizes both types of dialysis: 
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Figure 3.38. The two types of dialysis: in one step dialysis (left), the concentration of denaturing agent is reduced 
all at once. Meanwhile in the step-wise dialysis (right), it is reduced gradually. 
The Dilution method involves diluting the unfolded protein solution by adding 
it dropwise directly into a 100 volume of refolding buffer (Yamaguchi and Miyazaki, 
2014). The protein concentration is so low when a drop is added that protein molecules 
should not aggregate and refold. When the next drop is added, the refolded molecules 
should (theoretically) not participate in aggregation. The disadvantage of this method 
is that it requires concentration of  a large volume of refolding buffer after the refolding 
(Yamaguchi and Miyazaki, 2014). Figure 3.39 summarizes the drop-wise refolding 
method: 
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Figure 3.39. Drop-wise refolding method, where denatured protein molecules in high concentrations of denaturing 
agent, are added drop-wise to a 100x volume with a low concentration of denaturing agent. 
 
3.8 Refolding buffer composition according to protein properties  
The composition of the refolding buffer is critical and must be determined 
according to the protein properties. A wide variety of compounds have been 
demonstrated to enhance the refolding process for specific proteins, including amino 
acids, mild detergents, polymers, prosthetic groups, sugars, ligands and mixed 
micelles (Yamaguchi and Miyazaki, 2014). Those additives are thought to decrease 
the tendency of folding intermediates or mis-folded proteins to aggregate, stabilize the 
folded proteins and inhibit non-productive refolding pathways, or a mixture of all of 
these. However, there is no “one size fits all” formulation. To determine optimal 
refolding conditions one must still test many different additives and conditions 
(Yamaguchi and Miyazaki, 2014).  
One key protein property that influences the refolding conditions is the 
presence of disulphide bonds. When disulphide bonds are required for correct protein 
folding, a reducing agent like DTT must be included in the solubilisation step and must 
be maintained during the initial refolding to prevent the formation of intermolecular 
disulphide cross-linking. In addition, thiol reagents such as the pair glutathione 
reduced (GSH) - glutathione oxidized (GSSG). These compounds facilitate the 
formation of disulphide bonds through a twostep process, where the protein forms a 
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mixed disulphide intermediate with the thiol, followed by a second exchange reaction 
with a second thiol to form the intra-molecular disulphide bond. Thus, the reversibility 
of any mis-paired disulphide bonds in folding intermediates’ is allowed.  The reducing 
agent is typically added in a five to ten-fold molar excess over the oxidant i.e. 1 mM 
GSH-0.2 mM GSSG. 
 Another protein property that influences the refolding conditions is the 
hydrophobicity. The presence of high numbers of aromatic and aliphatic residues (Ala, 
Cys, Val, Ile, Leu, Met, Phe and Trp) is believed to decrease solubility of proteins 
during refolding and contribute to aggregation. The easiest way to minimise 
hydrophobic aggregation and allow the recovery of monomeric active protein is to add 
a mild detergent like N-lauroylsarcosine to the refolding buffer.   
Knowledge of any essential prosthetic groups is also important. For example, 
bacterial alkaline phosphatase has been reported to require Zn2+ for proper refolding.   
Finally, the net charge must also be considered.  The net charge of a protein is 
calculated by summing the basic amino acid residues and subtracting the acidic amino 
acids. The pI of a protein is the pH at which it has a net charge of zero, and therefore 
its solubility is minimal. By shifting the pH away from neutral, greater solubility and 
recovery of functional protein is possible. It is recommended working at a pH at least 
one unit higher or lower than the protein’s pI (Yamaguchi and Miyazaki, 2014). 
3.9 Analysis of Siglec8 Ig-like V-type domain Met17-His155 (Cys42>Ser42) 
relevant characteristics for refolding 
Table 3.2 shows the analysis of the Siglec8 Ig-like V-type domain, using the 
ProtParam online tool. The presence of two cysteines require the usage of DTT in the 
washing and first refolding stages, as well as the redox pair GSH-GSSG in the last 
stages. Furthermore, the pI value 6.11 was considered when selecting the pH of the 
refolding buffer (pH 7.5 or higher). 
Table 3.2. Siglec8 Ig-like V-type (Cys42>Ser42) domain relevant parameters for refolding (ProtParam). 
  
Number of 
amino acids 
(aa’) 
 
MW 
(kDa) 
 
Cysteines 
 
Hydrophobic 
aa’ 
 
Prosthetic 
groups 
 
pI 
Siglec8 Met17-
His155 
(Cys42>Ser42) 
 
172 
 
19.82 
 
2 
 
67 (39%) 
 
None 
 
6.11 
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3.10 Comparison between one-step dialysis, step-wise dialysis and drop-wise 
methods to   refold the Siglec8 Ig-like V-type domain  
Cell pellets from 500 mL cell cultures were washed and extracted according to 
the protocol described in Materials and Methods. Subsequently, the concentration in 
extraction buffer was adjusted to 2 mg/mL by comparison of the size and intensity of 
SDS-PAGE bands with a sample of 2 mg/mL of Chicken Lysozyme, as shown in 
Figure 3.40, as well as measuring the absorbance.  
 
Figure 3.40. SDS-PAGE gel made to samples of unfolded protein in extraction buffer and to a 2 mg/mL solution 
of Chicken Lysozyme to adjust the concentration of the extracted Siglec8 Ig-like V-type protein domains to 2 
mg/mL. 
The three refolding methods, one-step and step-wise dialysis, and drop-wise 
dilution, were tested with the initial same amount of unfolded protein (2 mg/mL), 
solubilised in 2 mL of extraction buffer, following the protocols described in Materials 
and Methods. Subsequently, the three samples belonging to the three different 
refolding methods were purified using a 1mL HisTrap HP column, and buffer was 
exchanged into 500 μL of 20mM NaPi, 500mM NaCl, pH 7.5. Figure 3.41 shows the 
SDS-PAGE analyses of three 10 μL samples, belonging to samples refolded using the 
three different protocols: from left to right one-step dialysis, step-wise dialysis and 
drop-wise refolding. Drop-wise refolding provided turned out to be the method that 
provided a higher yield of protein after purification.  
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Figure 3.41. SDS-PAGE performed to three 10μL samples belonging to the three protein solutions refolded by 
means of three different methods (one step dialysis, step-wise dialysis and drop-wise).  
  
 Based on all cloning, expression, refolding and purification trials, I kept 
working with the Siglec8 Ig-like V-type Met17-His155 (Cys42>Ser42) construct 
cloned into the vector pET151/D-TOPO T, expressed in the E. coli strain Rosetta gami 
B (DE3), refolded using the drop-wise method and purified by means of Niquel 
affinity column into 20 mM NaPi, 500 mM NaCl, pH 7.5 buffer.  
3.11 Industrial collaboration with Mologic Ltd. Role of eosinophils in Chronic 
Obstructive Pulmonary Disease (COPD) and diagnostic through Siglec8.  
Apart from their well-known implication in asthma, eosinophils have recently 
been found in the airways, tissues, and circulation of patients with COPD, during both 
stable and disease exacerbations (Bafadhel, et al., 2017). Furthermore, 
epidemiological studies showed an association between the blood eosinophil count 
and the risk of COPD exacerbations, mortality and response to corticosteroid 
treatment. (Casanova, et al., 2017; Prins, et al., 2017; Zeiger, et al., 2017). Thus, 
eosinophils have been pointed out as biomarkers and mediators of the COPD, but their 
contribution to the mechanism of this disease remains to be elucidated (Bafadhel, et 
al., 2017).  
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This PhD project also encompassed an industrial collaboration with Mologic 
Ltd. (Bedford, UK). Mologic is an independent SME (Small and medium-sized 
enterprises) company with approximately 60 employees at two sites in the UK. 
Mologic develops diagnostic technologies using pure, well characterised, biologically 
relevant samples of the biomarkers of interest. Those biomarkers are usually proteins 
or peptides used to generate proprietary antibodies and serve as calibration standards. 
The antibodies are used to develop immunochromatographic diagnostic devices as 
lateral flow strips for the biomarkers of interest. This was the case of the Siglec8 
human receptor, an excellent biomarker to predict COPD exacerbations. The protocol 
to produce and purify Siglec8 recombinant protein domains was developed at 
Warwick in collaboration with Mologic. Subsequently some of the material produced 
was used to generate antibodies anti-Siglec8 by boosting the immune response of 
immunised animals. Thus, those antibodies may be employed in the development of a 
diagnostic test for chronic lung disease exacerbations by detecting increased levels of 
eosinophils in patient's body fluids. 
Mologic conducts exploratory research in biotechnology and healthcare 
diagnostics to develop novel assay systems, combinations of biomarkers and 
approaches to in-home testing and disease management. The company recently 
obtained a $4.8 M grant for the Bill and Melinda Gates Foundation to establish the 
Centre for Advance Rapid Diagnostics (CARD) at its Bedford site. The challenge of 
CARD is to create a step-change in simple, rapid diagnostic test technology for the 
detection of protein biomarkers at the point of care. The new, ultra-sensitive 
technology platform is being developed with a focus on manufacturing costs and ease-
of-use to enable deployment throughout the developing world. While new 
immunodiagnostic technology carried out in the laboratory is achieving unprecedent 
sensitivity and accuracy, rapid diagnostic tests, which are well suited for use at the 
point of care and in the field, have changed little since their invention in the mid-
1980s. The grant to establish CARD as the means to deliver a new ultra-sensitive point 
of care technology platform, is aligned with the Gates Foundation's strategy to 
eradicate poverty through enhancing healthcare and bring the diagnostic standards and 
capability of developed world care to those who need it most within low resource 
countries. 
Chapter 3 – Cloning, expression and purification 
94 
 
The Mologic team includes synthetic organic/peptide chemists, immunoassay 
experts, biochemists, microbiologists and immunologists, working in up-to-date 
laboratories. Mologic had a long-standing interest in developing diagnostics for 
markers of infection and inflammation in human disease. To understand how Mologic 
operates and the kind of products developed, it is helpful to look at the two first 
commercialised products as illustrative examples: 
• PERiPLEX®. Mologic's first diagnostic product was CE Marked in December 
2016. It is a rapid point-of-care test for the detection of infection in patients on 
Peritoneal Dialysis (PD). There are over 200,000 patients being treated with PD 
globally, and it is widely accepted as the preferred method for managing severe 
chronic kidney disease (CDK) or end stage renal disease (ESRD). PD is a type of 
dialysis that uses the peritoneum in a patient's abdomen as the membrane through 
which fluid and dissolved substances are exchanged with the blood. It is used to 
remove toxins and excess fluid, and correct electrolyte problems is those with 
kidney failure. However, PD is known to have a high rate of associated infections, 
which can lead to peritonitis. Using current methods, diagnosis of infection can 
take more than 24 hours. This delay risks damage to the peritoneal membrane or 
the formation of scar tissue, avoiding the long-term use of PD. PERiPLEX detects 
two critical biomarkers of infection in PD waste fluid using a lateral flow 
immunoassay system, and provides results within 10 minutes. A positive result 
can give PD patients warning of an infection, prompting them to contact their 
healthcare provider to initiate antibiotic therapy. Thus, earlier identification of 
infection would enable preventive use of available antibiotics, resulting in 
improved management of infection and prevention of infection-related damage to 
the peritoneal membrane.  
• BVPro® is a simple, rapid, point-of-care diagnostic intended for professional use 
as an aid in the diagnosis of bacterial vaginosis (BV). The test detects sialidase 
enzyme activity in vaginal fluid, using a lateral flow immunoassay system which 
gives results in 15 minutes. Sialidase is an enzyme produced by bacterial 
pathogens in the vagina. Untreated BV is associated with a slightly increased risk 
of developing complications during pregnancy, inclusing miscarriage or preterm 
birth. It also increases the chance of developing an infection after uterus 
operations and the risk of contracting STIs. BV can usually be successfully treated 
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with antibiotics, but for a number of woman, the first course of treatment is not 
effective with the symptoms returning within three months.  In these cases, a 
different form of treatment may be prescribed. BVPro® uses patented technology 
to detect sialidase activity. Sialidase is an enzyme that degrades sugars and has 
been reported to weaken the natural mucosal barriers in the vagina, allowing 
anaerobic bacteria to colonise and out-compete healthy lactobacilli. BVPro® 
detects this activity by supplying the enzyme with an artificial substrate. Thus, if 
sialidase is present, it will modify the substrate which is then captured on the test 
line using specific antibodies. Where no enzyme is present, the substrate remains 
unchanged and will not be captured. A procedural control line is included to 
indicate that the assay has been performed correctly. The presence of a red line in 
addition to the control line indicates a positive result.
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4. Biophysical characterization of Siglec8 
Ig-like V-type domains. 
4.1 Application of biophysical techniques to protein characterization 
Biophysics is defined as an interdisciplinary science that applies physical 
techniques to study and characterize biological systems. In this chapter bioinformatics 
and different biophysical techniques such as protein fluorescence, circular dichroism 
(CD), UV-vis absorbance, single X-ray scattering (SAXS) and mass spectrometry 
(MS) were employed to verify the identity, quantify and characterize the secondary 
structure of the Siglec8 Ig-like V-type carbohydrate binding domains after refolding 
and purification. 
The biophysical characterization of a recombinant protein is critical to 
determine its suitability for further ligand-binding studies. Those characterizations 
may reveal features such as the formation of protein aggregates in solution or the 
adoption of the correct protein three-dimensional conformation also known as native 
structure, which is essential for protein function.  
Protein folding is the process by which a protein structure assumes its 
functional shape or conformation, so it is able to perform its biological function. The 
main stages of the folding process are described and represented below using the NMR 
solution state resolved structure of the SUMO-1 protein (pdb ID 2ASQ) as an example 
in Figure 4.1.  
The linear amino-acid sequence of a protein is known as its primary structure. 
The formation of intramolecular hydrogen bonds between the carbonyl O of one amino 
acid and the amino H of another leads to regions in which chains are organised into 
secondary regular structures. The most common ones are known as alpha-helices and 
beta sheets. Alpha helices form a spiral shape and the beta sheets’ backbone can bend 
over itself in a parallel or an antiparallel way. Subsequently, the protein folds into its 
tertiary structure so that the hydrophilic sides remain in contact with the aqueous 
environment surrounding the protein and the hydrophobic patches face the core. There 
may be also covalent disulphide bridges formed between cysteine residues stabilizing 
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the protein. In some cases, the assembly of several subunits that have already folded 
may interact to form a fully functional quaternary protein. 
 
Figure 4.1. Representation of the main stages of the protein folding process using the solution state NMR resolved 
structure of the SUMO-1 protein (pdb ID 2ASQ) as an example. 
 The aim of this chapter is to characterize the soluble Siglec8 Ig-like V-type 
carbohydrate binding domains in 20 mM NaPi, 500 mM NaCl, pH 7.5 to determine if 
they are suitable to perform further ligand binding studies. 
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4.2 Siglec8 Ig-like V-type domain sequence, composition and structural analysis  
 The analysis of the amino acid sequence reveals important protein features and 
physicochemical parameters such as molecular weight (MW), isoelectric point (pI), 
extinction coefficient (ε) or hydrophobicity. These are required to manipulate the 
protein in the laboratory, optimise the composition of buffers and perform biophysical 
characterizations.  
The online software ProtParam from ExPASy (SIB) was used to calculate the 
number of amino acids, molecular weight (MW), isoelectric point (pI) and the amino 
acid composition of the Siglec8 Ig-like V-type domain (Table 4.1). The isoelectric 
point is the pH at which a protein carries no net electrical charge. It is an important 
property because it is at this pH that the protein is least soluble, and therefore unstable 
(Kozlowski, 2017). Thus, it is convenient to keep the pH of buffers at least one unit 
above or below this value when working with proteins. 
Table 4.1. Number of amino acids, molecular weight and pI of Siglec8 Ig-like V-type construct 
Siglec8 Ig-like V-type construct 
Number of amino acids 172 
Molecular weight (Da) 19,819.01 
pI 6.11 
 
The amino acid composition for the Siglec8 Ig-like V-type construct is 
represented in Figure 4.2, where the 20 naturally-occurring amino acids are classified 
into three groups according to the chemical nature of their side chain: non-polar, polar 
and charged. All 20 amino acids are present between 1.2 and 8.7%.  
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Figure 4.2. Proportion of each amino acid present in the Siglec8 Ig-like V-type construct. 
The amino acid spatial distribution may be more relevant than the simple 
composition to determine any hydrophobic or charged pockets and patches in the 
protein’s surface. Figure 4.3 presents the three-dimensional structure of Siglec8 Ig-
like V-type domain resolved by solution state NMR (Propster, et al., 2016) with the 
non-polar amino acids highlighted in blue, the polar residues in green, basic residues 
in pink and acidic ones in yellow. The three-dimensional structure reveals a 
homogeneous distribution of the different subgroups of amino acids with a higher 
proportion of hydrophobic patches across the domain. 
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Figure 4.3. Siglec8 Ig-like V-type domain resolved by ssNMR with the different types of amino acids highlighted in different 
colours: pink and yellow for positive and negative charged ones respectively, green for the polar ones and blue for the apolar 
ones (Propster, et al., 2016), PDB ID 2N7B.  
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4.3 Identity confirmation of the recombinant Siglec8 Ig-like V-type domain by 
Tandem Mass Spectrometry (nano-LC-ESI-MS/MS) 
Tandem Mass Spectrometry (MS) was used to confirm the identity of the 
bacterially-expressed Siglec8 Ig-like V-type protein domain after purification.  A 
SDS-PAGE gel with 10μL of pure protein was run and the protein band was excised 
and sent to the Proteomics facility in the School of Life Sciences at Warwick for 
analysis. The protein was extracted from the poly-acrylamide gel band and 
enzymatically digested with trypsin. Trypsin is an enzyme that cleaves proteins at the 
carboxyl side of the amino acids lysin or arginine, except when either is followed by 
proline, generating a mixture of peptides. 20μL of this peptide digest was injected in 
the nano-LC-ESI-MS/MS system (nano-liquid chromatography, electrospray, tandem 
mass spectrometry). 
 The resulting peptides were fractionated using liquid chromatography and 
directly introduced to the mass spectrometer through electrospray ionization. The 
mass-to-charge ratio of the ionized peptides was measured by tandem MS and the 
results were compared with Homo sapiens and Escherichia coli databases from 
MaxQuant (Stone, et al., 1998). MaxQuant software was used for protein 
identification and Scaffold software for data analysis and results visualization. Table 
4.2 shows a Table with the results. The identity of the protein sample as Siglec8 human 
receptor was confirmed with more than 95% probability and 14 out of 16 peptides 
yielded more than 98% sequence match with the receptor. 
Table 4.2. Identity confirmation of LC-ESI-MS/MS results of Siglec8 Ig-like V-type domain after comparison with 
MaxQuant database. 
Peptide Prob Exclusive To 
AGDRPYQDAPVATNNPDR 100% Sialic acid-binding Ig-like lectin 8-Homo sapiens-SIGLEC8 
AGDRPYQDAPVATNNPDRE
V 
99% Sialic acid-binding Ig-like lectin 8-Homo sapiens-SIGLEC8 
DKGSYFFR 99% Sialic acid-binding Ig-like lectin 8-Homo sapiens-SIGLEC8 
DKGSYFFRLER 100% Sialic acid-binding Ig-like lectin 8-Homo sapiens-SIGLEC8 
FQLLGDIWSNDCSLSIR 100% Sialic acid-binding Ig-like lectin 8-Homo sapiens-SIGLEC8 
FQLLGDIWSNDCSLSIRDAR 93% Sialic acid-binding Ig-like lectin 8-Homo sapiens-SIGLEC8 
Chapter 4 - Biophysical characterization 
102 
 
FQLLGDIWSNDCSLSIRDAR
K 
80% Sialic acid-binding Ig-like lectin 8-Homo sapiens-SIGLEC8 
GSMKWSYK 99% Sialic acid-binding Ig-like lectin 8-Homo sapiens-SIGLEC8 
GSMKWSYKSQLNYK 100% Sialic acid-binding Ig-like lectin 8-Homo sapiens-SIGLEC8 
GSYFFRLER 95% Sialic acid-binding Ig-like lectin 8-Homo sapiens-SIGLEC8 
LERGSMKWSYK 100% Sialic acid-binding Ig-like lectin 8-Homo sapiens-SIGLEC8 
PYQDAPVATNNPDR 100% Sialic acid-binding Ig-like lectin 8-Homo sapiens-SIGLEC8 
PYQDAPVATNNPDREVQAE
T 
99% Sialic acid-binding Ig-like lectin 8-Homo sapiens-SIGLEC8 
RDKGSYFFR 100% Sialic acid-binding Ig-like lectin 8-Homo sapiens-SIGLEC8 
WSYKSQLNYK 100% Sialic acid-binding Ig-like lectin 8-Homo sapiens-SIGLEC8 
WSYKSQLNYKTK 98% Sialic acid-binding Ig-like lectin 8-Homo sapiens-SIGLEC8 
 
4.4 Quantification of Siglec8 Ig-like V-type domain concentration by UV-vis 
absorbance 
The aromatic amino acids tryptophan (Trp), tyrosine (Tyr) and phenylalanine 
(Phe), and the disulphide linkages between cysteines (S-S) constitute chromophores 
that absorb in the near UV region. Absorption of near UV radiation by proteins is 
usually monitored at 280 nm (A280) due to the high absorption by Trp and Tyr at this 
wavelength. Thus, if the molar absorption coefficient of the protein and the path length 
of sample cell are known, the protein concentration (C) can directly be determined 
using the Beer-Lambert law (WADDELL, 1956):  
A280 = C · ε280 · l 
Where ε280 is the molar absorption coefficient and λ is the path length. The molar 
extinction coefficient can be easily determined if the composition of the protein is 
known. Table 4.3 shows the Trp, Tyr and disulphide absorption coefficients at 280 
nm. They vary depending on the polarity of the media in the case of Trp and Tyr, and 
on the oxidative state for the sulphide groups. Values differ for folded and unfolded 
proteins (WADDELL, 1956; Sapan and Lundblad, 2015): 
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Table 4.3. Molar extinction coefficients of Tryptophan, Tyrosine and Disulphide bonds at 280 nm.  
 
ε280 (M⁻1 cm⁻1) 
Trp Tyr (S-S/SH SH) 
Average value in folded proteins 5,500 1,490 125 
Value in unfolded proteins 5,690 1,280 120 
 
The calculation for an unfolded protein would be: 
ε280 = (5,690 · number of Trp) + (1,280 · number of Tyr) + (120 · number of reduced 
SH-SH) 
There are several online software programmes that calculate protein’s 
physicochemical parameters such as ε280. The molar absorption coefficient for the 
Siglec8 Ig-like V-type construct was determined from the sequence of amino acids, 
using the online tool ProtParam from ExPASy (SIB), as ε280ss 35,535 M-1·cm-1 and 
ε280SHSH 35,410 M-1·cm-1 for the folded and the unfolded domain respectively. 
Figure 4.4 displays the absorption spectra between 230 and 330 nm for the 
three fresh refolded Siglec8 Ig-like V-type domain samples by means of three different 
methods: one-step dialysis (blue) and step-wise dialysis (green) dialysis; and drop-
wise refolding (red). Absorption was measured to 2 mL samples after refolding and 
buffer exchange into 20 mM NaPi 500 mM NaCl, pH 7.5 buffer. The protein 
concentration in all samples was determined, by applying the Beer-Lambert law as 
described above, as 0.06 mg/mL (2.81 μM) for the one-step dialysed sample, 0.27 
mg/mL (13.7 μM) for the step-wise dialysed sample and 0.5 mg/mL (25.3 μM) for the 
drop-wise refolded sample. Refolding and purification yields were 3, 13.5 and 25 % 
respectively. 
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Figure 4.4. Absorption spectra of three Siglec8 Ig-like V-type domain samples refolded by means of one-step 
dialysis (blue), step-wise dialysis (green) and drop-wise (red). 
 
Figure 4.5 shows the absorption spectrum between 230 and 330 nm for the 
drop-wise refolded protein after being concentrated down to a volume of 500 μL 
reaching a concentration of 1 mg/mL (50.6 μM). 
 
Figure 4.5. Absorption spectrum between 330 and 230 nm of Siglec8 Ig-like V-type refolded domains into 20mM 
NaPi 500mM NaCl, pH 7.5 buffer.  
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4.5 Siglec8 Ig-like V-type domain fold monitored by Circular Dichroism (CD) 
Circular Dichroism (CD) is the difference in the absorption of left-handed 
circularly polarised light (L-CPL) and right-handed circularly polarised light (R-CPL), 
which occurs when a molecule contains one or more light-absorbing groups. In CD 
spectroscopy, the CD of molecules is measured over a range of wavelengths. The 
signal can be positive or negative, depending on whether L-CPL is absorbed to a 
greater extent than R-CPL (positive CD signal) or to a lesser extent (negative CD 
signal) (Micsonai, et al., 2015). 
One of the most important applications of CD is the analysis of protein 
secondary structures. Protein CD spectra are usually recorded between 180 and 260 
nm and can be used as input for software such as Dichroweb (London, 2010-2017) 
that compare the obtained spectrum to a database of previously obtained spectra for α-
helical, β-sheet and random coil proteins to yield an estimate of secondary structure 
content (Micsonai, et al., 2015).  
The typical model CD spectra belonging to the different pure secondary 
structures are represented in Figure 4.6 (CorrÊa and Ramos, 2009). α-helical 
structures’ spectra (in blue) are positive below 200 nm and show two negative minima 
around 210 nm and above 220 nm. β-sheet spectra (in red) are also positive below 200 
nm and display one less sharp negative minimum around 218 nm. Random coil spectra 
(in green) are flat or slightly positive above 210 nm and display a sharp minimum 
below 200 nm (CorrÊa and Ramos, 2009). 
 
Figure 4.6. Model spectra for α-helix, β-sheet and random coil pure secondary structures (CorrÊa and Ramos, 
2009). 
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A CD spectrum was recorded for a fresh Siglec8 Ig-like V-type domain sample 
after refolding, purification and buffer exchange into 50 mM Tris, pH 7.5. The 
concentration was approximately ~ 1 mg/mL (Figure 4.7). The spectrum shows two 
negative minima at 232 and 208 nm and one positive maximum at 199 nm and could 
not be fitted to any specific secondary structure by the Dichroweb algorithms (London, 
2010-2017). This was unsurprising as β-sheet rich proteins, such as Siglecs, have been 
described in the literature as problematic when fitting CD spectra (Micsonai, et al., 
2015). This is due to the fact that they can arrange in parallel or antiparallel 
orientations and twist, displaying a huge morphological a spectral variety of β 
structures.  
 
Figure 4.7. CD spectrum of Siglec8 Ig-like V-type domain in 50 mM Tris, pH 7.5 at a concentration of 1 mg/mL. 
The spectra obtained for the Siglec8 Ig-like V-type domain is in good 
agreement with spectra belonging to a set of β-rich proteins described in the literature, 
the βI-proteins (Manavalan and Johnson, 1983).  The characteristic spectrum for βI-
proteins is well defined in this published work (Sreerama and Woody, 2003), where 
the CD spectra of 16 β-rich proteins were measured and they were classified in two 
different subsets: βI or βII-proteins. βII-proteins have a characteristic negative band 
around 200 nm and some of them show a small positive band around 190 nm while 
others display a positive band or a negative shoulder around 220 nm. In contrast, βI-
proteins have a stronger positive band around 190 nm and a comparable negative band 
in the 210-220 nm region. Both subsets can also show CD bands above 225 nm due to 
aromatic and disulphide groups. In the same work, the crystal structures of those 
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proteins were analysed to determine the secondary structures that give rise to the basic 
features of the CD spectra of both subsets of β-proteins. The analysis pointed out that 
the relative compositions of β- and P2-helix (poly(Pro)II-helix) in β-rich proteins 
determine the type of a β-protein CD spectrum, as the βII-proteins generally have a 
larger fraction of residues in P2 structure than the βI ones, and the βI-proteins have a 
larger β-sheet content than the βII proteins. 
Thus, the Siglec8 Ig-like V-type domain CD spectrum agrees well with spectra 
for βI-proteins, with the second negative peak around 230 nm probably accounted for 
its aromatic amino acids and disulphide bond. This is spectrum, shown in Figure 4.8, 
is also in excellent agreement with the CD spectrum (Propster, et al., 2015) and 
solution state NMR structure published for Siglec8 in 2016 (Propster, et al., 2016). 
 
Figure 4.8. CD spectra for Siglec7 (green), Siglec8 (blue) and Siglec9 (red) published (Propster, et al., 2015). 
4.6 Siglec8 Ig-like V-type domain folding monitored by means of Fluorescence. 
 This experiment aims to obtain information about how the unfolding process 
of the Siglec8 Ig-like V-type domains happens in presence of increasing 
concentrations of the denaturing agent Guanidine Hydrochloride (GdnHCl). The 
unfolding process of the protein Lysozyme from chicken egg white, which has already 
been characterized (Chen, et al., 2014) was reproduced and used as a model to 
compare. 
There are three amino acids with intrinsic fluorescent properties: 
phenylalanine (Phe), tyrosine (Tyr) and tryptophan (Trp), but only tryptophan and 
tyrosine have high enough quantum yields (ratio of photons absorbed to photons 
emitted though fluorescence) to give a high fluorescence signal. Both amino acids can 
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be used to follow protein folding, as their fluorescent properties (quantum yields) are 
sensitive to the chemical environment which changes when the protein folds/unfolds 
as described in Figure 4.9 (Royer, 2006).  
 
Figure 4.9. Example of the unfolded (left) versus folded (right) structure of a protein. For the unfolded form, all 
amino acids are exposed to the solvent, while when the protein is folded the hydrophobic amino acids are exposed 
to the protein's core avoiding the solvent. 
At 280 nm both Trp and Tyr are excited, and at 295 nm tryptophan is 
selectively excited. In a folded protein, tryptophan and tyrosine are usually located 
within the core, surrounded by a hydrophobic environment where typically they have 
lower quantum yields and the wavelength of maximum emission intensity (λmax) is 
lower. In a partially folded or unfolded state, Trp and Tyr become exposed to the 
aqueous solvent, emit higher fluorescence intensity and λmax can be shifted to higher 
wavelengths for Trp (Royer, 2006). However, there are other phenomena that may 
affect the protein’s fluorescence yield, such as the quenching that occurs when there 
are several aromatic rings in the protein core and there is an energy transfer between 
them, leading to a decrease of the fluorescence intensity for a folded protein in relation 
to its unfolded form (Kosinski-Collins, et al., 2004; Royer, 2006). 
A good example of how the quenching phenomenon can affect the 
fluorescence emission of a protein is the work carried out with the β-sheet rich, human 
γD-crystallin protein which has four tryptophan residues (Kosinski-Collins, et al., 
2004). In that study, four different mutants with three out of the four tryptophan 
residues substituted with phenylalanine were generated. Fluorescence spectra were 
measured for each of the four mutants as well as the wild type protein in the presence 
and absence of 5.5 M GdnHCl. The wild-type protein and two of the mutants were 
significantly more fluorescent in their unfolded state. However, two mutants emitted 
less fluorescence in their unfolded state than in the native (folded) state, when the 
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tryptophan was surrounded by a hydrophobic environment. Thus, in the second case, 
there were quenching phenomena decreasing the fluorescence of the native protein 
structure. There was also a typical red shift of the maximum emission wavelength after 
denaturing in all cases.  
We monitored the unfolding process of both the standard protein Lysozyme 
and Siglec8 Ig-like V-type domains at a concentration of 1 mg/mL by measuring the 
Trp and Tyr fluorescence emission of samples with increasing concentrations of 
GdnHCl (from 0 M to 3.5 M for lysozyme and from 0 M to 2 M for the Siglec8 Ig-
like V-type domains). Lysozyme contains three Tyr and six Trp residues and the 
Siglec8 Ig-like V-type domain nine Tyr and four Trp residues. After preparation, 
samples were left overnight to equilibrate and the following day their fluorescence 
emission spectra were measured between 320 and 380 nm (excitation wavelength 280 
nm).  
The spectra are shown in Figure 4.10 for Lysozyme and Figure 4.11 for the 
Siglec8 Ig-like V-type domain. In both cases, as the concentration of GdnHCl was 
increased, the protein domains unfolded, and the maximum intensity of emission 
became higher. This suggests the presence of the quenching between aromatic rings 
in the native proteins’ fold which decreased the intensity of emission in comparison 
with the unfolded form, despite the hydrophobic environment surrounding the 
fluorescent aminoacids. Lysozyme spectra were very similar for all samples 
containing 0-2.0 M GdnHCl, indicating that the protein's native structure remained 
intact. However, with the addition of higher concentrations of the denaturing agent 
(2.5, 3.0 and 3.5 M GdnHCl), the fluorescence emission intensity increased 
dramatically. In contrast, the intensity of emission for the Siglec8 Ig-like V-type 
domain increased gradually with the addition of higher concentrations of GdnHCl, 
suggesting a step-wise unfolding process. Siglec8 spectra also showed the typical red 
shift of the maximum emission wavelength as the protein lost its native fold and 
fluorophores became exposed to the solvent. 
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Figure 4.10. Fluorescence emission spectra for Lysozyme samples with increasing concentrations of denaturing 
agent GdnHCl (0, 0.25, 0.5, 0.75, 1.0, 1.25, 1.5, 1.75, 2.0, 2.5, 3.0 and 3.5 M) and a blank with buffer and 4 M 
GdnHCl. Samples were excited at 280 nm and the emission spectra were measured between 380 and 320 nm.  
 
 
Figure 4.11. Fluorescence emission spectra for Siglec8 Ig-like V-type domain samples with increasing 
concentrations of denaturing agent GdnHCl (0, 0.5, 0.75, 1.0, 1.5 and 2.0 M) and a blank with buffer and 2M 
GdnHCl. Samples were excited at 280 nm and the emission spectra were measured between 380 and 320 nm. 
 
Figure 4.12 and Figure 4.13 show a plot of fluorescence intensity and λmax 
versus GdnHCl concentration for Lysozyme and Siglec8 Ig-like V-type domains, 
respectively.  
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Figure 4.12. Maximum fluorescence intensity for Lysozyme samples with addition of GdnHCl from 0 to 3.5 M. 
 
Figure 4.13. Maximum fluorescence intensity (left) and wavelength of maximum emission (right) for Siglec8 Ig-
like V-type domain samples with addition of GdnHCl from 0 to 2M. 
 
4.7 Siglec8 Ig-like V-type domain size characterization by Small Angle X-Ray 
Scattering (SAXS). 
The average diameter of Siglec8 Ig-like V-type domain particles in 20mM 
NaPi 500mM NaCl, pH 7.5 buffer has been measured using SAXS. In a SAXS 
experiment a solution of particles is illuminated by a collimated monochromatic X-
ray beam. The intensity of the scattered X-rays is recorded by an X-ray detector. 
Likewise, the scattering pattern of the pure solvent is also collected and subtracted 
from the sample solution. As molecules have different orientations in solution, the 
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obtained signal is related to the overall shape and size of the particles (a practical 
guide). 
Figure 4.14 shows the SAXS plot of the logarithmic scattering intensity in 
arbitrary units versus the inverse of the size (q) in Å¯¹. Data were fitted to calculate 
the average protein domain’s size. Extreme values of q do not fit the model as they 
belong to a small fraction of protein domains which are forming aggregates in solution 
(lowest q values) and buffer background (highest q values), respectively. 
 
Figure 4.14. SAXS plot of Scattering Intensity versus the inverse of particle size (q) fitted. 
Figure 4.15 displays the estimated radio according to a spherical model and 
Figure 4.16 the average value of the diameter of the Siglec8 Ig-like V-type domain 
particles in solution. Both calculated from the fitted data. The estimated radio for the 
protein domains supposing they had spherical shape was approximately 13 Å. 
However, as the protein domain structure has been previously resolved by means of 
solution state NMR, we know it does not have a spherical shape (Propster et al). 
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Figure 4.15. SAXS estimated radio for the Siglec8 Ig-like V-type domains according to a spherical model. 
The calculated protein domain average diameter was approximately 32 Å 
(Figure 4.16). This value is in good agreement with the estimation of a 16.2 Å radius 
gyration (Rg), using the Siglec8 Ig-like V-type domain solution state resolved 
structure (pdb ID 2N7A) (Propster, et al., 2016) and the software Gromacs, see Figure 
4.17.  
 
Figure 4.16. SAXS estimated average diameter for the Siglec8 Ig-like V-type domains. 
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Figure 4.17. Estimation of the Siglec8 Ig-like V-type resolved structure's radius gyration during a 1 ns simulation 
using the software Gromacs and the pdb file 7N2A as input. 
 
The 3D-structural model obtained from the SAXS data belonging to our 
soluble Siglec8 Ig-like V-type domains (above) in comparison with the Siglec8 Ig-like 
V-type domains solution state NMR resolved structure (below) (Propster, et al., 2016) 
are shown in figure 4.18. Both domains encompass the same Siglec8 sequence but 
differ slightly in the initial and terminal sequences. The model indicates that we 
produced globular and folded Siglec8 carbohydrate binding domains which also share 
the same shape as the solution state NMR Siglec8 Ig-like V-type resolved domains 
downloaded from the Protein Data Bank. Both figures were visualised using the 
software Pymol (Pymol). 
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Figure 4.18. 3D-model of Siglec8 carbohydrate binding domains produced in this work by means of SAXS (above). 
Siglec8 carbohydrate binding domains resolved by means of solution state NMR (Propster, et al., 2016) (below). 
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5. Exploring Siglec8 as a therapeutic 
target. 
5.1. An overview of current asthma treatments 
The treatments prescribed for asthma vary as a function of the severity of the 
disease. The most common type of therapeutic according to Asthma UK (AsthmaUK) 
is use of short-acting reliever inhalers. Inhalers such as Ventolin® are prescribed for 
every asthmatic person and must be taken when an exacerbation happens. They act 
locally and induce bronchial smooth muscle relaxation, opening the airways and 
facilitating the breathing. Daily preventer inhalers are also a common therapeutic 
approach. Small daily doses of steroids as Turbohaler® reduce patient’s sensitivity to 
triggers, as they inhibit the immune system response locally. They are prescribed to 
patients who need to use the short-acting reliever inhaler three or more times a week. 
Long-acting reliever inhalers are prescribed in addition to the short-acting relievers 
and higher doses of daily preventer inhalers to those patients who still cannot keep 
their asthma symptoms under control. They induce bronchial smooth muscle 
relaxation, opening the airways and facilitating breathing. But their effect takes longer 
in beginning to work and lasts longer than the short-acting reliever inhalers’ action. 
The inhaler Spiriva® Respimat® is an example. Add-on therapies are required when 
the other treatments are not enough to keep the disease under control. These include 
steroid tablets which help to reduce the inflammation during acute asthma attacks 
when the preventer inhaler is not enough, or leukotriene receptor antagonists that 
reduce the body’s response to certain allergens and situations triggering asthma 
attacks.   
There are cases of severe asthma in which the disease cannot be kept under 
control with the medicines mentioned above, and higher doses of daily preventer 
inhalers and steroid tablets are prescribed (AsthmaUK). Oral steroid tablets are usually 
administered during short occasional courses and come with possible side effects such 
as high blood pressure or lower resistance to infections. For this reason, they are only 
prescribed when the benefits outweigh the risks (AsthmaUK). Current research efforts 
in asthma therapies are focused on the development of new therapeutics that enable to 
keep the patients' severe asthma symptoms under control, minimizing emergency 
hospital admissions as well as side effects (AsthmaUK).  
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5.2 Role of eosinophils in asthma and targetability through Siglec8. 
Eosinophils’ enhanced survival and delayed apoptosis in tissues and 
circulation seem to be the cause of the accumulation of these cells in the lungs of 
asthmatic individuals (Simon, et al., 1997; Kankaanranta, et al., 2000). Biochemically, 
there is evidence of eosinophil survival-prolonging cytokines such as GM-CSF, IL-5, 
IL-3, and other life-supporting molecules being strong contributing factors towards 
initiation and maintenance of eosinophilic airway inflammation in asthma (Tai, et al., 
1991; Yamaguchi, et al., 1991; Stern, et al., 1992). At present, three drugs whose mode 
of action induces eosinophil apoptosis are being used to treat asthma: glucocorticoids, 
theophylline (both steroids) and leukotriene modifiers. Furthermore, potential novel 
anti-asthmatic drugs with eosinophilic apoptotic effects such as inhibitors of histone 
deacetylases (HDAC), antibodies targeting the IL-5 receptor alpha, cyclin-dependent 
kinase (CDK) inhibitors and Siglec8 activators are being investigated (Ilmarinen and 
Kankaanranta, 2014b). 
 There is evidence that the in vitro activation of Siglec8 induces apoptosis of 
eosinophils (Ilmarinen and Kankaanranta, 2014b). The mechanisms of regulation and 
signalling of this apoptotic effect have not been completely elucidated, but it is known 
that they may vary under different chemical environments (Ilmarinen and 
Kankaanranta, 2014b). Thus, in resting eosinophils, Siglec8-induced apoptosis is 
dependent on reactive oxygen species (ROS) and caspases, a family of endoproteases 
whose activation results in a cascade of signalling events that lead to the controlled 
demolition of eosinophils' cellular components, apoptosis (McIlwain, et al., 2015). 
Conversely, eosinophils activated with the growth factors IL-5 or IL-33 appeared to 
be more susceptible to death via Siglec8 activation by means of necrosis or autolysis 
instead of apoptosis. Production and accumulation of reactive oxygen species (ROS), 
and activation of the MAPK/ERK pathway have been demonstrated to play an 
essential role in mediating Siglec8-induced cell death (Kano, et al., 2014; Kano, et al., 
2017). The MAPK (mitogen-activated protein kinase) / ERK (extracellular receptor-
stimulated kinase) pathway is made up of a collection of cytosolic and nuclear 
enzymes that communicate a signal from a receptor on the cell’s surface to the DNA 
in the nucleus of the cell, involving phosphorylation of protein kinases belonging to 
the Src family (non-receptor tyrosine kinases) (Kano, et al., 2017). 
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The exclusive expression of the Siglec8 receptor in human eosinophils and 
mast cells makes Siglec8 a good target to specifically inhibit or deplete those cellular 
types in eosinophil and mast cell-related diseases. The challenge is to selectively 
deliver a therapeutic agent (Kiwamoto, et al., 2012b). 
5.3. Rational drug design in the pharmaceutical industry 
Structure-based or rational drug design is a method used by the pharmaceutical 
industry to find new active molecules based on the structural knowledge of a biological 
target. It involves the design of small molecules or peptides that are complementary 
in shape and charge to the target, which is normally a bio-molecule such a protein. 
The small molecules must specifically activate or inhibit the target’s function, 
triggering a therapeutic effect (Todd, et al., 2009). Figure 5.1 schematically shows a 
protein target and a series of different small molecules that are complementary to the 
target in charge and shape. 
 
Figure 5.1. Schematic representation of a target and five designed small molecules with complementary shape and 
charge. 
Rational drug design starts with the search for compounds that fulfil specific 
requirements such as size complementarity, charge complementarity or the addition 
of a donor, an acceptor or a hydrophobic ring in a specific position. Subsequently these 
molecules are synthesized and tested for activity. All activity assays will provide 
information about those chemical groups that are more likely to be active and the 
molecules can be redesigned in order to improve the activity over the target (Todd, et 
al., 2009). 
However, bringing a pharmaceutical drug to the market is a very long-term 
process whose current costs have been estimated at approximately 2.6 billion dollars. 
The probability of failure in the drug discovery and development pipeline is high, with 
90% of the drugs tested in clinical trials failing to obtain FDA approval and get into 
the market (Leelananda and Lindert, 2016). At present, pharma and biotech companies 
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use computer-aided drug discovery (CADD) and high throughput screening (HTS) 
technologies to optimise and accelerate the drug discovery process (Leelananda and 
Lindert, 2016). HTS technologies enable the activity of thousands of molecules to be 
tested against biological targets utilising robotic automation, miniaturized assays and 
large-scale data analysis, but these technologies are expensive and require resources 
of targets and ligands (Mayr and Bojanic, 2009; Leelananda and Lindert, 2016). 
CADD technologies are powerful tools that can reduce the number of ligands that need 
to be screened in experimental assays. They not only reduce costs by ensuring that the 
best possible lead compound enters animal studies, but also decrease the time it takes 
for a drug to reach the market. CADD tools can identify lead drug molecules for 
testing, predict effectiveness and possible side effects, and assist in improving 
bioavailability of possible candidates (Clark, et al., 2016). CADD methods can be 
generally classified into two groups: structure-based (SB) and ligand-based (LB). The 
method used depends on the availability of target structural information (Leelananda 
and Lindert, 2016).  
Structure-based methods are based on the knowledge of the 3D structure of the 
biological target and its active site. Sometimes the presence of reactive groups in the 
active site is also known. Target information is usually obtained experimentally by X-
ray crystallography or NMR spectroscopy, but computational methods that predict the 
three-dimensional structures of targets may be used as well. This structural 
information can be used to virtually evaluate the affinity of molecules to targets, as 
well as estimate their binding free energies. A final filtering and optimization lead to 
those molecules whose activity will be tested in vitro (Todd, et al., 2009; Leelananda 
and Lindert, 2016).  
When the target's structure has not been experimentally determined, ligand-
based CADD methods are the alternative. They are based on the knowledge of active 
binders to the target. Thus, the features of those active small molecules can be 
compared with the inactive ones to generate a structure-activity hypothesis about 
which chemical groups (pharmacophores) are relevant to trigger biological activity 
(Leelananda and Lindert, 2016). 
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5.4 Rational drug design of molecules targeting Siglec8 
In this work, several low molecular weight molecules targeting the Siglec8 Ig-
like V-type domain were rationally designed using the high-resolution structure 
reported for the Siglec8 Ig-like V-type domain in complex with 6’-Sulpho-Sialyl-
LewisX (Propster, et al., 2016). A schematic of the amino acids in Siglec8 that interact 
with 6’-Sulpho-Sialyl-LewisX is shown in Figure 5.2 and summarised in Table 5.1, 
where the nature of the interactions is indicated (Propster, et al., 2016).  
 
Figure 5.2. 6’-Sulpho-Sialyl-Lewis X and Siglec8 amino acids interacting with it. Amino acids and chemical 
groups carrying out hydrophobic interactions are represented in pink meanwhile the ones carrying out ionic 
interactions are shown in red and the ones forming hydrogen bonds in green (Propster, et al., 2016). 
Table 5.1. Summary of the Siglec8 amino acids interacting with 6’Sulpho-Sialyl LewisX and the types of 
interactions (Propster, et al., 2016). 
6’Sulpho-Sialyl LewisX 
chemical group  
Siglec8 amino acid  Chemical nature 
of the interaction 
 
Neu5Ac (COO¯) 
O1A/O1B 
 
Arg109 Nη1 
 
 
 
Salt Bridge 
 
Neu5Ac (COO¯) 
O1A/O1B 
 
Arg109 Nη2 
 
 
 
Salt Bridge 
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6’Sulpho-Sialyl LewisX 
chemical group  
Siglec8 amino acid  Chemical nature 
of the interaction 
 
Neu5Ac H3/H4 
 
Lys116 
 
 
Hydrophobic 
Contacts 
 
Neu5Ac N5 
 
Lys116 O 
 
 
Hydrogen Bonds 
 
Neu5Ac CH3 
 
Tyr11 
 
 
Hydrophobic 
Contacts 
 
Neu5Ac H6 
 
Trp117 Hα 
 
 
Hydrophobic 
Contacts 
 
Neu5Ac O7 
 
Tyr7 Oγ 
 
 
Hydrogen Bonds 
 
Neu5Ac O8 
Ser118 N 
 Ser118 Oγ 
 
 
Hydrogen Bonds 
Hydrogen Bonds 
 
Neu5Ac H7, H91, H92 
 
Trp117 
 
 
CH/π 
interactions 
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6’Sulpho-Sialyl LewisX 
chemical group  
Siglec8 amino acid  Chemical nature 
of the interaction 
 
 
 
 
Neu5Ac O9 
 
Ser118 O 
 
 
 
 
Lys120 Nζ 
 
 
Gln Oε1 
Gln Nε2 
 
 
 
 
 
 
Hydrogen Bonds 
 
 
 
 
Hydrogen Bonds 
 
Hydrogen Bonds 
Hydrogen Bonds 
 
 
Gal6S SO¯3 
Arg56 Nη1 
Arg56 Nη2 
Arg56 Nε 
 
Gln59 Nε2 
 
 
Salt Bridge 
Salt Bridge 
Salt Bridge 
 
Hydrogen Bonds 
 
Gal6S H3, H4, H5 
 
Tyr58 
 
 
CH/π 
interactions 
 
GlcNAc O5 
 
Gln122 Nε2 
 
 
Hydrogen Bonds 
 
 
GlcNAc O6 
 
 
 
Lys120 Nζ 
 
 
 
 
 
Gln122 Nε2 
 
 
 
 
Hydrogen Bonds 
 
 
Hydrogen Bonds 
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The model highlights the interactions of an essential arginine (Arg109) which 
is conserved in all Siglecs and plays an important role in their ligand binding by 
anchoring the carboxyl group of the terminal sialic acid inside the binding pocket. 
Mutations of this residue have been shown to result in loss of binding of most Siglecs, 
including Siglec8 (Propster, et al., 2016). In addition, this work reveals the importance 
of both sulphate groups attached to the D-Galactose 6-Sulphate (Gal6S) and the N-
Acetyl-D-Glucosamine (GlcNAc) as pharmacophores that enhance the affinity of the 
interaction. The dissociation constant of the 6,6’-Disulphated Sialyl-LewisX (KD = 
183±18 μM) was the lowest of all ligands tested in the study, followed by the 6’-
Sulpho Sialyl-LewisX (KD = 295±26 μM) whose sulphate group is attached to the 
Gal6S (see Figure 5.3). The 6-Sulpho Sialyl LewisX (sulphate attached to GlcNAc) 
showed lower affinity for the Siglec8 Ig-like V-type domain (KD = 2.7±0.8 mM) and 
finally, Sialyl LewisX (KD = 8.3±1.9 mM) had the lowest affinity (Propster, et al., 
2016). Therefore, the sulphate group attached to Gal6S plays a key role in the binding 
through its interaction with arginine 56 (Arg56), and the addition of another sulphate 
group to the GlcNAc enhanced the affinity of the ligand for the protein domain as 
represented in Figure 5.3. Furthermore, the model showed a lack of contacts between 
the α1,3-linked Fucose (Fuc) and Siglec8. However, the Fucose takes part stabilizing 
the LewisX trisaccharide conformation for binding with an inter-carbohydrate 
hydrogen bond between the Fucose C5-H5 and the O5 pyranose ring oxygen of Gal6S, 
and it may also contribute to enhance the affinity. 
 
Figure 5.3. From left to right, structures of the Disulphated Sialyl LewisX which binds Siglec8 with stronger 
affinity than the monosulphated 6’-Sulpho-Sialyl LewisX and 6-Sulpho-Sialyl LewisX which did not show any 
binding to Siglec8 in the glycan microarrays (Campanero-Rhodes, et al., 2006). 
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Using the molecular model described above as a basis, we designed a library 
of six peptide-based and three glycan-based commercially available small molecules 
as possible Siglec8 Ig-like V-type domain binders. The approach taken for the glycan 
ligands was fragment based, encompassing the N-acetylneuraminic acid (NeuAc) and 
the D-Galactose 6-Sulphate (GalS6). The D-Glucuronic Acid (GluA) was also 
included due to its hexacyclic structure with a carboxylic group that provides it with a 
negative charge (Table 5.2). All peptide-based ligands included at least one negative 
charge and either carbohydrate chains or aromatic rings or a pentacyclic structure in 
an attempt to partially imitate the chemical environment of the large 6’-Sulpho Sialyl 
LewisX (Table 5.3). Ligands’ structures and molecular weights are presented in 
Tables 5.2 and 5.3. 
Table 5.2. Glycan based designed library attempting to imitate the chemical environment of the 6’-Sialyl LewisX 
ligand. 
 Glycan based library  
Glycan Compound Structure Molecular Weight (MW) 
(g/mol) 
 
N-acetylneuraminic acid 
(NeuAc) 
 
 
309.273 
 
D-Glucuronic Acid (GluA) 
 
 
194.139 
 
D-Galactose 6-Sulphate (GalS6) 
 
 
260.213 
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Table 5.3. Peptide based designed library attempting to imitate the chemical environment of the 6’-Sialyl LewisX 
ligand. 
 Peptide based library  
Peptide  Structure Molecular Weight (MW) 
(g/mol) 
 
Glutamic Acid-Leucine 
(Glu-Leu) 
 
 
260.29 
 
 
Glutamic Acid-Phenylalanine 
(Glu-Phe) 
 
 
294.3 
 
 
Glutamic Acid-Valine 
(Glu-Val) 
 
 
246.26 
 
 
Glutamic Acid-Proline 
(Glu-Pro) 
 
 
244.24 
 
 
 
Glutamic Acid-Aspartic Acid 
(Glu-Asp) 
 
 
262.22 
 
 
O-Phospho-L-Tyrosine  
(P-Tyr) 
 
261.17 
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5.5 Binding of molecular libraries designed to target Siglec8 using the Octet 
The Octet system enables high throughput, real-time and label-free kinetic and 
affinity characterization of biomolecular interactions, including binding between 
proteins and small molecules (Fortebio). Here we analysed Siglec8-small molecule 
interactions. The experiment involved immobilization of the Siglec8 Ig-like V-type 
domain onto the surface of a sensor, followed by its immersion in a series of solutions 
(including buffer and ligand solutions), emulating the protein-ligand association and 
dissociation processes. Inside the instrument, a white light is emitted and passed 
through the biosensor tip. Subsequently, the detector analyses the interference pattern 
of white light reflected from two surfaces: the layer of immobilized protein on the 
biosensor tip and an internal reference layer. Thus, when a ligand is interacting with 
the protein, there is an increase in optical thickness at the biosensor tip, which results 
in a wavelength shift, Δλ (Fortebio). Only molecules binding to or dissociating from 
the biosensor can shift the interference pattern and generate a response profile in the 
Octet System. By exposing the protein to a buffer solution containing ligand, and 
subsequently washing it with buffer, rates of association ka (on-rate) and dissociation 
kd (off-rate) as well as affinity constants KD can be monitored (Fortebio). The basis of 
the Octet instrument’s working principles is represented in Figure 5.4. 
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Figure 5.4. Representation of the Octet instrument working principle. Protein is immobilised in the biosensor 
surface (green). When there is not ligand attached (above), the incident white light is reflected according to a pattern 
which changes when there is ligand (purple) bound to the protein (below), leading to a shift in the phase of reflected 
light (Δλ) (Fortebio). 
 
The initial binding screen was carried out for each of the nine ligands at a 
constant concentration of 10 mM. First, the Siglec8 Ig-like V-type domains were 
biotinylated, by covalent attachment of biotin to the protein through its free primary 
amine groups (N-terminus or lysines side chain epsilon amines). This does not usually 
perturb the protein’s natural function, due to the small size of biotin (MW = 244.31 
g/mol). A lysine biotinylation reaction is shown in Figure 5.5 below. 
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Figure 5.5. Protein biotinylation reaction. Condensation between a lysine’s epsilon side chain amine and biotin 
with loss of a water molecule. 
The distribution of seven lysine residues across the primary sequence of the 
Siglec8 Ig-like V-type domain used in this work is shown below (see circled residues 
in Figure 5.6). The biotynilation reaction was set up to achieve a yield of one biotin 
molecule reacting with either a random lysine or the N-terminal amine per protein 
domain, leading to a random distribution of eight different orientations when the 
protein domain is attached to the Octet sensor. 
 
Figure 5.6. Distribution of Lysine amino acids across the Siglec8 Ig-like V-type domain sequence. 
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After biotinylating, the Octet experiment was set up as shown in Figure 5.7. 
Eleven sensors (one per ligand plus a reference without protein and a reference without 
ligand) were sequentially immersed into five different wells from left to right, 
following the five steps described below: 
 
Figure 5.7. Representation of the Siglec8 ligand binding screening Octet experimental set up. 
1. Equilibration. 
A sensor coated with the protein Streptavidin is immersed in 20 mM NaPi, 500 
mM NaCl, pH 7.0 buffer to establish a constant chemical environment.  
2. Protein loading. 
The sensor is then immersed in a solution of 20 μM biotinylated Siglec8 Ig-like 
V-type domain in matching buffer. Biotin binds to Streptavidin with an extremely 
high affinity, fast on-rate, and high specificity. Furthermore, biotin binding to 
streptavidin is resistant to heat, pH and proteolysis, making the capture of 
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biotinylated molecules possible in a wide variety of environments. Thus, the 
sensor surface was covered with Siglec8 Ig-like V-type domains randomly 
orientated depending on the site of biotin attachment (i.e. attachment to one of six 
lysines or to the N-terminus). In this step, one well contained no protein as a 
negative control, so one of the sensors was not loaded with protein. 
3. Wash. 
The sensor is dipped in the matching buffer to get rid of any excess of protein. 
4. Association. 
Each sensor is immersed in a specific concentration of ligand solution in buffer, 
enabling protein-ligand association. For the reference experiment, one of the 
sensors loaded with protein was immersed in buffer, as a second negative control. 
5. Dissociation. 
The sensor is dipped in buffer again enabling the ligand dissociation process. 
The reflected light signal is collected at each of the five steps for each sensor. 
Figure 5.8 displays idealised raw data for the binding of an immobilised protein and 
two different ligands (graphic on the left) and the data after subtracting the reference 
experiments (graphic on the right). The processed data give information about the 
protein-ligand association and dissociation rates as well as the magnitude of the 
interaction. Thus, for the same concentration of ligands 1 and 2, the association to the 
protein occurs more rapidly for ligand 1 (red curve) than for ligand 2 (green curve) 
(ka1 > ka2), but ligand 2 dissociates more slowly from the protein than ligand 1 (kd1 > 
kd2). Ligand 1 also produces a higher response than ligand 2, meaning that more 
molecules of ligand 1 bind to the protein.  
However, affinity information cannot be obtained until more experiments are 
carried out for each ligand at different concentrations, and all data are fitted according 
to the suitable model. That will provide a dissociation constant (KD=kd/ka) for each 
ligand. The comparison of association and dissociation rates, the magnitude of the 
binding response as well as the dissociation constants between ligands is relevant to 
select the best candidates. 
Chapter 5- Exploring Siglec8 as a therapeutic target 
132 
 
 
Figure 5.8. Hypothetical Octet data for the binding of two different ligands to an immobilised protein (ligand 1 in 
red and ligand 2 in green). Raw data are shown in the graphic on the left, while the processed data after the 
subtraction of references are represented in the graphic on the right. 
The first Siglec8 ligand binding screen was performed at a constant ligand 
concentration of 10 mM for each one of the nine ligand molecules. Figures 5.9 and 
5.10 display the processed Octet data for this Siglec8 binding screen for all ligands. 
Curves are labelled with the name of each ligand. In Figure 5.10, there are also curves 
belonging to experiments performed for the ligand L-Phosphotyrosine at three 
additional concentrations (5, 2.5 and 1.25 mM).  
 
Figure 5.9. Six Octet Siglec8 binding experiments performed with a 10 mM concentration of Phospho L-Tyrosine, 
Glu-Val, Glu-Asp, D-Galactose-6-Sulphate, N-Acetyl Neuraminic Acid and Glucuronic Acid.  
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Figure 5.10. Three Octet Siglec8 binding experiments performed with a 10 mM concentration of Glu-Leu, Glu-
Phe and Glu-Pro. Three extra experiments with 5, 2.5 and 1.25 mM Phospho-L-Tyrosine are also included. 
 
L-Phospho-Tyrosine showed by far the highest Siglec8 binding response at a 
concentration of 10 mM (0.602 nm), followed by Glu-Val (0.269 nm), Glu-Asp 
(0.233), D-Gal-6-O-Sulphate (0.0827) and Glu-Leu (0.056).  
Further Siglec8 Octet binding experiments were performed with the four 
ligands that gave the highest binding response (L-Phospho-Tyrosine, Glu-Asp, Glu-
Val and Glu-Leu) at different concentrations in the millimolar range. The aim was to 
obtain information about affinity, association and dissociation rates. Table 5.4 
includes all concentrations tested for each ligand. 
Table 5.4. Different concentrations of each ligand tested with the Octet to estimate their affinity for Siglec8. 
Ligand L-Phospho-
Tyrosine 
Glu-Asp Glu-Val Glu-Leu 
 
 
 
Concentrations 
(mM) 
20 30 22.5 25 
8 15 18 12.5 
4 6 9 7 
0.4 3 0.9 5 
0.2 0.3 0.45 2.5 
0.04 0.15 0.09 0.5 
 0.03   
 
Figures 5.11 to 5.14 display the Octet ligand binding curves for L-Phospho-
Tyrosine, Glu-Asp, Glu-Val and Glu-Leu, respectively. As before, L-Phospho-
Tyrosine was the ligand demonstrating the highest response, followed by Glu-Leu and 
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Glu-Asp. The results for Glu-Val showed a very low binding response, inconsistent 
with the first 10 mM screening.  
 
Figure 5.11. Octet experiment to test the binding between Siglec8 and L-Phospho-Tyrosine at different ligand 
concentrations. 
 
 
Figure 5.12. Octet experiment to test the binding between Siglec8 and Glu-Asp at different ligand concentrations. 
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Figure 5.13. Octet experiment to test the binding between Siglec8 and Glu-Leu at different ligand concentrations. 
 
Figure 5.14. Octet experiment to test the binding between Siglec8 and Glu-Val at different ligand concentrations. 
 
After trying different models, the best fitting results were obtained using an 
heterogeneous (n ligand molecules : 1 protein domain), local and partial model. 
Heterogeneous modelling is in good agreement with the multivalent ligand binding of 
other Siglecs described in the literature (Attrill, et al., 2006a). The term local means 
that every concentration was fitted independently for each ligand, and the term partial 
indicates that association and dissociation were considered separately. L-Phospho-
Tyrosine showed the highest Siglec8 binding response above 4 mM and dissociated 
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slowly from the protein domain. Glu-Asp bound Siglec8 at concentrations above 6 
mM and dissociated slowly from the protein domain. However, the binding response 
was lower than for L-Phospho-Tyrosine. Glu-Leu bound Siglec8 at concentrations 
above 0.5 mM and dissociated faster than P-Tyr and Glu-Asp from the protein domain 
and its binding response was lower than for L-Phospho-Tyrosine too. 
5.6 Equilibrium dialysis combined with 1D H+ NMR to monitor Siglec8-Phospho-
Tyrosine binding interactions. 
 Equilibrium dialysis enables the estimation of protein-ligand binding affinity 
constants in combination with any suitable ligand quantifying technique (Tipping, et 
al., 2015). Each equilibrium dialysis device has two compartments separated by a 
dialysis membrane with smaller pore size than the protein but larger than the ligand. 
Thus, ligand and salts can diffuse between both chambers, but the protein will remain 
in the compartment where it was initially put.  
The basics of the equilibrium dialysis experiment are illustrated in Figure 5.15. 
For each tested ligand concentration, two equilibrium dialysis devices were used: a 
control without Siglec8, and a sample with a fixed Siglec8 concentration in 20 mM 
NaPi, 500 mM NaCl, pH 7.5 buffer.  
In the control device, one chamber was filled with 50 μL of the same buffer, 
and the other with 50 μL of a solution with a specific Phospho-Tyrosine concentration 
in buffer. In the sample device, one chamber was filled with 50 μL of a 50 μM 
concentration solution of Siglec8 domains in buffer, and the other with 50 μL of the 
same Phospho-Tyrosine solution added to the control device. Thus, in both devices 
the ligand diffused through the dialysis membrane until it reached an equilibrium 
concentration. After 2 hours of gently shaking, the chamber with the ligand solution 
was opened, and the 50 μL recovered from both devices.  
Subsequently, the concentration of ligand was measured using 1D H+ NMR 
and fluorescence when possible. When there is protein-ligand binding, the 
concentration of free ligand in the control should be higher than in the sample as some 
of the ligand would be bound to the protein, shifting the equilibrium and making more 
ligand to diffuse through the dialysis membrane (Figure 5.15c). Contrarily, in absence 
of interaction, for both control and sample devices, the same amount of ligand would 
diffuse through the dialysis membrane leading to an equal ligand concentration in 
control and sample (Figure 5.15b). 
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The same experiment with a fixed concentration of 50 μM Siglec8 was 
repeated at different ligand concentrations to build binding curves for some of the 
ligands. 
 
Figure 5.15. Representation for one equilibrium dialysis experiment at one ligand concentration. The picture 
illustrates both the sample and control devices in different situations: a) Before the equilibrium is reached. b) After 
equilibrium was reached but there was no protein-ligand interaction. c) After equilibrium was reached but there 
was protein-ligand interaction. 
Estimation of the L-Phospho-Tyrosine fraction bound to Siglec 8 by means of 1D 1H 
NMR. 
 An equilibrium dialysis experiment was set up with a constant Siglec8 
concentration (50 μΜ) and different Phospho-Tyrosine concentrations as described 
above. The aim of this experiment was to estimate a KD value for the interaction 
between Siglec 8 and this ligand using 1D 1H NMR as a quantitative technique for 
measurement of ligand concentration. Table 5.5 displays the concentration values of 
L-Phospho-Tyrosine added to the ligand chamber for all equilibrium dialysis samples: 
Table 5.5. Equilibrium dialysis concentration values of Phospho-Tyrosine 
C P-Tyr Samples (μM) C P-Tyr Controls (μM) 
50 50 
100 100 
500 500 
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After the six equilibrium dialysis chambers reached equilibrium, each chamber 
with ligand solution was opened, and 50 μL of the resulting ligand solution were 
recovered from all devices. Samples were then diluted with 85 μL of HPLC quality 
H2O and 15 μL of D2O (10% v/v) to reach a volume of 150 μL for NMR 
measurements.  
All solution state NMR measurements were performed on the 700 MHz 
Spectrometer using identical acquisition parameters for every sample in order to allow 
direct comparison of peak integrals in the spectra. An additional sample of 50 μL of 
100 μM DDS (4, 4-dimethyl-4-silapentane-1-sulfonic acid) diluted with 85 μL of 
HPLC quality H2O and 15 μL of D2O (10% v/v) was prepared and measured in the 
same way as an external standard of accurately known concentration. The structure of 
this compound is displayed in Figure 5.16. 
 
Figure 5.16. Structure of the NMR standard DSS (4, 4-dimethyl-4-silapentane-1-sulfonic acid). 
 
Figure 5.17 shows an assigned L-Phospho-Tyrosine 1D 1H NMR spectrum 
where the numbers indicate which peak belongs to each proton or pair of equivalent 
protons in the molecule. The intensity of an NMR peak is proportional to the number 
of equivalent protons that give rise to that signal as well as the sample concentration. 
Therefore, for a specific peak corresponding to two samples with different 
concentrations of the same ligand, the intensity increments are proportional to the 
concentration difference between them.  The peaks 2 and 3 belonging to the aromatic 
ring protons were used to compare the intensities of each control-sample pair (ΔI = 
Icontrol - Isample). Subsequently, the concentration increments (ΔC = Ccontrol - Csample) 
were calculated using the DSS's methyl proton peak at 0 ppm.  Since DSS is of 
accurately known concentration, it can be used as an external reference by normalising 
all intensities to a one proton intensity value. The spectrum belonging to the DSS 
sample used as the external standard is shown in Figure 5.18.  
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Figure 5.17. L-Phospho-Tyrosine 1D H+ solution state NMR assigned spectrum. 
 
 
Figure 5.18. DSS solution state NMR 1D H+ spectrum. 
 
The intensity (ΔI = Icontrol - Isample) and concentration (ΔC = Ccontrol - Csample) 
increments, concentration of ligand bound to the protein (Cbound = (Ccontrol – Csample) 
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*2) and fraction of ligand bound to the protein receptor (B = Cbound / Creceptor) values 
for peak 2 are shown in Table 5.6 and for peak 3 in Table 5.7. 
Table 5.6. Intensity, concentration and fraction of P-Tyr bound to Siglec8 values using the NMR peak 2. 
Peak 2 
L (μM) Icontrol 
1H+ 
Isample 
1H+ 
(Icontrol - Isample) 
1H+ 
IDSS 1H+ (Cbound) 
(μM) 
B = Cbound/Creceptor 
50 0.2709 0.1715 0.09935 - 29.81 0.5961 
100 0.5 0.2505 0.2495 0.111 74.85 1.497 
500 0.9122 0.2339 0.6783 - 203.5 4.070 
 
Table 5.7. Intensity, concentration and fraction of P-Tyr bound to Siglec8 values using the NMR peak 3. 
Peak 3 
L (μM) Icontrol 
1H+ 
Isample 
1H+ 
(Icontrol - Isample) 
1H+ 
IDSS 1H+ (Cbound) 
(μM) 
B = Cbound/Creceptor 
50 0.2472 0.1503 0.09695 - 29.09 0.5817 
100 0.4848 0.2302 0.2546 0.111 76.38 1.528 
500 0.8464 0.2188 0.6276 - 188.3 3.765 
The fraction of ligand bound to the protein receptor B (Cbound/Creceptor) is also 
the fraction of receptor occupied by ligand when the stoichiometry of a protein-
receptor interaction is 1:1. Thus, for a 1:1 stoichiometry the expected values of B 
should be lower or equal to one, meaning that for a 50 μM total concentration of 
protein receptor, the maximal concentration of ligand that could interact with it would 
be 50 μM. However, our data show values of B higher than 1 for ligand concentrations 
higher than 50 μM (Tables 5.6 and 5.7) supporting the heterogeneous binding model 
indicated by the Octet data, that is a stoichiometry n·ligand molecules :1 protein 
domain (nL: R). 
Estimation of the L-Phospho-Tyrosine fraction bound to Siglec 8 by means of 
Fluorescence. 
 Another equilibrium dialysis experiment was set up with a constant Siglec8 
concentration (50 μΜ) and different Phospho-Tyrosine concentrations. The aim of this 
experiment was to estimate a KD value for the interaction between Siglec 8 and this 
ligand using Fluorescence as a quantitative technique for measurement of ligand 
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concentration. Table 5.8 displays the concentration values of L-Phospho-Tyrosine 
added to the ligand chamber for all equilibrium dialysis samples: 
Table 5.8. Equilibrium dialysis concentration values of Phospho-Tyrosine 
C P-Tyr Samples (μM) C P-Tyr Controls (μM) 
1 1 
10 10 
25 25 
50 50 
100 100 
 
After the ten equilibrium dialysis chambers reached equilibrium, each chamber 
with ligand solution was opened, and 50 μL of the resulting ligand solution were 
recovered from all devices. Subsequently, a fluorescence emission spectrum was 
measured for each sample. Samples were excited at 268 nm, the Phospho-Tyrosine’s 
maximum absorbance wavelength, and fluorescence emission spectra were recorded 
between 250 and 500 nm, revealing a maximum of emission at 297 nm. The intensity 
of emission at 297 nm was used to compare sample and control and calculate the 
fraction of Phospho-Tyrosine bound to the Siglec8 carbohydrate protein domains. The 
intensity (ΔF = Fcontrol - Fsample) and concentration (ΔC = Ccontrol - Csample) increments, 
concentration of ligand bound to the protein (Cbound = (Ccontrol – Csample) *2) and fraction 
of ligand bound to the protein receptor (B = Cbound / Creceptor) values are shown in Table 
5.9. 
Table 5.9. Intensity, concentration and fraction of P-Tyr bound to Siglec8 values obtained using fluorescence. 
L (μM) Fcontrol  Fsample  (Fcontrol - Fsample) (Cbound) (μM) B = Cbound/Creceptor 
1 30.72 23.99 6.736 0.438 0.00876 
10 126.89 109.07 17.823 1.16 0.0232 
25 141.54 24.04 117.50 7.64 0.1528 
100 560.07 159.40 400.67 26.08 0.5216 
 
5.7 Estimation of Siglec 8-ligand dissociation constant values. 
Receptor-ligand (R-L) binding kinetics describes the rate at which a receptor 
(R) and its ligand (L) bind to each other. When a receptor and a ligand with affinity 
for it are mixed in solution, kon (M¯¹·s¯¹) and koff  (s¯¹) are the kinetic constants that 
provide information about the rate of forward and reverse binding: 
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After equilibrium is reached, the rates of the association and dissociation 
reactions become equal. This means that free receptor (R) and n ligand (nL) molecules 
and receptor-ligand complex (R-nL) are being created at the same rate as represented 
below assuming a stoichiometry 1:1 (n=1): 
kon · [R] · [L] = koff · [RL] 
The affinity of the receptor-ligand interaction measures the strengh of the 
binding. It is commonly measured and reported by the equilibrium dissociation 
constant KD (M). 
KD =
koff
kon
=  
[L] · [R]
[RL]
  
[RL] =  
[L] · [R]
KD
 
Other important concepts are the fractional occupancy (F.O.), and the binding 
occupancy (B). F.O. is expressed as the fraction of all receptors that are bound to the 
ligand and B as the fraction of all ligands bound to the receptor as shown below: 
F. O. =  
[RL]
[R] + [RL]
 
B =  
[L]bound
[R]total
  
Using the definition of the equilibrium dissociation constant KD, the fractional 
occupancy can be expressed as follows: 
F. O. =  
[RL]
[R] + [RL]
=
[L] · [R]
KD⁄
[R] + (
[L] · [R]
KD⁄ )
=
[L] · [R]
KD⁄
(KD · [R] + [L] · [R])
KD⁄
=
[L]
KD + [L]
 
Assuming a one to one stoichiometry for the ligand-receptor interaction, and 
introducing the maximal binding occupancy (Bmax), which represents the  maximum 
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number of receptors that can interact with the ligand, the fractional occupancy may 
also be writen as: 
( Bmax =
[L]max
[R]total
 ) 
F. O. =  
[L − R]
[R]total
=
[L]bound
[R]total
=
[L]bound
[R]max
=
[L]bound
[L]max
=
B
Bmax
 
Making the last two fractional occupancy expressions equal, the following 
equation enables to fit a binding curve to determine Bmax and KD, by representing 
different concentrations of ligand for a constant amount of receptor in solution, against 
the binding occupancy of the receptor at each concentration. 
B =  
[L] · Bmax
KD + [L]
 
By linearizing the equation, the KD can be determined as the negative 
reciprocal of the slope of the line, and Bmax is given by its X-axis intercept (Figure 
5.19): 
B · KD + B · [L] = Bmax · [L] 
B · KD = (Bmax − B) · [L] 
B
[L]
= (Bmax − B) ·
1
KD
 
 
Figure 5.19. Graphical representation of a binding curve and its linearized form. 
 
However, this model is not useful in all situations as it makes the following 
assumptions: 
• The stoichiometry of the interaction is 1:1 (n=1). 
• All receptors are equally accessible to ligands. 
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• There is no state of partial binding, so receptors are either free or bound to the 
ligand. 
• Binding does not alter the ligand or receptor as enzymes do.  
• Binding is reversible. 
The model described above was applied to the data obtained from the 
equilibrium dyalisis-1D 1H NMR experiment for the interaction between Siglec8 and 
P-Tyr but the data do not fit the model which requires B values lower than 1 (B < 1). 
This is in good agreement with the heterogeneous binding model used to fit the Octet 
data where the number of ligand molecules interacting with each protein domain is 
higher than 1 (n >1) and therefore B is also higher than 1 for some of the data points 
(B > 1).  
The best fit was obtained using a variant of the Hill equation. The Hill equation 
was originally formulated in 1910 to describe the sigmoidal O2 binding curve of 
haemoglobin or the fraction of protein saturated (Goutelle, et al., 2008) by ligand as a 
function of the ligand concentration or cooperativity: 
B′ =
[L]ᵑ
KD + [L]ᵑ
 
In the Hill equation B’ is the fraction of protein receptor occupied by ligand 
(B’=Rbound/Rtotal), L is the total ligand concentration, KD is the dissociation constant 
and n is the Hill coefficient. The Hill coefficient describes the cooperativity of the 
binding, where ᶇ>1 indicates a positively cooperative interaction, meaning that the 
binding of one ligand molecule enhances the affinity for other ligand molecules and 
ᶇ<1 indicates the opposite case. In addition, ᶇ=1 means non-cooperative binding, 
where the affinity of the protein for a ligand molecule is not dependent on other ligand 
molecules.  
Our experimental data did not allow us to calculate the value of B’ or the 
fraction of occupied Siglec 8 domains, due to the lack of information about the 
stoichiometry of the Siglec 8-P-Tyr interaction. B’ (fraction of occupied receptor) is 
different from B (fraction of bound ligand) when the stoichiometry of the interaction 
is nL:R and n is higher than 1 (n>1). However, we represented the fraction of ligand 
bound to the receptor (B) against the total ligand concentration (L).  
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Figures 5.20 and 5.21 display the Hill equation fitting for the Phospho-
Tyrosine fraction bound to Siglec 8 (B) versus the initial concentration of ligand used 
for the equilibrium dialysis experiment (L) according to the NMR 1D 1H spectrum 
peaks 2 and 3, using the software Origin. The estimated values for each of the Hill 
equation components are represented below with an extra constant that we have called 
A. Thus, we hypothesized that the meaning of this constant is related to the number of 
Phospho-Tyrosine molecules interacting with each Siglec 8 domain, and B’ may be 
calculated as the quotient between B and A (B’=B/A). The KD, A and ᶇ values 
resulting from the Hill equation fitting for the NMR 1D H+ spectrum peaks 2 and 3 are 
represented in Tables 5.10 and 5.11. 
 
 
 
Figure 5.20. Representation of Phospho-Tyrosine concentration against the fraction of Phospho-Tyrosine bound 
calculated from the 1D H+ NMR peak 2 and fitting according to the Hill equation. 
Table 5.10. Hill equation parameters for the Siglec8 and P-Tyr interaction according to the NMR peak 2. 
Hill equation parameters for the Siglec8 and Phospho-Tyrosine interaction. 
NMR Peak 2 
A 4.63 ± 1.12157E-15 
KD (μM) 154.58 ± 8.08213E-14 
η 1.69 ± 8.83144E-16 
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Figure 5.21. Representation of Phospho-Tyrosine concentration against the fraction of Phospho-Tyrosine bound 
calculated from the 1D H+ NMR peak 3 and fitting according to the Hill equation. 
 
Table 5.11. Hill equation parameters for the Siglec8 and P-Tyr interaction according to the NMR peak 3. 
Hill equation parameters for the Siglec8 and Phospho-Tyrosine interaction. 
NMR Peak 3 
A 4.09 ± 6.76153E-16 
KD (μM) 132.29 ± 4.80302E-14 
η 1.85 ± 8.9904E-16 
 
Figure 5.22 display the Hill equation fitting for the Phospho-Tyrosine fraction 
bound to Siglec 8 (B) versus the initial concentration of ligand used for the equilibrium 
dialysis experiment (L) according to Fluorescence measurements, using the software 
Origin. The estimated values for each of the Hill equation components are represented 
in table 5.12. 
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Figure 5.22. Representation of Phospho-Tyrosine concentration against the fraction of Phospho-Tyrosine bound 
calculated from fluorescence measurements and fitting according to the Hill equation. 
Table 5.12. Hill equation parameters for the Siglec8 and P-Tyr interaction according to the NMR peak 3. 
Hill equation parameters for the Siglec8 and Phospho-Tyrosine interaction.  
Fluorescence 
A 0.57832 ± 0.03121 
KD (μM) 38.73537 ± 3.83112 
η 2.33946 ± 0.32154 
 
In summary, this chapter provided information about the interaction between 
Siglec8 and nine different small mimetic molecules, with four of them (Glu-Asp, Glu-
Leu, Glu-Val and Phospho-Tyr) showing a significant binding response in the Octet 
experiments. Phospho-Tyrosine was the ligand which demonstrated the highest 
binding response to our soluble Siglec8 carbohydrate binding domains. All binding 
curves were fitted according to a heterogeneous, local and partial binding model, 
suggesting a stoichiometry of more than 1 ligand molecule interacting with 1 protein 
receptor. Further equilibrium dialysis together with 1D H+ NMR and fluorescence 
measurements for the Siglec8-Phospho-Tyrosine interaction supported the 
heterogeneous binding interaction model. Those data fitted the Hill equation and 
revealed a positive cooperative binding between Siglec8 and Phospho-Tyrosine with 
an affinity constant value around 140 μM according to NMR and around 40 μM 
according to fluorescence measurements. Table 5.13 summarizes all dissociation 
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constant values obtained for Siglec8-Phospho-Tyrosine interaction by means of the 
two different techniques. 
Table 5.13. Summary of the dissociation constant values obtained by means of equilibrium dialysis plus NMR 1D 
+H and fluorescence. 
Technique used to complement Equilibrium Dialysis Dissociation constant obtained value (μM) 
NMR 1D +H Peak 2 154.58 
NMR 1D +H Peak 3 132.29 
Fluorescence 38.735 
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6. Discussion and future perspectives. 
In this work, the Siglec8 Ig-like V-type domain has been expressed in E. coli, 
refolded from inclusion bodies and purified to test interaction with small sialic acid 
mimetic molecules in solution with therapeutic purposes.  
To produce this domain, production of which has only been reported by one 
other group (Propster, et al., 2015), several different E. coli strains, expression vectors, 
chaperones, media additives and culture conditions were screened to achieve 
prokaryotic soluble expression. In some 2 L cultures grown at 15°C, very low levels 
of soluble expression could be detected, but the concentration was not high enough to 
obtain a pure sample due to the high concentration of bacterial soluble proteins present 
in the culture's soluble fraction. Although there are not many examples of Siglec 
soluble expression in the literature, previous works reflect the difficulty of producing 
human Siglecs' carbohydrate binding domains in prokaryotic expression systems. 
Human Siglec7 Ig-like V-type domains were produced in Chinese Hamster ovary Lec1 
cells for X-ray structure resolution (Alphey, et al., 2003) and human Siglec5 
extracellular domains were expressed in E. coli and refolded from inclusion bodies 
with a final yield of 2 mg/mL for the same purpose (Barb, et al., 2013). The presence 
of disulphide bonds, a secondary structure based on β-sheets together with the Asn-
linked glycosylation of Siglecs' extracellular domains may be the main reasons for 
their challenging expression in bacteria. However, Siglec8 Ig-like V-type domains 
were solubly expressed in E. coli Rosetta gami B (DE3) cells in milligram quantities 
(Propster, et al., 2015) for multidimensional solution state NMR structural 
characterization (Propster, et al., 2016). We attempted to replicate the cloning 
construct and expression conditions used in that work, where the construct Siglec8 Ig-
like V-type Met17-His155 (Cys42>Ser42) was expressed in E. coli Rosetta gami B 
(DE3) cells using the vector pET-43(a+) but could not obtain the soluble expression 
levels reported in this work. This is probably due to a lack of means in our chemical 
biology facility to achieve their culture shaking speed, 250 rpm. Shaking speed is 
crucial to deliver oxygen to cells in liquid cultures, with the rate of oxygen demand 
increasing as the cell mass increases and it affects the yields and solubility of 
overexpressed recombinant proteins. After many attempts to improve our Siglec8 Ig-
like V-type domain's solubility, a protocol for refolding from inclusion bodies was 
Chapter 6 – Discussion and future perspectives 
151 
 
developed in collaboration with Mologic Ltd., and pure samples were obtained at an 
approximate concentration of 1 mg/mL. This concentration was sufficient to perform 
a biophysical characterization of the domain as well as protein-ligand binding studies. 
Likewise, Mologic made use of those samples to produce antibodies anti-Siglec8 for 
diagnostic purposes.  
The circular dichroism spectrum of our soluble Siglec8 Ig-like V-type domains 
(Figure 4.7) confirmed the production of folded domains with a predominant β-sheet 
composition and suggested the presence of the disulphide bond. CD data also matched 
the published spectrum for the soluble Siglec 8 domains expressed in previous work 
(Propster, et al., 2015). In addition, SAXS data (Figure 4.16) confirmed the production 
of well-folded soluble Siglec8 Ig-like V-type domain with an average diameter of 32 
Å, which is in good agreement with the estimation of a 16.2 Å radius of gyration for 
the Siglec8 Ig-like V-type domain structure resolved by means of solution state NMR 
(Propster, et al., 2016). 
Due to its restrictive expression in eosinophils and mast cells, Siglec8 has been 
pointed out as a promising pharmaceutical target to treat allergic diseases such as 
asthma where those inflammatory cells are involved. Siglec8 agonists have been 
demonstrated to inhibit cell function and survival, a desirable effect to modulate the 
excessive eosinophilic response that occurs in the airways of a high proportion of 
asthmatic patients (Feng and Mao, 2012; Kiwamoto, et al., 2012; Kiwamoto, et al., 
2013; Gangwar, et al., 2017). However, the identity of Siglec8's physiological 
sialylated ligands still remains unknown, with all Siglec8 binding information coming 
from glycan array data and biophysical studies (Campanero-Rhodes, et al., 2006; 
Propster, et al., 2016) which revealed 6,6’- Sulpho-Sialyl-Lewis X as the best 
candidate (estimated KD = 183±18 μM). In this work, that information was employed 
to design nine glycan and peptide-based 6,6’- Sulpho-Sialyl-Lewis X mimetic small 
molecule candidates. Octet and equilibrium dialysis together with either 1D 1H NMR 
or fluorescence binding experiments revealed the ligand L-Phospho-Tyrosine as our 
best Siglec8 ligand candidate, with an estimated dissociation constant between 130 - 
150 μM in case of NMR and around 40 μM using fluorescence. With this study, we 
aim to provide some insight and basis for the development of highly-specific ligands 
with a suitable affinity for the receptor Siglec8. Good candidates could include larger 
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molecules than L-Phospho-Tyrosine which may contain one or more sulphate or other 
negatively charged groups together with aromatic rings, as they seem to be important 
pharmacophores for the interaction.  
In our body, drugs can produce dangerous side effects through non-specific 
interactions with non-target proteins if they are not designed to interact specifically 
with a particular target protein. Likewise, it is very important to be aware of the 
important self-defence role that immune system cells play and find a balance between 
highly specific Siglec8 ligands with the suitable affinity, so they do not induce 
apoptosis of all eosinophils and affect the immune system physiological response.  
Thus, ligands must have enough affinity for the receptor to reduce the levels of 
eosinophils in the patient’s airways during an asthmatic crisis without depleting or 
affecting the immune system responses in a physiological environment. 
Siglecs carry out critical immune system regulatory functions in our body and 
this may be the reason why only low-affinity Siglec ligands with lower than millimolar 
KD values have been previously reported. In a physiological situation where the 
immune system cells release hundreds of enzymes, cytokines and cytotoxic molecules, 
it is likely that the same balance between high-specificity and the suitable affinity is 
required to regulate in the right proportion the immune system cellular activity through 
Siglecs.  
Despite the huge advance in the investigation of Siglecs since this important 
protein family was described ten years ago (Crocker, et al., 2007), there is still much 
about the molecular structures and ligand interactions that remains unknown. Probably 
the most important key to moving this field forward is the collaboration between 
professionals from different disciplines including immunology, glycobiology, 
synthetic and computational chemistry, biochemistry, cellular biology and biophysics.  
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